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Abstract  
Background: Exercise-based cardiac rehabilitation (CR) is considered routine 
practice for patients following an acute cardiac event or surgical intervention. 
Although there is a seemingly strong evidence base supporting it for patients 
with chronic heart failure (CHF), provision in the UK remains poor for this 
patient group. In addition, data for CHF patients reported in key CR reviews and 
meta-analyses are not a true representation of the UKs CHF population. The 
transferability of current evidence into actual practice settings in the UK 
therefore remains incongruous.  
Rationale and aims: Study outcomes have typically included an increase in 
VO2 peak/ VO2 max, a decrease in natriuretic peptides, improved left ventricular 
function and improved health related quality of life (QoL). Access to facilities 
and equipment, such as cardiopulmonary exercise testing equipment is limited 
in the UK for the majority of CR services thus an alternative means of 
assessment and exercise prescription is required. The recommended 
alternative for testing CHF patients is the six-minute walk test (6MWT); this 
requires a given space and a full practice test, the latter which adds to valuable 
clinical and staff time available.  
Methods: The first set of studies of this thesis therefore investigated two 
adapted assessment procedures for use with CHF patients: i. the use of a 
shorter practice walk test of two minutes vs six minutes prior to a 6MWT and ii. 
the use of the space saving Chester step test with an adapted lower step height 
protocol to accommodate the anticipated lower fitness in CHF (4-inch vs 6-
inch). Having determined a more practical and efficient means of assessing 
exercise capacity in CHF patients, this thesis then used the 6MWT to evaluate 
the efficacy of a typically recommended 12-week programme (for the UK) of 
exercise-based rehabilitation. It was the aim of this PhD to also combine the 
use of the Chester step test with cardiopulmonary measures as a corresponding 
physiological outcome in a sub-sample of participants; however due to resource 
problems, only validation of the low-step protocol was possible. In the main 
intervention study, the efficacy of a 12-week course of supervised moderate 
intensity exercise in CHF patients (ejection fraction <44%, NYHA class II to III) 
was then evaluated. For purposes of evaluating safety and recovery of any 
acute myocardial stress induced by exercise in CHF, a sub-group study was 
performed to evaluate the influence of an acute exercise session on two-day 
post-exercise levels of circulating NT-proBNP.  
Results: In this current suite of studies, participants were more representative 
of the UK CHF population than typically reported in the current evidence. Their 
profile involved a median age of 76 ± 16 years (mean: 67 years and range: 30 
to 84 years). 98% of whom were prescribed beta-blockers, 66% were 
diagnosed with atrial fibrillation and 98% had two or more co-morbidities. Study 
1 (Chapter 3a) verified the efficacy of a two-minute practice walk in comparison 
to the recommended six-minute practice walk prior to performing a baseline 
6MWT in patients with CHF. Study 2 (Chapter 3b) demonstrated that a 4-inch 
Chester step test is a reliable assessment when space is an issue, but the 
criterion validity of the actual oxygen costs at each stage compared with those 
estimated in healthy populations were significantly lower than recommended 
estimations from healthy populations.  Study 3 (Chapter 4) revealed individual 
variability in the acute response of NT-proBNP release to exercise that is worthy 
of further study.  However the NT-proBNP data overall did not suggest a need 
for ‘rest days’ between exercise training sessions. The main intervention study 
(Study 4, Chapter 5) demonstrated a significant improvement in 6MWT 
performance responses, compared with control, where an increased walking 
distance of 25 m (p < .0001) was coupled with a reduction in heart-rate-walking 
speed index (T1 16.3 ± 7.3 vs T2 15.3 ± 8.7 beats per 10 walked; p < .0001). 
Perceptually, patients were walking faster for the same rating of perceived 
exertion (RPE 12 to 13). This improved aerobic functioning coincided with an 
improved NYHA class (T1 2.3 ± .5 vs T2 1.8 ± .6; p < .0001); however there 
was no change in resting NT-proBNP levels after 12 weeks. Patients in the 
“control group” who then went on to be offered the same 12-week intervention 
achieved similar outcomes, but delaying their commencement of an exercise 
programme by 12 weeks negatively impacted on participation uptake.  
Key findings and conclusions: These results have demonstrated that 
exercise training in CHF can lead to an improvement in both physical and 
perceived functioning (NYHA class). In light of some previous studies showing 
decreases in BNP following an exercise programme and others like this one 
showing no change, further questions are raised about the effect of different 
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types and doses of activity being offered to CHF patients and the 
responsiveness to training of different types of patients (disease severity and 
demographics). The nature of the cross-over design of this study revealed that 
delayed commencement of exercise negatively affects participation uptake by 
patients, which supports current UK standards in aiming for early referral to CR. 
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Glossary 
 
ACE inhibitors Angiotensin converting enzyme inhibitors reduce peripheral 
vascular resistance by blocking the angiotensin converting enzyme, thereby 
reducing myocardial oxygen consumption which results in improved cardiac 
output and moderation of left ventricle hypertrophy. 
 
Aerobic In the presence of oxygen. 
 
Afterload The tension or stress developed in the wall of the left ventricle during 
ejection i.e. the end load against which the heart contracts to eject blood. 
 
ARBs Angiotensin II receptor blockers (ARBs) are medications that block the 
action of angiotensin II by preventing angiotensin II from binding to angiotensin 
II receptors on blood vessels. As a result, blood vessels dilate and blood 
pressure is reduced. Reduced blood pressure makes it easier for the heart to 
pump blood. 
 
Arrhythmia Any deviation from the normal heart rhythm. 
 
Atrial fibrillation Irregular heart rhythm affecting the atria. 
 
Beta-blocker Medication that blocks the action of adrenalin to help keep heart 
rate and blood pressure down. 
 
Blood pressure The pressure exerted on the walls of the blood vessels as the 
heart pumps blood around the body. 
 
Borg scale A scale used to rate perceived exertion. 
 
Cachexia A state of malnutrition and general ill-health. 
 
Cardiac biomarkers Measured indicators to evaluate heart function. 
 
Cardiac output The total volume of blood pumped by the ventricles per minute; 
the product of stroke volume and heart rate.  
Cardiomyopathy A disorder of the heart muscle of unknown aetiology. 
Cardiopulmonary Exercise Testing (CPET) A non-invasive simultaneous 
measurement of the cardiovascular and respiratory systems during exercise to 
assess exercise capacity. 
Chronic heart failure A condition caused by the gradual onset of the heart 
failing to pump enough blood around the body at the right pressure. 
Chronotropic incompetence The inability of the heart to regulate its rate 
appropriately in response to physiologic stress. 
 
COPD Chronic obstructive pulmonary disease, such as bronchitis. 
 
Diastolic blood pressure The lower pressure produced by ventricular diastole 
(relaxation). 
 
Dyspnoea Difficulty in breathing/shortness of breath. 
 
Heart rate The number of ventricular beats per minute. 
 
Heart rate reserve The difference between a person's measured or predicted 
maximum heart rate and resting heart rate. 
 
Heart-rate-walking speed A ratio that can be calculated by dividing the total 
number of heart beats by walking distance attained during exercise testing. 
 
Homeostasis A physiological process to maintain functions such as blood 
pressure and body temperature within normal limits. 
 
ICH GCP International Conference on Harmonisation Good Clinical Practice is 
a quality standard. 
 
Ischaemia Deficient blood supply to an area of the body. 
 
Ischaemic heart disease Deficient blood supply to cardiac muscle, usually 
caused by atheromatous plaques.   
Karvonen formula A method of calculating training heart rate. 
Keteyian method A formula for calculating maximum heart rate 
Left ventricular ejection fraction The proportion of the volume of blood in the 
ventricles at the end of diastole that is ejected during systole. 
Left ventricular systolic dysfunction (LVSD) The left ventricle becomes 
weak and fails to efficiently pump blood around the body.  
Metabolic equivalents A metabolic unit used to quantify the intensity of 
physical activity, which is defined as the ratio of the metabolic rate during 
exercise to the metabolic rate at rest. One MET corresponds to an energy 
expenditure of approximately 1 kcal/kg of body weight/hour, or an oxygen 
uptake of 3.5 ml of O2 consumption/kg/hour. 
Myocardial infarction Damage to the heart muscle usually due to a blocked 
coronary artery, also known as a heart attack. 
 
Natriuresis The process of excretion of sodium in the urine via action of the 
kidneys.  
Neurohormone  A hormone secreted by a specialised neuron into the 
bloodstream, the cerebrospinal fluid, or the intercellular spaces of the nervous 
system.  
NRES National Research Ethics Service supports ethical research in the NHS. 
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Oedema The abnormal infiltration of tissues with fluid. 
 
Preload The end diastolic pressure that stretches the right or left ventricle of the 
heart i.e. the initial stretching of the cardiomyocytes prior to contraction. 
 
Pulse pressure The difference between the systolic and diastolic pressures. 
 
Rating of perceived exertion Interpreting sensations from the body during 
physical exertion. 
Remodelling Changes in size, shape, structure and physiology of the heart 
after injury to the myocardium. 
Renin-angiotensin-aldosterone system A hormone system that regulates 
blood pressure and fluid balance. 
SNS The sympathetic nervous system. The primary process is to stimulate the 
body's fight-or-flight response. 
 
Stroke volume Volume of blood ejected with each heartbeat. 
 
Sub-maximal exercise Any physical activity whose intensity increases at 
regular intervals up to but never exceeding 85% of maximum heart rate. 
 
Systolic blood pressure The higher pressure produced by ventricular systole 
(contraction). 
 
Vasodilation The widening of the lumen of blood vessels. 
 
VO2 max Maximal oxygen consumption. 
 
VO2 peak Peak oxygen consumption.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Background 
Chronic Heart Failure (CHF) is a pathophysiological syndrome whereby the 
heart fails to pump blood at a rate proportionate to the requirements of the 
metabolising tissues (Shave et al., 2007). CHF patients typically present with 
symptoms of fatigue, exercise intolerance, oedema and dyspnoea (Rees et al., 
2004). Until the late 1980s CHF was considered an absolute contraindication to 
exercise training (Rees et al., 2004). Common causes of CHF include previous 
myocardial infarction, chronic hypertension, dilated and hypertrophic 
cardiomyopathy, abnormalities of the heart valves and cardiac arrhythmias 
(Pollentier et al., 2010). CHF affects an estimated 800,000 (1.5%) people in the 
UK (British Society of Heart Failure, 2013). This number is expected to rise due 
to an ageing population and improved survival rates following myocardial 
infarction (British Society of Heart Failure, 2013). Poor exercise tolerance in 
patients with CHF has a multifactorial aetiology including:  left ventricular 
performance, peripheral arterial and muscle metabolic-histological changes and 
altered neurohormonal interactions between the periphery and the heart 
(Giannuzzi et al., 2001). Release of natriuretic peptides is caused by increases 
in preload and afterload due to the compensatory actions of the sympathetic 
nervous system and the renin-angiotensin-aldosterone system (Conraads et al., 
2004). The structural changes to the muscles and rises in circulating 
neurohormones is paralleled by a simultaneous increase in the degree of 
exercise intolerance (Gademan et al., 2007).  
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In addition to pharmacotherapy, exercise training is now recognised as a 
fundamental part of the holistic care of patients with systolic CHF (Carvalho and 
Mezzani, 2011; Smart, 2011), and is recommended by The European Society of 
Cardiology (Dickstein et al., 2008) and the National Institute for Health and 
Clinical Excellence (NICE) guidelines (2010). Exercise training improves the key 
symptoms of CHF (dyspnoea, fatigue and poor quality of life) through effects on 
the cardiopulmonary, vascular and musculoskeletal systems. Overall, these 
changes are collectively captured in an improved New York Heart Association 
(NYHA) classification of functional capacity (The Criteria Committee of the New 
York Heart Association, 1994). Furthermore exercise training has a positive 
influence on risk of hospitalisation, hospital re-admissions, morbidity and 
mortality (Normandin et al., 2013; Taylor et al., 2014).  
 
The current evidence base is biased (see Chapter 1), as CHF patients recruited 
to most of the studies (typically younger males without comorbidity) 
underrepresent the actual population of CHF patients referred to rehabilitation in 
the UK CR programmes (Rees et al., 2004; Davies et al., 2010; NACR, 2013; 
Taylor et al., 2014; British Society for Heart Failure, 2014). In delivering 
exercise rehabilitation, service demands and limitations also create practical 
and technical challenges to the utility of assessing fitness/function and 
prescribing exercise in ways commensurate with that performed in most of the 
published evidence. Areas relevant to this thesis, where there are limitations in 
existing evidence leading to questions being answered in the studies to follow, 
include: 
a) Translation of evidence into practice in terms of demographics and co-
morbidities. 
b) Technical, time and staff limitations in performing exercise assessments 
and interventions in ‘the real world’. 
 
Overview and rationale of thesis 
In light of the limitations found in the current evidence, this thesis initially 
reviews the existing evidence in relation to the utility and importance of the six-
minute walk test, Chester step test, plasma NT-proBNP levels, ventricular 
remodelling, pulse pressure, perceived QoL and the referral to and uptake of a 
standardised programme of exercise rehabilitation.  As current UK practice of 
CR is challenged in reflecting the demographics, programmes and protocols 
found within the existing evidence base it may not be surprising that the 
outcomes are not as adequately achieved in clinical practice. One recent study 
of rehabilitation in post-MI patients (The RAMIT trial, West et al., 2012) cast 
doubt over the ability of UK CR programmes to reduce mortality and morbidity 
or to increase QoL. However, the programme protocols and the “old” data from 
RAMIT clearly did not meet the recommended standards and core components 
(BACPR, 2012; Sandercock et al., 2013; Buckley et al.; BACPR 2013). 
 
In light of many years of personal observation and management of a heart 
failure rehabilitation service, corroborated by the questions raised in the 
literature review, the aim of this PhD was to perform a controlled study within a 
“real” clinically-based CR service for CHF patients. After addressing a number 
of underpinning technical issues around assessment parameters and 
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techniques, the key evaluation is presented in the final study of this thesis. The 
underpinning series of studies on technical issues have included four studies: 
 
 Study 1: The validity of a time-saving 2-minute practice walk test prior to 
undertaking a 6-minute walk test in patients with CHF 
 Study 2: The validity of a space-saving 4-inch step test in patients with 
CHF 
 Study 3: The kinetics of NT-proBNP following a moderate intensity 
exercise training session (i.e. acute exercise response) 
 
The final evaluation, Study 4, then applied the technical elements of the first 
four studies to evaluate the efficacy of exercise training on functionality, cardiac 
biomarkers, ventricular remodelling, QoL and uptake participation in a “real 
world” CHF rehabilitation service. Undertaken in a clinical environment, the 
studies have recruited patients with stable CHF, optimised on recommended 
CHF medication, that are representative of the clinical population in the UK 
(NACR, 2013).  
  
 
 
 
CHAPTER 1 
 
 
Review of Literature: Functionality, cardiac biomarkers and 
quality of life in heart failure rehabilitation 
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1.1 Introduction  
The existing evidence base for the efficacy of exercise training in patients with 
CHF demonstrates the improvements in functional capacity, natriuretic 
peptides, antiremodelling and QoL; there are also data which show the impact 
on hospital readmissions, mortality and morbidity (Piepoli et al., 2004; Davies et 
al., 2010; Taylor et al., 2014) as well as proving that exercise is safe (Rees et 
al., 2004). However, the early systematic reviews were based on small trials in 
patients who are not representative of the total population with CHF (Rees et 
al., 2004; Davies et al., 2010). It is apparent from the published research and 
systematic reviews that the demographic trends of the HF patients recruited into 
exercise training studies differ from those generally enrolled on CR exercise 
training programmes in the UK and in prevalence studies (British Society of 
Heart Failure, 2013). CHF patients participating in exercise training research 
tend to be younger males with few or no co-morbidities, suggesting the 
possibility of selection bias (Smart, 2011). This has been acknowledged by the 
professional bodies responsible for the production of the exercise training in HF 
guidelines; recognising that women, the elderly and minority groups are often 
excluded from clinical trials (Piepoli et al., 2011; McMurray et al., 2012).  
Indeed, the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise 
(HF-ACTION) study (O’Connor et al., 2009) – the largest (2,300 patients) 
exercise training study of HF patients to date – confirmed that exercise plays a 
beneficial role in the non-pharmacological treatment of relatively young (mean 
age 59 years) patients with CHF. The Cochrane Collaboration: Exercise based 
rehabilitation for heart failure (Review) from 2010 (Davies et al.) questioned the 
transferability of the research findings to the general HF population due to the 
age (mean age of 58 years) and gender (predominantly male) of the 
populations in the included studies. Moreover, 18 of the 20 studies included in 
the review cited significant co-morbidity as an exclusion criterion. The recent 
Cochrane Review by Taylor et al. (2014) included 33 randomised controlled 
trials (4740 participants) and the findings were consistent with the previous 
2010 Review. Data confirmed the important benefits of exercise-based 
rehabilitation and there was no evidence to suggest that patients with CHF are 
at risk of a cardiac event during exercise training. Furthermore, a small body of 
evidence indicated that exercise-based rehabilitation is cost-effective. But 
despite clinical guidelines supporting exercise-based rehabilitation for patients 
with CHF, the provision and uptake remains poor in this population (Taylor et 
al., 2014). 
 
Some of the key metrics and outcomes used in published studies to 
demonstrate the safety and efficacy of exercise training in CHF have some 
elements which require further evaluation, including: 
a. The value and precision of reporting the six-minute walk test (6MWT) 
distance alone and considerations for using other types of practical 
assessments (for example, step tests) for CHF populations. 
b. Levels of circulating BNP both in terms of acute responses to a single 
session of exercise and chronic changes over a period of training. 
c.  Evidence of left ventricle remodelling 
d.  The pulse pressure (PP) relationship with risk, functional capacity and 
related outcomes from training and  
e. Quality of life (QoL).  
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These questions, raised around the above elements, form the basis of this PhD, 
commencing with the critical review to follow. 
 
 
 
1.2 Assessing functional capacity in chronic heart failure (CHF) 
 
1.2.1 Introduction 
CHF research studies have invariably used maximal exercise tolerance testing 
to measure cardiopulmonary responses (e.g. peak VO2and ventilator exchange 
ratios) from which training intensity targets and programme outcomes are 
assessed. This is, however, not routine clinical practice in the UK (ACPICR, 
2009; BACPR 2012). Cardiac Rehabilitation (CR) practitioners adhere to 
professional standards and guidelines which currently recommend sub-maximal 
tests – in particular the 6MWT - to prescribe exercise, with the suggested heart 
rate training targets and training intensities being somewhat lower than those 
used in the reported trials (Davies et al., 2010). The validity and reliability of 
these sub-maximal exercise assessments to give optimum exercise prescription 
and physical activity advice for patients with CHF remain to be confirmed. 
Further questions regarding UK practice arise from the use of these sub-
maximal tests in addition to the practical constraints of time, space, finance, 
equipment and staffing. 
 
 
 
1.2.2 Effects of exercise training on six-minute walk distance in patients 
CHF 
In 1982 Butland et al. demonstrated that a six minute walk test (6MWT) could 
evaluate patients with chronic respiratory diseases (Faggiano et al., 2004).  
Performance on the 6MWT has since become a popular and useful clinical 
measure of functional capacity and endurance, aimed particularly at people with 
moderately severe impairment (ATS, 2002; Enright, 2003), and is widely used 
for measuring the response to therapeutic interventions for chronic heart failure 
(CHF); thus 6MWD is now used as an outcome measure for CHF-rehabilitation 
(Guazzi et al., 2009). It is predictive of mortality and morbidity outcomes; 
furthermore 6MWD correlates with activities of daily living and quality of life 
(Enright, 2003). Individuals walking less than 300 metres in 6 minutes are at the 
highest risk of adverse events (Bittner et al., 1993; Haass et al., 2000; Rostagno 
et al., 2003) with a one-year-mortality of up to 50% (Haass et al., 2000). 
 
Patients with CHF typically suffer exertional dyspnoea and fatigue (Pollentier et 
al., 2010), resulting in reduced exercise capacity (Shoemaker et al., 2012) and 
so the aim of exercise-based rehabilitation is to improve exercise tolerance with 
a corresponding reduction in symptoms. Peak oxygen consumption (peak VO2) 
is reduced in patients with CHF when compared with age-matched controls due 
to reduced exercise cardiac output response, reduced peripheral blood flow, 
skeletal muscle abnormalities and metabolic abnormalities similar to those seen 
in severe deconditioning and as a result of these changes muscle atrophy is 
also common in patients with CHF (Giannuzzi et al., 2001).  Breathlessness is 
frequently a prominent symptom during rapidly incremental protocols, and 
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fatigue often occurs during gradually incremented tests (Tavazzi et al., 2001). 
The 6MWT is considered a sub-maximal exercise test due to execution time, 
simplicity and greater acceptance by patients (Faggiano et al, 2004). Several 
studies have reported a correlation between peak VO2 measured at maximal 
exercise and the 6MWD in patients with CHF (Guyatt et al., 1985; Lipkin et al., 
1986; Riley et al., 1992; Cahalin et al., 1996; Roul et al., 1998; Morales et al., 
1999; Zugck et al., 2000; Green et al., 2001; Opasich et al., 2001; Myers et al., 
2006; Pulz et al., 2008 and Guazzi et al., 2009). The self-paced 6MWT thereby 
gives a more accurate representation of the ability of patients with CHF to 
perform sub-maximal activities of daily living (Riley et al., 1992). Statistically and 
clinically significant increases in 6MWD have been reported in several studies 
following exercise training (Table 1.1). In order to be considered as related to 
the intervention, the improvement in distance walked must be at least > 5% 
from baseline (Rostagno and Gensini, 2008); however, if the increase in 
distance is less than 10%, even with statistically significant results, the variation 
is quite possibly due to familiarisation (Opasich et al., 1998). Improvements in 
6MWD ranging from 30 m (Guyatt et al., 1985) to 90 m (Spertus et al., 2005) 
have been associated with a significant improvement in walk performance.  
 
Accuracy may be improved by the addition of demographic, anthropometric 
(height, weight, body mass index, body composition) and functional 
characteristics (Mandic et al. 2013). 
Table 1.1 Summary of studies included in Cochrane Review (Rees et al., 2004): effects of exercise training on 6MWD 
Study  Participants  Protocol  Key Findings 
Tyni-Lenne R, Gordon 
A, Sylven C. 
(1996) 
21 patients randomised 
Mean age 60 years 
100% male 
 
Endurance training 3 x 
per week for 8 weeks 
 
Treatment 1: Δ6MWD 56 m. 
Treatment 2: Δ6MWD 21 m. 
Control: Δ6MWD -7 m. 
Tyni-Lenne R, Gordon 
A, Jansson E et al. 
(1997) 
16 patients randomised 
Mean age 62 years 
0% male 
 
Endurance training 3 x 
per week for 8  
 
The distance ambulated during 6 minutes increased 
37 m (p <0.03). 
Gottlieb SS, Fisher ML, 
Freudenberger R et al. 
(1999) 
33 patients randomised 
Age 64 – 67 years 
88% male 
 
Aerobic exercise 3 x per 
week for 6 months  
 
6-minute walk increased by 194 ft/44.8 m (p < 0.05). 
Owen A and Croucher L 
(2000) 
22 patients randomised 
Mean age 81 years 
75% male 
Resistance training 1 x 
per week for 12 weeks  
 
 
There was a significant (p < 0.012) improvement in 
6MWD amounting to approximately 20%. 
 
Pu CT, Johnson MT, 
Forman DE et al. 
(2001) 
16 patients randomised 
Mean age 77 years 
0% male 
Resistance training 3 x 
per week for 10 weeks 
 
 
6MWD increased by 49 ± 14 m (13%) in the 
intervention group.  
Tyni-Lenne R, Dencker 
K, Gordon A et al. 
(2001) 
24 patients randomised 
Mean age 63 years 
54% male 
Resistance exercise 
training 3 x per week for 
8 weeks 
 
 
The distance walked during the 6MWT increased in 
the intervention group from 500 ± 64 m to 555 ± 59 
m (p < 0.002).  
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Study  Participants  Protocol  Key Findings 
McKelvie RS, Teo KK, 
Roberts R et al. 
(2002) 
181 patients 
randomised 
Mean age 66 years 
81% male 
Aerobic and resistance 
exercise 2 x per week 
for 3  
 
There was a significant increase in 6MWD 
compared with baseline at 3 months (p < 0 .01) for 
both exercise (+22 ± 5 m) and control (+15 ± 5 m) 
groups.  
A significant increase in 6MWD compared with 
baseline at 12 months (p < 0.05) was found for both 
exercise (+17 ± 8 m) and control (+20 ± 9 m) 
groups.  
 
Parnell MM, Holst DP, 
Kaye DM et al. 
(2002) 
21 patients randomised 
Age 53 – 57 years 
91% male 
 
Aerobic exercise 5 – 7 x 
per week for 8 weeks  
 
Exercise training significantly increased 6MWD (474 
± 27 to 547± 34 m; p = 0.008). 
 
 
 
 
 
1.2.3 Reproducibility and validity of the six-minute walk test (Table 1.2)  
In 1985 Guyatt el al. first validated the 6MWT for use with CHF patients and 
also reported the effects of encouragement on walking performance. Subjects 
undertook a maximal cycle ergometer test and a 6MWT was administered six 
times over a 12-week period. Their study of 18 patients with CHF and 25 
patients with chronic lung disease showed that reproducible results were 
achieved after the first two walks and that encouragement significantly improved 
walk test performance (p = 0.02); thus demonstrating that results of a 6MWT 
are reproducible when a standardised protocol is followed. A systematic review 
by Pollentier et al in 2010 extracted data from 14 trials to examine the ability of 
the 6MWT in determining functional capacity in patients with CHF. The authors 
reported on reproducibility of the 6MWT using data from 9/14 trials, validity from 
12/14 and predictive value of the 6MWT from 5/14. Sample size ranged from 14 
to 63 participants in the majority of trials, with 3 reporting sample sizes > 100 
participants. Many used maximal exercise testing in order to assess VO2 max: 
7/14 used a cycle ergometer, 6/14 used a treadmill and the shuttle-walk test 
was also used in several studies. One study that was included in the review 
examined the reproducibility and responsiveness to change of a 6MWT and a 
quality of life measure specifically in elderly patients with CHF (O’Keefe et 
al.,1998). The authors recruited 60 elderly patients with a mean age 82 years, 
and patients completed a 6MWT at baseline and at 3 to 8 weeks. An intraclass 
correlation coefficient (ICC) of 0.91 was reported for 24 patients with no change 
in cardiac status at review. In a large trial, involving over 1000 patients over the 
age of 60 years, Ingle et al. (2005) examined 1-year reproducibility of the 
6MWT, the sensitivity to self-perceived changes in symptoms of CHF and 
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patient numbers required for studies using the 6MWT. They used a 
questionnaire to assess CHF symptoms, and patients performed a baseline 
6MWT, with follow-up at 1 year. Seventy four patients who reported unchanged 
symptoms also had an unchanged 6MWD, with an ICC of 0.80. There was a 
negative correlation between change in symptoms and change in 6MWD (r = - 
0.55; p = 0.0001) in 423 patients who reported an improvement in symptoms, 
and a moderate inverse correlation (r = - 0.53; p = 0.0001) in 516 patients who 
reported a deterioration of symptoms. For all patients, regardless of symptom 
status, a high inverse correlation (r = - 0.75; p = 0.0001) was observed. The use 
of questionnaires in the studies by O’Keefe et al. (1998) and Ingle et al. (2005) 
could present bias due to their subjective nature. Nonetheless, the 6MWT did 
demonstrate reasonable reproducibility and responsiveness in elderly patients 
with CHF and change in 6MWD appeared to be sensitive to change in self-
perceived symptoms of CHF. However, Buckley (2011) has since demonstrated 
that the combined use of an ICC and Bland and Altman’s (1986) bias ± 95% 
limits of agreement (95%LoA) analysis concurrently highlight clinical and 
statistical significance and thereby confirm reliability, which is crucial in 
populations with a low functional capacity such as CHF patients. 
 
 
 
 
 
Table 1.2 Reproducibility and validity of the 6MWT 
Study  Participants  Protocol  Key Findings 
Guyatt, Sullivan, 
Thompson et al. 
(1985) 
 
 
 
 
18 patients with CHF 
25 patients with chronic 
lung disease 
34 male, 9 female 
Mean age 64.7 ± 8.3 
years 
6MWT administered six 
times over 12 weeks (2-
week intervals) 
Encouragement improved walk test performance (p 
< 0.02). 
Improvement in walk distance seen up to the third 
walk. 
Lipkin, Scriven, Crake, 
Poole-Wilson. 
(1986) 
26 patients with stable 
CHF 
Mean age 58 years 
NYHA II to III 
 
Maximal treadmill test to 
determine oxygen 
consumption and 6MWT 
Relation between maximum oxygen consumption 
and 6MWD was curvilinear. 
In patients with low maximum oxygen consumption 
6MWD varied considerably. 
In patients with high maximum oxygen consumption 
and normal subjects 6MWD varied very little. 
 
Riley, McParland, 
Stanford, Nicholls. 
(1992) 
16 patients with CHF 
Mean age 65.2 years 
NYHA II to IV 
14 male, 2 female 
Maximal treadmill test to 
determine VO2. 
3 x 6MWT with 
VO2measured 
6MWD correlated with peak VO2 as measured during 
treadmill test (r = 0.88; p < 0.001). 
6MWT good reproducibility (coefficient of variation = 
6.71). 
 
 
Faggiano, D’Aloia, 
Gualeni et al. 
(1997) 
26 patients with mild to 
severe heart failure 
24 male, 2 female 
Mean age 56 ± 11 years 
NYHA II to IV 
Symptom-limited cycle 
ergometer test. 
6MWT. 
VO2 also measured 
during 6MWT 
Peak VO2 during cycle test 15 ± 4ml/kg/min; during 
6MWT 12.9 ± 4.4ml/kg/min (p < 0.05). 
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Study  Participants  Protocol  Key Findings 
Roul, Germain, Bareiss. 
(1998) 
121 patients with CHF 
Mean age 59 ± 11 years 
 
Symptom-limited cycle 
ergometer test. 
6MWT x 2 in 40 of the 
121 patients 
 
Peak VO2 group 1 = 18.5 ± 4 vs group 2 = 13.9 ± 
4ml/kg/min (p = 0.0001). 
In patients who walked < 300m there was a 
significant correlation between distance and peak 
VO2 (r = 0.65; p = 0.011). 
 
O’Keefe, Lye, 
Donnellan, Carmichael. 
(1998) 
60 elderly patients with 
CHF 
Mean age 82 years 
22 male, 38 female 
NYHA I to IV 
Standardised 6MWT. 
CHF questionnaire 
(CHQ). 
Repeated in 45 patients 
at 3 to 8 weeks 
 
6MWT demonstrated good reproducibility (ICC 0.91) 
in the 24 patients who, at review, reported no 
change in cardiac status. 
Good correlation at baseline between 6MWD and 
CHQ score (r = 0.79). 
 
Zugck, Krüger, Dürr et 
al. 
(2000) 
113 patients with stable 
CHF 
Mean age 54 ± 12 years 
NYHA class 2.2 ± 0.8 
 
Symptom-limited cycle 
ergometer test. 
6MWT repeated in 10 
patients on 3 
consecutive days 
 
Moderate correlation between 6MWD and peak VO2 
(r = 0.69 in males, r = 0.59 in females; p = 0.001). 
 
Demers, McKelvie, 
Negassa, Yusuf. 
(2001) 
768 patients enrolled in 
the RESOLVD pilot 
study 
6MWT performed once 
at screening and twice 
at baseline, 18 weeks 
and 43 weeks 
 
ICC 0.90 at baseline, 0.88 at 18 weeks, 0.91 at 43 
weeks. 
Baseline 6MWD moderately inversely correlated to 
NYHA class (r = -0.43; p = 0.001). 
 
Ingle, Shelton, Rigby et 
al. 
(2005) 
1077 patients with CHF 
> 60 years 
NYHA class > II 
Questionnaire and 
baseline 6MWT. 
1-year follow-up 
 
74 patients with unchanged symptoms had 
unchanged 6MWD (ICC 0.80). 
 
Study  
 
Participants  Protocol  Key Findings  
Guimarães, Carvalho, 
Bocchi. 
(2008) 
23 males with CHF 
Mean age 50 ± 9 years 
NYHA class II to III 
Treadmill 6MWT guided 
by Borg scale (RPE 11 
– 13). 
Repeated. 
VO2 measured during 6th 
minute 
ICC at minute 6: VO2 r = 0.92, p < 0.0001; RQ < 1 r 
= 0.60, p = 0.004. 
6MWD highly reproducible between the 2 tests (0.20 
± 0.03 vs 0.20 ± 0.04 miles or 321 metres; r = 0.88, 
p<0.0001). 
 
Guazzi, Dickstein, 
Vicenzi, Ross. 
(2009) 
253 patients with 
systolic (n = 211) or 
diastolic (n = 42) heart 
failure 
Mean age 61.9 ± 10 
years 
NYHA class 2.2 ± 0.78 
 
2 x 6MWT on separate 
days. 
Symptom-limited cycle 
ergometer test.  
 
6MWD correlated with CPET variables. 
No significant difference in distance walked between 
survivors and non survivors (353.2 ± 95.8 vs 338.5 ± 
76.4m; p = NS). 
6MWD not associated with survival. 
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Table 1.3 Studies presenting concurrent changes in exercise-based controlled trial outcomes from the systematic review 
by Shoemaker et al. (2012) 
Author  Participants  6MWT Peak 
VO2 
QoL Summary  Included 
in the 
Cochrane 
Review 
2004/2014 
Tyni-Lenne et al. 
(1996) 
Intervention 1 n = 7 
Intervention 2 n = 7 
Control n = 7 
√ √ √ Intervention1: Δ6MWD 56 m 
Intervention 2: Δ6MWD 21 m 
Control: Δ6MWD -7 m 
√  
Tyni-Lenne et al. 
(1997) 
Intervention n = 8 
Control n = 8 
√ √  Intervention: Δ6MWD 37 m 
Control: Δ6MWD -2 m 
√  
Gottlieb et al. 
(1999) 
Intervention n = 11 
Control n = 14 
√ √ √ Intervention: Δ6MWD 44.8(59.1) m 
Control: Δ6MWD -18.6(40.8) m 
√ √ 
Tyni-Lenne et al. 
(2001) 
Intervention n = 16 
Control n = 8 
√ √  Intervention: Δ6MWD 55 m 
Control: Δ6MWD 0 m 
√  
Pu et al. 
(2001) 
Intervention n = 9 
Control n = 7 
√ √  Intervention: Δ6MWD 49 m 
Control: Δ6MWD -3 m 
√  
McKelvie et al. 
(2002) 
Intervention n = 90 
Control n = 91 
√  √ Intervention: Δ6MWD 22(47) m 
Control: Δ6MWD 15(48) m 
√ √ 
Parnell et al. 
(2002) 
Intervention n = 11 
Control n = 10 
√  √ Intervention: Δ6MWD 73 m 
Control: Δ6MWD -2 m 
√  
Van den Berg-Emons 
et al. 
(2004) 
Intervention n = 18 
Control n = 16 
√ √ √ Intervention: Δ6MWD 46 m 
Control: Δ6MWD 13 m 
  
Corvera-Tindel et al. 
(2004) 
Intervention n = 42 
Control n = 37 
√ √ √ Intervention: Δ6MWD 36 m 
Control: Δ6MWD -3 m 
  
Gary et al. 
(2004) 
Intervention n = 32 
Control n = 32 
√  √ Intervention: Δ6MWD 62 m 
Control: Δ6MWD 28 m 
  
Authors  Participants  6MWT Peak 
VO2 
QoL Summary  Included 
in the  
Cochrane 
Review 
2004/2014 
Yeh et al. 
(2004) 
Intervention n = 15 
Control n = 15 
√ √ √ Intervention: Δ6MWD 85 m 
Control: Δ6MWD -51 m 
  
Witham et al. 
(2005) 
Intervention n = 41 
Control n = 41 
√  √ Intervention: Δ6MWD 1 m 
Control: Δ6MWD 6 m 
 √ 
Austin et al. 
(2005) 
Intervention n = 100 
Control n = 100 
√  √ Intervention: Δ6MWD 44 m 
Control: Δ6MWD -6 m 
 √ 
Jonsdottir et al. 
(2006) 
Intervention n = 21 
Control n = 22 
√ √  Intervention: Δ6MWD 37 m 
Control: Δ6MWD 6 m 
 √ 
Brubaker et al. 
(2009) 
Intervention n = 30 
Control n = 29 
√ √ √ Intervention: Δ6MWD 56 m 
Control: Δ6MWD 47 m 
  
Davidson et al. 
(2010) 
Intervention n = 53 
Control n = 52 
√  √ Intervention: Δ6MWD 82 m 
Control: Δ6MWD 24 m 
 √ 
Kitzman et al. 
(2010) 
Intervention n = 26 
Control n = 27 
√ √ √ Intervention: Δ6MWD 51 m 
Control: Δ6MWD 15 m 
  
Gary et al. 
(2010) 
Intervention n = 17 
Control n = 18 
√  √ Intervention: Δ6MWD 38 m 
Control: Δ6MWD -60 m 
 √ 
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Table 1.4 Summary of 2MWT studies 
Study  Participants  Diagnosis  Protocol  Key Findings 
Butland, Pang, Gross et 
al. 
(1982) 
Study 1: 10 patients  
 
Study 2: 30 patients  
 
Study 3: 13 patients 
Chronic airflow 
obstruction due to 
chronic respiratory 
disease 
Study 1: Pacing during 
12-minute test 
Study 2: Comparison of 
two-, six- and 12-minute 
tests 
Study 3: Reproducibility 
of two-minute test 
 
Repeated  
 
Study 1: Patients walked 
further during first two 
minutes. 
Study 2: the three tests 
were highly correlated.  
 
 
Upton, Tyrrell and Hiller 
(1988) 
Group1: 32 female, 57 
male healthy children 
 
Group 2: 27 female, 23 
male children with 
Cystic Fibrosis 
Cystic Fibrosis Evaluation of two-
minute walk distance as 
an objective measure of 
exercise tolerance 
 
Repeated  
Group 1: significant 
improvement on second 
test (p < 0.01). 
 
Group 2: no significant 
difference between first 
and second walks. 
 
Brooks, Parsons, Hunter 
et al. 
(2001) 
290 patients Unilateral transtibial, 
unilateral transfemoral 
or bilateral amputations 
Validity and 
responsiveness of a 
2MWT in individuals 
with lower extremity 
amputation 
 
Repeated   
Significant improvement 
in two-minute walk 
distance at discharge and 
follow up compared with 
baseline (increase of 13.6 
± 19.9m at discharge, at 
follow up 41.2 ± 34m; p < 
0.001). 
 
Study  
 
Participants  Diagnosis  Protocol  Key Findings 
Brooks, Parsons, Jeng 
et al. 
(2004) 
122 patients Cardiac surgery (CABG) Validity and sensitivity of 
the 2MWT 
 
Repeated  
Two-minute walk distance 
reduced post operatively 
from 138 ± 26m to 84 ± 
33m (p < 0.001), but 
increased again at follow 
up to 151 ± 31m (p < 
0.0001). 
Kosak and Smith 
(2005) 
12 female, 6 male 
patients 
Stroke  Reliability and sensitivity 
to change of two-, six- 
and 12-minute walk test 
 
Repeated  
ICCs for two- and six-
minute walk tests 0.85 
and 0.78 respectively (p < 
0.0007). 
Correlations for 2- and 6-
minute walk tests were r 
= 0.997 
6MWD overestimated 
based on two minute 
assessment.  
Leung, Keung, Chan et 
al. 
(2006) 
8 female, 37 male 
patients 
COPD Reliability, validity and 
responsiveness of a 
2MWT in patients with 
moderate to severe 
COPD.  
 
High test-retest reliability 
for 2MWT. 
Significant correlations 
between 2MWT and 
6MWT. 
2MWT is a reliable and 
valid test for assessment 
of responsiveness 
following rehab in COPD. 
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1.2.4 Changes in 6MWT distance following training in CHF patients 
Statistically and clinically significant increases in 6MWD have been reported in 
several studies following exercise training. The first Cochrane Review of 
exercise based rehabilitation for heart failure by Rees et al. in 2004 (Table 1.1) 
and an update by Davies et al. in 2010 reported a weighted mean difference for 
the exercise intervention versus usual care of 41 m (95% CI -64.65 – 17.10). 
However, this distance only accounts for the differences between the 
intervention and the control groups. The degree of change that is considered to 
be clinically meaningful has not been well studied, and as stated above this 
could be anything from 30 m (Guyatt et al., 1985) to 90 m (Spertus et al., 2005). 
In addition, familiarisation with the test can influence final outcome tests, hence 
the need for a practice test. Analysis of change in the 6MWD and simultaneous 
change in other outcome measures would test the responsiveness of the 6MWT 
as a study endpoint more rigorously. In a review to determine the amount of 
change in the 6MWD (Δ6MWD) that was clinically meaningful in CHF patients, 
Shoemaker et al. (2012) analysed data from 13 studies reporting the ICC of the 
6MWT, and 18 studies using the 6MWT along with either aerobic capacity 
and/or quality of life (QoL). They used a novel approach for triangulating the 
Δ6MWD that should be regarded as clinically meaningful and concluded that a 
Δ6MWD of approximately 45 m exceeded measurement error and was 
associated with significant changes in either aerobic capacity and/or QoL (Table 
1.3). It is worth noting that studies examining 6MWD as an outcome measure 
have not reported changes in other measures of functional capacity. In patients 
with poor exercise capacity the 6MWD alone may not be sensitive enough to 
increases in functional capacity. It may be beneficial for CR programmes to 
examine differences in heart rate, for example, in combination with changes in 
6MWD (Buckley et al., 2010) and as such, this was examined further in Study 4 
(Chapter 5). 
 
1.2.5 Practice test of 6MWT 
Both in clinical practice and in research when using the 6MWT in CHF, a 
practice test is recommended to increase the reliability of the test by filtering out 
the influences of familiarisation on final outcome tests, as discussed in above 
(Opasich et al., 1998). Current recommendations suggest that patients need to 
perform a full practice test, but there is concern that this may induce significant 
fatigue and the need for rest stops. Patients with severe CHF may become 
exhausted after only a few minutes of exercise testing, therefore actual exercise 
capacity may be underestimated (Leung et al., 2006). The two-minute walk test 
(2MWT) was first proposed by Butland et al. in 1982 and was reported as being 
a valid test in COPD patients (no p value reported); its validity and 
responsiveness were later confirmed as further studies (Table 1.4) have shown 
that a 2MWT is a reliable, valid and sensitive test for the assessment of 
exercise capacity in patients with moderate to severe COPD (Leung et al, 
2006), neurologic impairment (Rossier and Wade, 2001), stroke (Kosak and 
Smith, 2005) and cardiac surgery (Brooks et al., 2004). The two-minute walk 
distance correlates well with longer walk tests (Butland et al., 1982; Upton et al., 
1988; Kosak and Smith, 2005; Leung et al., 2006). Interestingly, Leung et al. 
(2006) found small but significant differences in the end of test RPEs between 
2MWT and 6MWT in their study of 45 patients with COPD, indicating that the 
6MWT was more exhausting to perform than the 2MWT. Thus, pacing may be 
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different in a 2MWT compared with a 6MWT, as a patient who knew that a test 
was only going to last two minutes would probably walk faster and therefore 
further than a patient would walk in the first two minutes of a longer test. 
Furthermore, 6MWD is significantly overestimated based on the two minute 
walk distance (2MWD), possibly due to fatigue (Kosak and Smith, 2005); 
nonetheless, the 2MWT is considered a valid and time-efficient measure of self-
paced walking speed, less hampered by fatigue than longer walking tests.   
 
In conclusion the 6MWT is a simple test, requiring very little equipment. The test 
does, however, require considerable space, unlike the Chester step test (CST) 
which is an alternative test often adapted for use in CR. The CST has not yet 
been validated for use with CHF patients, however, and this was assessed 
further in Study 2 (Chapter 3b). The 6MWT shows good test-retest reliability 
across the literature particularly when a standardised protocol is used. The 
results, however, are not valid until after the first trial due to the learning effect 
of the test (Riley et al., 1992; Morales et al., 1999); hence the need for a 
practice test. However, this can prove time consuming within the restrictions of 
clinical time available for CR teams. The use of a two-minute practice test was 
questioned in Study 1 (Chapter 3a). The correlation of the 6MWT to peak VO2 is 
good; with a 6MWD < 450 to 490 m the 6MWT is between 83% and 91% 
accurate, respectively, in predicting peak VO2 (Pollentier et al., 2010). 
Furthermore, stronger correlations are observed in advanced CHF where 
patients have a reported 6MWD < 300 m or a VO2 < 10 ml/kg/min. As the 
6MWT is time limited it is difficult to predict VO2 in patients who are fitter and 
therefore have a higher VO2 max; thus the 6MWT is less accurate in predicting 
peak VO2in patients who have a 6MWD > 490 m (Pollentier et al., 2010).  
 
 
1.3 Effects of acute moderate-intensity exercise on B-type natriuretic 
peptides in patients with CHF 
 
1.3.1 Introduction 
Cardiac biomarkers are used in the diagnosis and risk stratification of patients 
with CHF (Kociol et al., 2010). Not only are biomarkers useful clinical tools, they 
often provide insight into the underlying pathophysiology. For example, evolving 
evidence suggests that CHF patients have increased levels of cardiac troponins 
(cTn) – biomarkers for myocardial injury. Levels are more marked in patients 
with advanced disease and decompensated HF, and these increased levels are 
associated with poor outcomes (Kociol et al., 2010). Several mechanisms for 
cTn release have been proposed but it is not yet clear whether myocardial injury 
is a cause or effect of decompensation.  
Plasma atrial natriuretic peptide (ANP) and brain or B-type natriuretic peptide 
(BNP) levels increase in patients with HF commensurate with the deterioration 
of clinical symptoms and haemodynamics; consequently, assays for these 
peptides are useful in the diagnosis and follow-up of cardiac patients (Clerico et 
al., 1998; Koglin et al., 2001). ANP is released from the atria and ventricles in 
response predominantly to atrial wall stress and stretch, leading to vasodilation 
and natriuresis. Together ANP and BNP form an integrated natriuretic peptide 
system with important compensatory (cardiovascular, renal and endocrinologic) 
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actions in patients with HF (Bonow, 1996). However, BNP is considered 
superior to ANP for distinction between normal subjects and patients with 
various degrees of HF (Cowie et al., 1997; Clerico et al., 1998). Being an 
antagonist of the renin-angiotensin-aldosterone system, brain or B-type 
natriuretic peptide (BNP) levels are raised due to pathologic (chronic heart 
failure) or physiologic (exercise) stimuli due to ventricular myocyte stretch 
resulting from increased central blood volume. The function of BNP is to reduce 
myocardial wall stress (Scharhag et al, 2008) in order to maintain homeostasis 
(Shave et al., 2007).  It achieves this by increasing vasodilation (reduces 
afterload) as well as being sympathoinhibitory and diuretic (reduces preload). 
The increase in BNP release consequent to endurance and/or strength training 
in healthy sedentary individuals is well known (Scharhag et al., 2008). These 
increases are short-term and are thought to be due to the physiologic stimulus 
of exercise (Shave et al., 2007) and not pathological in  nature; in fact Scharhag 
et al. (2008) suggest that they may have cytoprotective and growth-regulating 
effects on the athletes’ heart.  
 
1.3.2 Changes in BNP levels following acute exercise 
Exercise is known to stimulate secretion of atrial natriuretic peptide (ANP) levels 
in patients with CHF due to increases in atrial pressure and wall stretch (Kato et 
al., 2000).  Despite this, the effect of exercise on plasma BNP levels in CHF 
patients has received less attention. There are apparent differences in the 
tissue specific expression and production of ANP and BNP, and in the mode of 
release (Friedl et al., 1999). The release of BNP appears to be directly 
proportional to ventricular volume expansion and caused by a pressure-related 
release mechanism (Steele et al.,1997; Kato et al., 2000). Unlike ANP, which is 
contained in storage granules, BNP is synthesised in bursts (McNairy et al., 
2002) and is under constant renewal following production by the transcription 
and translation of messenger RNA (Shave et al., 2007). The half-life of BNP in 
plasma is 5 to 10 times longer than for ANP, which is cleared almost 
immediately thus BNP may not be subject to rapid changes. BNP has a half-life 
of approximately 20 minutes, and NT-proBNP has a half-life of 1 to 2 hours 
(Januzzi, 2006). The synthesis of BNP is considered to be regulated at a 
constant rate which would suggest that exercise of a short duration might not be 
sufficient to increase BNP secretion and thereby result in an increase in plasma 
levels (Kato et al., 2000). Koglin et al. (2001) examined the role of BNP in risk 
stratifying patients with CHF, which indicated that any observed increase in 
BNP of < 100 ng/l (or pg/ml) would signify that patients remain stable. A few 
studies involving vigorous exercise (Table 1.5) have reported increased plasma 
BNP levels in relatively young CHF patients (48 years to 62 years, and one 
study median age 66 years). These changes were associated with both left 
ventricular systolic dysfunction (LVSD) and diastolic dysfunction (Matsumoto et 
al., 1995; Steele et al., 1997; Kato et al., 2000; Mottram et al., 2004). 
Matsumoto et al. (1995) reported an increase of 157 ± 79 pg/ml in 7 patients 
with dilated cardiomyopathy (DCM), which was significantly larger than the 
increment seen in 9 patients with mitral stenosis (+17 ± 5 pg/ml, p < .05). 
Similarly, Steele et al. (1997) and Kato et al. (2000) reported that BNP levels 
increased significantly at peak exercise when compared with resting levels in 
their CHF groups. Interestingly, Steele et al. (1997) found that there was a 
significant reduction in LVEF from rest to peak exercise only in the control group 
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(p < .001), but the measurements did not relate to exercise performance. This 
suggests that changes in LVEF do not contribute to the increase in BNP levels 
as there would also have been an anticipated rise in BNP levels in the control 
group at peak exercise. The authors attributed this lower LVEF to the age of the 
subjects (65 – 69 years). In 2004, Mottram et al. recruited 26 patients with 
suspected diastolic heart failure (DHF). BNP increased with exercise from 48 ± 
57 to 74 ± 97 pg/ml (p = .007) and was higher in patients with elevated filling 
pressures at peak exercise. Though this increase was statistically significant it 
was not of clinical significance (Koglin et al., 2001). Patients with DHF had 
higher diastolic pressure at any given cardiac volume: there was a preserved 
end-systolic pressure-volume relationship but an abnormal diastolic 
relationship, which suggests that a pressure-related release mechanism is 
responsible for the observed increases in BNP levels (Steele et al., 1997; Kato 
et al., 2000).  
 In contrast to the above, Friedl et al. (1999), McNairy et al. (2002) and Krüger 
et al. (2004) reported that BNP levels do not increase with exercise (Table 1.5). 
Friedl et al (1999) assessed 16 patients with LVSD using a supine ergometric 
maximal stress test, where BNP levels were measured 3 minutes post exercise, 
with no significant increases (86 ng/l to 104 ng/l; +18 ng/l). McNairy et al. (2002) 
assessed 30 CHF patients (10 NYHA class I or II, 10 patients NYHA class III or 
IV and 10 controls), where BNP was assessed at rest and immediately after 
exercise on a cycle ergometer at 75% of maximum heart rate. BNP levels 
increased by 55% in the control group (with values remaining within normal 
limits), by 30% in the NYHA I-II group from 126 pg/ml to 164 pg/ml (+38 pg/ml) 
and in the NYHA III-IV group from 1712 pg/ml to 2019 pg/ml. Although the 
increase of 18% (+307pg/ml) in the NYHA III-IV group was not statistically 
significant, this increase would be considered significant clinically (Koglin et al., 
2001). Unlike other studies a further BNP measurement was performed one 
hour after exercise, with levels returning to within 5% of baseline. Krüger et al. 
(2004) similarly concluded that, in 37 patients with CHF, BNP could be safely 
used in an outpatient setting to accurately diagnose CHF without fear of a false-
positive result caused by exercise prior to testing, stating that significant 
changes in BNP levels in patients with CHF reflected changes in their clinical 
status and did not result from physical activity even when exercised to 
anaerobic threshold. Interestingly, in six of the 37 patients BNP levels 
decreased following exercise. A similar finding was reported only in one 
previous abstract by Lainchbury et al. (2001). Recently Normandin et al. (2013) 
compared high-intensity interval exercise with moderate-intensity continuous 
exercise and measured BNP levels before and at 20 minutes and 24 hours after 
exercise. In neither of these exercise training protocols nor at these two time 
points were there any increases in BNP. 
 
The studies referred to above have examined BNP responses only as far as 24 
hours post acute exercise. Despite the half-life, this may not be a sufficient 
duration in pathological populations, especially moving beyond 24 hours post 
exercise where the longer term effects of acute exercise could be determined. 
CR standards and guidelines recommend that patients attend supervised 
exercise sessions at least twice per week, but there is no supporting evidence 
regarding the number of days there should be between sessions and 
knowledge of changes in BNP data would provide novel insight into the short 
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and long term stress placed on the cardiovascular system by rehabilitation 
exercise and thus add to the debate about adequate recovery between 
sessions.  Changes in NT-proBNP levels in patients with CHF immediately after 
and up to 72 hours following moderate intensity exercise were examined in 
Study 3 (Chapter 4).
Table 1.5 Summary of studies investigating acute BNP response following exercise in CHF  
Study  Participants  Protocol  Key Findings 
Responders     
Matsumoto A, Hirata Y, 
Momomura S et al. 
(1995) 
7 patients with dilated 
cardiomyopathy (6 
male) 
 
Baseline BNP 221 ± 80 
pg/ml 
Symptom-limited cycle 
ergometer. 
BNP sample at rest and 
at peak exercise. 
 
Medication stopped 24 
hours prior to study. 
BNP increased > 100 pg/ml from 221 ± 80 pg/ml at 
rest to 378 ± 115 pg/ml at peak exercise; p < 0.01).  
Limitations: small numbers recruited, mean age very 
young and not representative of CHF population. 
Effects of stopping medication prior to testing 
unknown. 
 
Steele IC, McDowell G, 
Moore A et al. 
(1997) 
10 patients with 
compensated CHF 
10 normal controls 
 
Baseline BNP 42 pg/ml 
Symptom-limited cycle 
ergometer. 
BNP sample at rest, at 
peak exercise and at 3 
and 6 minutes of 
recovery. 
 
Medication not taken on 
day of testing. 
Significant rise in BNP at peak exercise compared 
with resting level in patients with CHF (42 pg/ml to 
46 pg/ml; p < 0.001) but no change in control group. 
At rest and at peak exercise BNP significantly 
negatively correlated with LVEF (p < 0.0001). 
Limitations: small number of patients recruited. 
Effects of stopping medication prior to testing 
unknown. Mean baseline BNP is low compared to 
other studies. 
Kato M, Kinugawa T, 
Ogino K et al. 
(2000) 
29 patients with LVD 
32 patients with CHF  
LVD group baseline 
BNP 124 ± 28 pg/ml 
CHF group baseline 268 
± 38 pg/ml 
Symptom-limited cycle 
ergometer. 
 
BNP sample at rest and 
at peak exercise. 
 
 
BNP levels increased significantly post exercise in 
all groups. 
 
Patients with CHF had progressively higher BNP 
exercise ratio, demonstrating that the augmented 
exercise BNP response exists early in the course of 
developing CHF. 
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Study  Participants  Protocol  Key Findings 
 
Mottram PM, Haluska 
BA, Marwick TH 
(2004) 
26 patients with 
hypertension and 
suspected DHF 
  
Baseline BNP levels not 
reported; however graph 
shows all baseline 
values < 1000 pg/ml 
Symptom-limited 
treadmill ETT (Bruce 
protocol). 
BNP sample at rest and 
within 1 minute of peak 
exercise. 
 
Medication not withheld.  
 
BNP increased with exercise from 48 ± 57 to 74 ± 97 
pg/ml; p = 0.001. 
Peak exercise BNP was higher in patients with 
elevated filling pressures at peak exercise (p = 
0.027). 
 
Limitations: unclear as to whether results of this 
study are transferable to general CHF population, 
including those with systolic dysfunction. 
Non-responders  
 
   
Friedl et al. 
(1999) 
16 patients with CHF  
Normal, age-matched 
controls 
 
Baseline BNP in CHF 
group 86 ng/l 
Symptom-limited supine 
cycle ergometer. 
 
Medication stopped 12 
hours prior to testing. 
 
BNP activity increased with exercise; however the 
increase was statistically not significant.  
 
Limitations: small number of patients recruited. 
Effects of stopping medication prior to testing 
unknown. 
McNairy M, Gardetto N, 
Clopton P et al. 
(2002) 
10 patients NYHA class 
I – II, 10 patients NYHA 
class III – IV  
10 healthy subjects 
 
NYHA I/II group 
baseline 126 ± 26 pg/ml 
NYHA III/IV group 
baseline 1712 ± 356 
pg/ml 
Cycle ergometer to 75% 
of calculated MHR. 
BNP sample at rest, 
immediately after and 1 
hour after completion of 
exercise test. 
 
Medication stopped on 
the day of testing. 
55% increase from baseline in BNP level (29 to 
45pg/ml) in control group. 
30% increase in BNP level (126 to 164 pg/ml) in 
NYHA I – II group. 
18% increase in BNP level (1712 to 2019 pg/ml) in 
NYHA III – IV group (an increase > 100 pg/ml). 
One hour after exercise BNP levels had returned to 
within 5% of baseline. 
 
 
Study  Participants  Protocol  Key Findings 
 
Krüger S, Graf J, Merx 
MW et al.  
(2004) 
37 patients with CHF 
 
Baseline BNP in 
patients with an 
observed increase 447 
± 432 pg/ml (mean age 
57 years) 
 
Baseline BNP in 
patients with an 
observed decrease 294 
± 369 pg/ml (mean age 
71 years) 
Symptom-limited cycle 
ergometer. 
BNP sample at rest, at 
peak exercise and at 1 
and 5 minutes of 
recovery time. 
 
Assumed medication 
not stopped. 
 
No significant change during exercise in control 
group. 
No significant change during exercise in CHF group, 
although levels increased in 84% of CHF patients 
and decreased in 16% compared to resting levels. 
 
Limitations: not reported whether medication was 
withheld prior to testing. 
 
 
 
 
 
 
Normandin E, Nigam A, 
Meyer P et al. 
(2013) 
 
 
 
 
 
 
 
 
 
 
20 patients with CHF 
and reduced LVEF 
 
Baseline levels not 
reported 
 
Patients performed 1 
session of high intensity 
interval exercise and 1 
of moderate intensity 
continuous exercise. 
 
BNP measured before 
exercise and 20 minutes 
and 24 hours after an 
exercise session. 
 
Assumed medication 
not stopped. 
No significant increase in BNP seen at 20 minutes 
and 24 hours post HIIE and post MICE. 
 
Limitations: not reported whether medication was 
withheld prior to testing. 
 
 
 
53 
 
1.4 Effects of exercise training on B-type natriuretic peptides in patients 
with CHF 
 
1.4.1 Introduction 
The specific use of BNP (a biomarker of myocardial dysfunction) testing is 
recommended in the current National Institute for Health and Clinical Excellence 
(NICE) Guidelines for Chronic Heart Failure (2010) and in the European Society 
of Cardiology Guidelines (Dickstein et al., 2008). BNP is a neurohormone 
released predominantly from ventricular myocytes in response to increased 
stretch (Shave et al., 2007) and pressure overload (Smart et al., 2011). It is also 
produced by cardiofibroblasts to elicit its anti-fibrotic effects in the heart 
(Mangiafico et al., 2013). BNP is produced and released as a 108 amino acid 
prohormone in a glycosylated form (pre-pro-BNP), which is gradually 
deglycosylated (cleaved) in the circulation into biologically active BNP and into 
inactive N-terminal (NT)-proBNP. NT-proBNP appears to be more stable than 
BNP (i.e. a larger half-life); hence it’s preferred use as an outcome measure in 
many studies (Smart and Steele, 2010). In stable ischaemic heart disease 
(IHD), BNP and NT-proBNP have proven accuracy and near identical test 
performance in ruling out severely reduced left ventricular ejection fraction 
(LVEF), prediction of all-cause mortality or HF regardless of the effects of age, 
gender and renal function - all factors known to affect BNP levels (Richards et 
al., 2006). 
 
BNP has powerful systemic cardiovascular actions, including a reduction in 
cardiac output and filling pressures which result from vasodilation and 
decreased venous return. As an antagonist of the renin-angiotensin-aldosterone 
system, the biological properties of BNP include natriuresis and 
sympathoinhibitory effects as well as vasodilation (Scharhag et al., 2008; 
Mangiafico et al., 2013). It has been suggested that the levels of natriuretic 
peptides denote the severity of heart failure and also reflect the body’s attempt 
to compensate and maintain homeostasis (Koglin et al., 2001). Adverse effects 
of increased BNP release may be reduced skeletal blood flow, cachexia, left 
ventricle and vascular remodelling, depression of cardiac contractility, oxidative 
stress, vasoconstriction and endothelial cell apoptosis (Anker and Von 
Haehling, 2004). 
 
CHF is also accompanied by an increase in other neurohormonal markers, such 
as noradrenaline/norepinephrine, renin, aldosterone, endothelin and arginine 
vasopressin) but evaluation of these markers is not considered of use for 
diagnostic or prognostic purposes, although they are of interest in research 
studies (ECS, 2008). 
 
1.4.2 Changes in BNP levels following exercise training in CHF patients 
As mentioned above, it was initially thought that the heart increases production 
and release of BNP during CHF as a compensatory mechanism in response to 
increased water retention and cardiac stress; indeed increasing levels of BNP 
have been associated with poor mortality and morbidity. However, Mangiafico et 
al. (2013) reported that recent studies using more sensitive technologies 
demonstrated that, in patients with CHF and high plasma BNP levels assessed 
by conventional assays, there was a lack of mature BNP in its active form. 
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Thus, despite the elevated levels of BNP seen in advanced CHF, sensitive 
mass-spectrometry indicated that less biologically active precursors and 
multiple degraded forms of BNP were actually present. This suggests that 
altered processing of BNP occurs in patients with CHF, resulting in a deficiency 
of the active hormone and thereby it’s compensatory and protective properties. 
Nonetheless, measurements of both BNP and NT-proBNP continue to be 
valuable in the diagnosis of suspected acute or CHF (Januzzi, 2006; NICE 
Guidelines, 2010; Cowie et al, 2010) and as a prognostic aid (Koglin et al., 
2001). Interventions to reduce levels of BNP are clearly of importance in the 
management of CHF, and evidence demonstrates that pharmacotherapy can 
reduce BNP as a result of the favourable effects on cardiac remodelling 
(McCullogh, 2004). BNP levels have been used to guide up-titration of HF 
medication (Januzzi and Troughton, 2013) and the effects of exercise training 
on BNP and NT-proBNP levels have also been reported. With such a 
magnitude of standard deviation it is essential that a standardised blood 
sampling technique is used otherwise the evidence might be considered 
equivocal (Smart and Steele, 2010).  In their meta-analysis (Table 1.6) Smart 
and Steele (2010) demonstrated that a course of exercise training did 
significantly lower BNP and NT-proBNP levels. Their systematic review of nine 
randomised, controlled studies included 250 exercise participants and 213 
controls. Most were males aged 53 to 75 years and New York Heart Association 
(NYHA) class I to III; six studies measured NT-proBNP and two studies 
measured both BNP and NT-proBNP. Seven of the selected individual studies 
demonstrated that moderate intensity exercise training reduced BNP and NT-
proBNP independent of frequency and duration of training, perhaps due to a 
blunted neurohormonal response at rest, resulting in a reduction in BNP release 
(Passino et al., 2006). Two studies (Butterfield et al., 2008; Jónsdóttir et al., 
2006) had low weekly energy expenditure of less than 400Kcal/week and 
changes in BNP and NT-proBNP were not significant, therefore the authors 
concluded from their analysis that a minimum weekly energy expenditure of 400 
to 450 Kcal may be required to elicit similar positive results. In contrast to most 
UK CR programmes, where a circuit based approach to exercise training is 
implemented, eight of the studies used cycling as the only mode of exercise. 
Training frequency was between two and seven sessions weekly for three to 
nine months, with an intensity between 50% and 70% of maximum peak VO2 
and a session duration of 30 to 50 minutes. The authors carried out a sensitivity 
analysis: for NT-proBNP this involved the removal of the studies that showed 
large standard deviation - and confirmed that changes in both BNP and NT-
proBNP remained statistically significant. When assessing study quality the 
authors found that six of the studies had standardised the timing of the blood 
sampling, but only two provided information regarding inter-assay coefficient of 
variation. Only two studies provided sufficient detail about randomisation, four 
studies provided information regarding recruitment and only three provided 
details of adherence to exercise training. In 2011 Smart et al. carried out an 
individual patient meta-analysis (Table 1.6) and confirmed previous findings, 
namely exercise training was able to modulate BNP and NT-proBNP levels in 
patients with CHF. Ten randomised, controlled studies met their inclusion 
criteria, with 313 exercise participants and 252 controls. Exercise and control 
group participants were matched at baseline in nine studies; 80% were male 
and were NYHA class I to III. As with the previous review, all but one study 
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used cycling as the mode of exercise training, the frequency was two to seven 
sessions per week, intensity 50 to 95% of peak VO2, 30 to 50 minutes per 
session and three to nine months duration. Mean weekly energy expenditure 
was 457 ± 135 Kcal per week. Again, two studies with the lowest energy 
expenditure did not show significant changes in BNP. Overall, compared to the 
control group, exercise training significantly lowered BNP (-28.3%, p < 0.0001) 
and NT-proBNP (-7.4%, p < 0.0001). After sensitivity analysis, removing two 
studies where energy expenditure could not be calculated, significant changes 
in BNP remained. To add further strength to the evidence base, the authors 
examined the relationship between changes in BNP/NT-proBNP and peak VO2. 
Baseline measures of peak VO2 and BNP (r = -0.33, p < 0.001) and NT-proBNP 
(r = -0.32, p < 0.001) were both inversely correlated. Correlation coefficients 
also showed inverse relationships between change in peak VO2 and change in 
BNP and NT-proBNP (r = -0.31, p < 0.0001; r = -0.21, p = 0.001 respectively) 
and change in BNP was also related to energy expenditure (r = -0.19, p = 0.04). 
Patients with a positive training response showed a greater reduction in both 
BNP and NT-proBNP (p < 0.003), and those with LVEF <34% showed greater 
improvements in BNP (p = 0.003) and NT-proBNP (p = 0.002).  Further data 
analysis suggested that the use of beta-blockade medication did not attenuate 
exercise training effects on BNP and NT-proBNP.  
 
As mentioned above, factors other than CHF can affect BNP levels therefore it 
is important to take these into consideration. BNP levels are influenced by age 
and gender (elderly females have higher BNP levels than males), by obesity, 
liver cirrhosis and renal failure (Peacock, 2002). Pharmacotherapy also affects 
BNP concentrations: ACE inhibitors and diuretics will reduce BNP levels (Cowie 
et al., 2003), but the effects of beta-blockade medication are equivocal with 
studies showing an increase, a decrease or no change (Olsson et al., 2007). 
Although third generation beta-blockers such as carvedilol lack the 
cardioselective (beta¹-selective) properties of second generation beta blockers 
such as bisoprolol and metoprolol, they do have additional vasodilating 
properties which could account for the varying results. Vasodilators and 
diuretics reduce plasma natriuretic peptide levels through reductions in 
intracardiac pressures (Davis et al., 2006); however, there is often an initial 
increase in circulating levels. Davis et al. (2006) demonstrated that the 
introduction of metoprolol increased plasma natriuretic peptides over several 
weeks/months without causing deterioration in CHF symptoms. There was a 
subsequent reduction that possibly reflected the attainment of reverse 
remodeling of the left ventricle. 
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 Table 1.6 Summary of studies: effects of exercise training on BNP levels 
Study  Participants  Protocol  Key Findings 
Responders    
Conraads VM, Beckers 
P, Vaes J et al.  
(2003) 
Non-randomised study 
 
Intervention group: 27 
patients with CHF 
 
Control group: 22 
patients unable to 
attend exercise 
programme 
 
Stable condition on 
medical therapy for at 
least 1 month prior  
Treadmill CPET. 
NT-proBNP level. 
Fasting blood samples 
taken between 8 and 
9am.  
 
Intervention: 4-months 
combined 
endurance/resistance 
training programme. 
3 x per week for 1 hour. 
 
NT-proBNP levels reduced significantly after training 
(2124 ± 397 pg/ml before, 1635 ± 304 pg/ml after; p 
= 0.015). 
 
 
 
Limitations: small sample size, non-randomised 
study, possibility of selection bias. 
 
 
 
Giallauria F, De Lorenzo 
A, Pilerci F et al 
(2006) 
Randomised study 
 
 
Intervention group: 22 
 
Control group: 22 
 
 
 
 
Cycle CPET. 
NT-proBNP levels. 
Fasting blood samples 
obtained between 8am 
and 9am.  
 
Intervention: 3-months 
endurance training 
programme. 
3 x per week. 
3 months training reduced NT-proBNP from 1498 ± 
438 pg/ml at baseline to 470 ± 375 pg/ml (p = 
0.003). 
 
 
Limitations: small sample size, predominantly male, 
mean age < 56 years, LVEF indicates only 
mild/borderline LVSD. 
Study  Participants  Protocol  Key Findings 
Passino C, Severino S, 
Poletti R et al 
(2006) 
Randomised study  
 
 
Intervention group: 44 
 
 
Control group: 41 
 
 
Stable condition on 
optimal medical therapy 
  
Cycle CPET. 
Echocardiography. 
Quality of life 
questionnaire. 
BNP and NT-proBNP 
levels.  
 
Intervention: 9-months 
endurance (cycling) 
training programme. 
Minimum 3 x per week. 
Significant changes in baseline BNP (187 ± 29 ng/l) 
compared with post exercise BNP (123 ± 23 ng/l; p < 
0.01) and NT-proBNP (baseline 1,370 ± 234 ng/l, 
post exercise 929 ± 206 ng/l; p < 0.05). 
 
 
Limitations: The study recruited predominantly 
males, under the age of 65 years. 
 
 
 
Sarullo FM, Gristina T, 
Brusca I et al. 
(2006) 
Randomised study  
 
Intervention group: 30 
 
Control group: 30 
 
Stable condition on 
medical therapy in the 3 
months before the study  
 
 
 
Cycle CPET. 
Echocardiography. 
NT-proBNP levels.  
Quality of life 
questionnaire. 
 
Intervention: 3 months 
endurance (cycling) 
training programme. 
3 x per week for 30 
minutes, 
60 to 70% of VO2 peak. 
NT-proBNP levels decreased significantly in the 
exercise group compared with baseline (baseline 
3376 ± 3133 pg/ml, post training 1434 ± 1673 pg/ml; 
p = 0.0001). 
 
Limitations: mean age for both the intervention 
group and the control group < 55 years therefore not 
necessarily representative of patients attending 
routine UK-based cardiac rehabilitation 
programmes. 
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Study  Participants  Protocol  Key Findings 
Passino C, Del Ry S, 
Severino S et al  
(2008) 
Randomised study  
 
Intervention group: 71 
 
Control group: 19 
 
Stable systolic heart 
failure, optimal medical 
treatment 
 
 
CPET. 
Echocardiography. 
BNP levels. Blood 
samples obtained at rest 
between 8am and 9am. 
 
Intervention: 9 month 
home based endurance 
(cycling) training 
programme. 
3 x per week for 30 
minutes, at 65%of VO2 
peak. 
 
BNP decreased significantly in the exercise group 
from 179 ± 23 ng/l at baseline to 129 ± 19 ng/l (p < 
0.001) post training. 
 
 
Limitations: low prevalence of females in the study 
population.  
 
 
 
Rengo G, Pagano G, 
Parisi V et al. 
(2014) 
Non randomised study 
No control group 
 
 
221 patients completed 
an exercise programme 
 
Stable symptoms for 1 
month, on optimal 
medical therapy apart 
from beta blockers. 
Existing co-morbidities 
Cycle CPET. 
6MWT. 
NT-proBNP. Fasting 
blood samples obtained 
at rest between 8am 
and 9am. 
Quality of life 
questionnaire. 
 
Intervention: 3 months 
structured exercise 
training. 
2 - 3 x per week. 
NT-proBNP reduced from 2111.4 ± 1145.6 pg/ml at 
baseline to 1532 ± 851.5 pg/ml post training (p < 
0.0001). 
 
Limitations: non randomised, no control group. Low 
use of beta blockers reported. 
 
 
 
Study  Participants  Protocol  Key Findings 
Non responders  
 
   
Jónsdóttir S, Anderson 
KK, Sigurðsson AF, 
Sigurðsson SB 
(2006) 
Randomised study  
 
Intervention group: 21 
patients 
 
Control group: 22 
patients  
 
Previously hospitalised 
due to heart failure 
Cycle CPET. 
6MWT. 
Muscle strength test. 
ANP and BNP levels.  
Echocardiography. 
Quality of life 
questionnaire. 
Rehospitalisation. 
 
Intervention: 5-months 
combined 
endurance/resistance 
training programme. 
2 x per week. 
 
No significant difference in BNP levels post training. 
 
Limitations: small sample size, only included 
patients who were able to complete a symptom-
limited exercise test therefore results may not be 
representative of all CHF patients. 
 
 
 
Butterfield JA, Faddy 
SC, Davidson P and 
Ridge B 
(2008) 
Randomised study 
 
Intervention group: 13 
 
Control group: 6 
 
Subgroup recruited from 
the St. George Living 
with Heart Failure study 
  
6MWT. 
BNP levels. Blood 
samples obtained at rest 
between 2pm and 3pm. 
Quality of life 
questionnaire. 
No significant difference in BNP levels post training. 
 
Limitations: small sample size of 14 males and 5 
females.  
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Study  Participants  Protocol  Key Findings 
Nilsson BB, Westheim 
A, Risberg MA et al. 
(2010) 
Randomised study  
 
Intervention group: 39  
 
Control group: 39 
 
Stable condition for 4 
weeks on optimal 
medical therapy.  
Cycle CPET. 
6MWT. 
NT-proBNP. Fasting 
blood samples obtained 
at rest between 8am 
and 9am. 
Quality of life 
questionnaire. 
 
Intervention: 4 months 
aerobic interval training 
programme, including 3 
intervals of high 
intensity (15 – 18 on the 
Borg Scale). 
2 x per week for 50 
minutes. 
 
 
 
 
 
 
 
 
 
No significant changes from baseline to post 
exercise. 
 
Limitations: relatively small sample size. The study 
included patients with signs of heart failure but 
preserved LVEF (> 40%). 
 
 
 
Study  Participants  Protocol  Key Findings 
Meta-analyses and 
reviews 
 
   
Smart NA and Steele M 
(2010) 
Evidenced based 
analysis of benefits of 
exercise on natriuretic 
peptide expression 
Systematic search for 
randomised controlled 
trials examining the 
effects of exercise 
training (aerobic and/or 
resistance) on BNP 
and/or NT-proBNP. 
9 trials met the eligibility 
criteria. 
 
Individual patient data 
for 565 patients. 
Exercise training with a weekly expenditure of more 
than 400 Kcal reduced BNP (mean difference -79 
pg/ml, 95% CI  -141 to -17 pg/ml, p = 0.01) and NT-
proBNP (mean difference -621 pg/ml, 95% CI -844 
to -398 pg/ml, p < 0.00001). 
 
 
Limitations: Patients recruited to the included studies 
were mostly male (50 – 91%); mean age range 53 to 
75 years. 
 
 
 
Smart NA, Meyer T, 
Butterfield JA et al 
(2011) 
Evidenced based 
analysis of benefits of 
exercise on natriuretic 
peptide expression 
Meta-analysis of the 
effect of exercise 
training on BNP 
expression in heart 
failure.  
10 trials met the 
eligibility criteria. 
 
Individual patient data 
for 565 patients. 
 
Exercise training reduced BNP (-28.3%, p < 0.0001) 
and NT-proBNP (-37.4%, p < 0.0001). 
Change in BNP (r = -0.31, p < 0.0001) and NT-
proBNP (r = -0.22, p < 0.0001) were correlated with 
peak VO2 change. 
 
 
Limitations: 80% of the patients recruited to the 
included studies were male, mean age of 60 years 
(62 years in control group). 
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1.4.3 The link between BNP and remodelling of the left ventricle 
 Left ventricle remodelling is a process characterised by changes in wall 
thickness and enlargement of the left ventricle cavity (Giallauria et al., 2006). 
BNP and NT-proBNP levels correlate with left ventricular end-diastolic pressure 
and impaired LVEF (Rengo et al., 2014). Elevated end-diastolic pressure is 
linked closely with dyspnoea in patients with CHF (McCullough, 2004). It is 
therefore unsurprising that levels also correlate with heart failure severity and 
NYHA class (Sakurai et al., 2003) and with outcomes (Doust et al., 2005). 
Several studies investigating the effect of exercise training on BNP and NT-
proBNP levels have found a reduction in post training natriuretic peptide levels 
and a corresponding increase in LVEF (Passino et al., 2006; Passino et al., 
2008; Rengo et al., 2014), a reduction in end-diastolic volume (EDV) (Conraads 
et al., 2004; Passino et al., 2006) and an increase in E-wave and E/A ratio 
(Conraads et al., 2004; Giallauria et al., 2006). In contrast, Sarullo et al. (2006) 
found no change in LVEF or in the diameter of the left ventricle despite a post 
exercise training reduction in NT-proBNP levels. And although the NT-proBNP 
levels remained unchanged following HIIT in their study, Nilsson et al. (2010) 
found an inverse correlation between NT-proBNP and LVEF. Their study 
included CHF patients with preserved ejection fraction; data from these patients 
could have skewed the overall results and unfortunately the authors failed to 
complete a sub-group analysis. 
 
From the results of published research studies and meta-analyses it appears 
that exercise training competes with the pathophysiologic afferent stimuli and 
mechanisms responsible for many of the signs and symptoms of the failing 
heart, thereby complimenting pharmacotherapy (Gaderman et al., 2007) to 
reduce circulating plasma BNP levels. Study 4 (Chapter 5) examined the effect 
of moderate-intensity exercise training, following current UK guidelines, on 
circulating NT-proBNP levels in CHF patients who were optimised on beta-
blockers and ACE inhibitors. 
 
 
1.5 Effects of exercise training on remodelling of the left ventricle in 
patients with CHF 
 
1.5.1 Introduction 
Patients often remain symptomatic even when on optimum CHF medication 
(Giannuzzi et al., 2003). Left ventricle remodelling is significant in the 
progression of HF and involves several factors, including haemodynamic and 
neurohormonal derangement. Remodelling is characterised by changes in left 
ventricle dimensions and continues long after healing following acute 
myocardial infarction (AMI) (Giallauria et al., 2008). The term remodelling, 
initially seen following AMI, has since extended to cardiomyopathies of non-
ischaemic origin (Pieske, 2004). There is progressive chamber enlargement 
and deterioration in “pump” function as a result of increased haemodynamic 
load and neurohormonal stress (Haykowsky et al., 2007). End-diastolic volume 
(EDV) and end-systolic volume (ESV) increase; there is wall thinning and a 
change in left ventricle shape, usually accompanied by a reduction in LVEF. 
This results in worsening systolic and diastolic function, development of mitral 
regurgitation and increased incidence of arrhythmias (Pieske, 2004).  
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1.5.2 Remodelling following exercise training in CHF patients 
Meta-analysis data have shown that aerobic exercise training improves LVEF, 
EDV and ESV in patients with stable CHF due to systolic dysfunction 
(Haykowsky et al., 2007; Chen et al., 2012). The effects of combined aerobic 
and resistance training or isolated resistance training remain inconclusive. 
Although resistance training is not associated with improvements in left 
ventricular remodelling, it does not appear worsen it. The weighted mean 
difference (WMD) in LVEF from 9 trials, and the EDV and ESV from 5 trials in 
the meta-analysis by Haykowsky et al. (2007) was significantly different 
following aerobic training (Table 1.7). The use of beta-blockers in the included 
studies was low and the number of studies examining the effects of exercise 
training on EDV and ESV was small (7 in total). The subsequent meta-analysis 
by Chen et al. in 2012 (Table 1.7) included 8 new randomised controlled trials, 
with 15 trials in total (813 patients; 425 in the exercise group and 338 in the 
control group).  As with many studies recruiting patients with CHF, the study 
populations included relatively young patients (mean age ranged from 54 to 75 
years), who were predominantly male. Twelve of the included studies examined 
the effects of aerobic exercise training at an intensity between 60% and 80% of 
VO2 peak. Only three studies examined the effects of combined aerobic and 
strength training and one examined strength alone, which may account for the 
inconclusive results when data were pooled in meta-analyses. The general 
outcome of this meta-analysis was in accordance with that of Haykowsky et al. 
(2007). Aerobic exercise training was associated with a significant increase in 
LVEF (standardised mean difference (SMD) = 0.44; 95% CI 0.28 to 0.61), with 
long-term (≥6 months) aerobic training achieving superior results to short-term 
training. Overall, exercise training was not associated with an improvement in 
EDV and ESV; however aerobic training alone led to significant improvements 
in both EDV (SMD = -0.33; 95% CI -0.49 to -0.16) and ESV (SMD = -0.40; 95% 
CI -0.57 to -0.23). Again, long-term (≥6 months) aerobic training had a greater 
effect on EDV and ESV but there was no evidence of benefit with short-term 
training. 
 
Included in the meta-analysis by Chen et al. (2012) were data from Wisløff et 
al.’s study (2007) which demonstrated that HIIT at 95% of maximal heart rate 
elicited greater improvements in systolic function. They recruited 27 elderly 
patients (75.5 ± 11.1 years) with CHF following AMI and randomised them into 
3 groups: HIIT, moderate continuous training (MCT) and a control. 12-weeks of 
HIIT induced reverse remodelling, but there was no significant difference in the 
MCT or control groups. Following HIIT, left ventricle EDV and ESV reduced by 
18% and 25% respectively (p < 0.01) and LVEF  increased from 28 ± 7% to 38 
± 10% (p < 0.01). There was a corresponding 40% reduction in NT-proBNP 
levels (p < 0.02), which further reflects the effectiveness of HIIT in modifying 
remodelling. The authors suggest that HIIT has an effect on EDV and ESV 
similar to that of 3-months of cardiac resynchronisation therapy and an effect on 
LVEF similar to that of combined treatment with ACE inhibitors and beta-
blockers. Diastolic function also improved significantly following HIIT 
demonstrated by an improved E/Ea ratio which suggests a reduction in filling 
pressure. Malfatto et al. (2009) also found evidence of improved diastolic 
function in their study, reporting improved left ventricular diastolic stiffness.  
69 
 
Giannuzzi et al. (2003) were first to investigate the anti-remodelling effects of 
long term (>6 months) exercise training in patients with stable CHF. They 
recruited 90 patients to their multicentre study, and randomised them into a 6-
month exercise training programme or a control group. In the exercise group 
91% of patients were prescribed ACE inhibitors, but only 22% were taking beta-
blockers. The percentage taking beta-blockers was actually higher than in 
previous studies, and was equal between the 2 groups. Therefore the benefits 
seen following exercise training were in addition to those elicited by prescribed 
medication. After six months of moderate intensity exercise training EDV and 
ESV had reduced in the intervention group (EDV from 142 ±  26 ml/m² to 135 ± 
26 ml/m², p < 0.0006; ESV from 107 ± 24 ml/m² to 97 ± 24 ml/m², p < 0.05) but 
had increased significantly in the control group. LVEF also increased by 16% 
(25 ± 4% to 29 ± 4%; p < 0.001) in the intervention group but was unchanged in 
the control group. The authors suggested that the significant decrease seen in 
resting blood pressure and sub-maximal rate pressure product in the exercise 
group may have favourably affected LV wall tension, which could have 
attenuated the abnormal remodelling process. In 2008, Giallauria et al. found 
similar results in 30 post infarction patients with moderate LVSD following a 6-
month exercise training programme. Patients enrolled into this study were, 
again, relatively young – in the intervention group the mean age 56 ± 3 years, 
patients were predominantly male (73%) and had a mean LVEF 42 ± 11%. 
Nonetheless exercise training resulted in a 9% (p < 0.001) reduction in left 
ventricle end-diastolic volume index (LVEDVI) and a 71% (p < 0.001) reduction 
in circulating NT-proBNP. E-wave and E/A ratio increased following training, 
suggesting an exercise-induced decrease in left ventricle wall stress. This is 
confirmed by the observed correlation between the decrease in NT-proBNP and 
the change in left ventricle volumes and by the inverse correlation between 
changes in NT-proBNP and changes in E-wave. However, it appears that CHF 
medication was still being titrated to the maximal dose during the study, 
therefore the effects of medication on the observed improvements cannot be 
ruled out. Subsequent studies have since confirmed these results as referred to 
above in the meta-analysis by Chen et al. (2012) and as detailed in Table 1.7. 
Suggested mechanisms for the anti-remodelling effects of aerobic exercise 
training seen in published studies include reduced sympathetic tone and 
decreased resting circulating neurohormones, thereby counteracting the 
possible deleterious effects of neurohormonal activation seen in CHF. Improved 
sympathovagal balance combined with a decrease in vasoconstrictive 
neurohormones will lead to a reduction in vascular load which may attenuate 
left ventricle remodelling. Increased LVEF seen after a period of aerobic 
exercise training is most likely due to enhanced preload, myocardial contractility 
and vascular reserve (Haykowsky et al., 2007).  
 
In summary, data demonstrate that long-term aerobic training (≥6 months) of 
moderate to high intensity reverses left ventricular remodelling in clinically 
stable patients with CHF; these beneficial effects are supplementary to 
pharmacotherapy. In Study 4 (Chapter 5) echocardiography studies were used 
to examine changes in left ventricular modelling in a sub-group of patients from 
the cohort.  
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Table 1.7 Summary of studies: effects of exercise training on remodelling 
Study  Participants  Protocol  Key Findings 
Responders    
Hambrecht R, Gielen S, 
Linke A et al. 
(2000) 
Randomised study 
 
Intervention group: 36 
Control group: 37 
 
Clinically stable for 3 
months 
Intervention: 2 weeks – 
exercised in hospital 4 
to 6 times daily. On 
discharge from hospital 
patients exercised daily 
for 20 minutes for 6 
months. 
Resting LVEF % increased from 30 ± 8 to 35 ± 8 (p 
= 0.003). 
Left ventricle EDD reduced by 3 ± 6 mm (p < 0.001). 
Left ventricle ESD reduced by 5 ± 7 mm (p < 0.001). 
EDV reduced by 22 ± 53 ml (p = 0.008) and ESV by 
24 ± 36 ml (p = 0.009). 
Limitations: no females, the mean age of 55 years is 
relatively young and the use of beta-blockers was 
low. 
Giannuzzi P, Temporelli 
PL, Corrà U and 
Tavazzi  L for the ELVD-
CHF Study Group 
(2003) 
Randomised study 
 
Intervention group: 45 
Control group: 45 
 
Stable on optimal 
medication for 3 months 
Intervention: 6 month 
supervised cycle 
training programme. 
 
EDV and ESV had reduced in the intervention group 
(EDV from 142 ±  26 to 135 ± 26, p < 0.0006; ESV 
from 107 ± 24 to 97 ± 24, p < 0.05) but had 
increased significantly in the control group. 
LVEF % increased from 25 ± 4 to 29 ± 4 (p < 0.001). 
No change in the control group. 
Limitations: Young patients, predominantly men. 
Passino C, Severino S, 
Poletti R et al. 
(2006) 
 
 
 
 
 
Randomised study  
 
Intervention group: 44 
Control group: 41 
 
Stable condition on 
optimal medical therapy 
  
Intervention: 9-months 
cycling. Minimum 3 x 
per week, 30 minutes 
cycling at 60 rpm.  
 
 
 
 
Mean LVEF % increased to 38 ± 2 (p < 0.01) post 
training. No increase in the control group. 
EDV and ESV normalised for body surface area 
(EDVi and ESVi) reduced significantly (EDVi from 
111 ± 8 ml/m² to 96 ± 6 ml/m², EDVi from 72 ± 6 
ml/m² to 58 ± 5 ml/m²; p < 0.05). 
Limitations: The study recruited predominantly 
males, under the age of 65 years. 
Study 
 
Participants 
 
Protocol Key Findings 
 
Conraads VMA, 
Vanderheyden M, 
Paelinck B et al. 
(2007) 
Randomised study 
 
Intervention group (with 
CRT): 8 
Control group (No CRT): 
9 
 
Clinically stable on 
optimum medication for 
1 month 
Intervention: ambulatory 
exercise programme 3 x 
per week for 1 hour (50 
minutes cycling/walking) 
for 5 months.  
Both groups benefitted equally in terms of LV 
remodelling – LVEDD and LVESD diameters were 
reduced and LVEF % was significantly increased. 
Limitations: small number of patients enrolled to 
each group was small. 
 
 
Klecha A, Kawecka-
Jaszcz K, Bacior B et al. 
(2007) 
Randomised study  
 
Intervention group: 25 
Control group: 25 
 
Stable condition on 
optimal medical therapy 
for at least 6 weeks 
Intervention: 3 x per 
week for 6 months; 25 
minutes cycling at a 
maximum of 80% of the 
predicted heart rate at 
peak VO2. 
There was no significant change in the LV although 
there was a trend towards an improvement in LVEF 
% (27.4 ± 5.7 to 30.2 ± 7.8) and EDV (ml/m²) (122.6 
± 20.1 to 114.8 ± 19.3). 
Limitations: due to the restricted inclusion and 
exclusion criteria the population recruited in this trial 
may not be representative of a typical clinical 
population attending cardiac rehabilitation. 
Wisløff U, Støylen A, 
Loennachen JP et al.  
(2007) 
Randomised study 
 
HIIT intervention: 9 
MCT intervention: 9 
Control: 9 
 
All patients stable on 
optimal medication 
HIIT: 90 – 95% peak HR  
 
MCT: 70 – 75% peak 
HR  
Following HIIT left ventricle EDV and ESV reduced 
by 18% and 25% respectively (p < 0.01), LVEF % 
increased from 28.0 ± 7.3 to 38.0 ± 9.8 (p < 0.01) 
and Ea improved by 49% (p < 0.01) and the E/A 
ratio by 15% (p = 0.05).  
Both HIIT and MCT reduced E/Ea by 26% (p = 
0.001) and 15% (p = 0.043). 
Limitations: small number of patients in each group. 
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Study  Participants  Protocol  Key Findings 
Giallauria F, Cirillo P, 
Lucci R et al. 
(2008) 
Randomised study 
 
Intervention group: 30 
Control group: 31 
 
Intervention: 6 month 
supervised cycle 
training programme. 
3 x per week for 30 
minutes, at 60 - 70% of 
VO2 peak. 
Following training E-wave increased (pre training 
59.5 ± 6.3, post training 65.2 ± 6.6; p < 0.001), E/A 
ratio also increased (pre training 0.98 ± 0.1, post 
training 1.22 ± 0.2; p < 0.001). 
LVEDVI decreased following training (pre training 
107.3 ± 18.8, post training 97.4 ± 17.9; p < 0.001). 
Limitations: the study involved relatively young 
patients, predominantly men. It appears that CHF 
medication was still being titrated to the maximal 
dose during the study. 
Malfatto G, Branzi G, 
Osculati G et al. 
(2009) 
Randomised study 
 
Intervention group: 27 
Control group: 427 
 
No change in 
pharmacological 
treatment allowed  
Intervention: cycle or 
treadmill x 40 minutes, 3 
x per week for 3 
months. 
No significant change in LVEF % or EDV following 
exercise training. 
 
E/A reduced from 1.59 ± 0.08 to 1.11 ± 0.59 (p < 
0.02). 
 
Palevo G, Keteyian SJ, 
Kang M and Caputo JL. 
(2009) 
Randomised study 
 
Intervention group: 10 
Control group: 6 
 
 
 
 
Intervention: 8-weeks of 
strength training, 3 
sessions per week. 
There was a significant improvement in LVEF % (32 
± 12 pre training to 37 ± 10 post training, p < 0.05). 
 
There was a slight (NS) increase in EDV, and a 
slight (NS) reduction in ESV. 
 
Limitations: small sample size of 16 subjects (1 
female). 
 
Non-responders    
Belardinelli R, Georgiou 
D, Cianci G and Purcaro 
A 
(1999) 
Randomised study 
 
Intervention group: 50 
Control group: 49 
 
All patients stable for at 
least 3 months 
 
Intervention: 3 x per 
week cycling for 8 
weeks at 60% of VO2 
peak followed by a 12 
month maintenance 
programme  
No significant change in LVEF, EDV or ESV. 
 
Limitations: mainly males with ischaemic aetiology. 
 
 
McKelvie RS, Teo KK, 
Roberts R et al. 
(2002) 
Randomised study 
 
Intervention group: 90 
Control group: 91 
 
Intervention: 3-month 
supervised exercise 
training programme 2 x 
per week. Followed by 9 
months of home-based 
exercise training  
 
No significant changes seen in LVEF, EDV and 
ESV. 
 
 
Myers J, Wagner D, 
Schertler T et al. 
(2002) 
 
 
 
 
 
 
 
 
 
 
Randomised study 
 
Intervention group: 12 
Control group: 12 
 
 
 
 
 
 
 
 
 
Intervention: 5 x 45 
minute supervised 
cycling per week for 2 
months, at 60 – 80% of 
VO2 max 
 
 
 
 
 
 
 
 
There was no significant change in LVEF, EDV or 
ESV. 
Increased relaxation velocity suggests an 
improvement in diastolic function. 
Limitations: short training period of 2 months and 
small number of patients in each group. 
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Study 
 
Participants Protocol Key Findings 
Klocek M, Kubinyi A, 
Bacior B and Kawecka-
Jaszcz K 
(2005) 
Randomised study  
 
Intervention group A: 14 
Intervention group B: 14 
Control group: 14 
 
Stable condition on 
optimal medical therapy 
for at least 3 months 
Intervention A: 4 minute 
cycle at 60% of maximal 
heart rate followed by 1 
minute rest, repeated 5 
times, 3 x per week for 6 
months. 
Intervention B: as above 
with 4 minute cycle at 
an increasing load 
 
There was no improvement in LVEF %, LVDD, 
LVSD, E-wave or E/A ratio following training. 
 
Limitations: the study was relatively small consisting 
exclusively of men of a young age.  
 
 
Jónsdóttir S, Anderson 
KK, Sigurðsson AF, 
Sigurðsson SB 
(2006) 
Randomised study  
 
Intervention group: 21  
Control group: 22  
 
Intervention: 5-months 
combined endurance 
/resistance training 2 x 
per week 
No significant improvement found in LVEF %. 
 
Limitations: small sample size, only included 
patients who were able to complete a symptom-
limited exercise test therefore results may not be 
representative of all CHF patients. 
 
Fraga R, Franco FG, 
Roveda F 
(2007) 
 
 
 
 
 
 
 
Randomised study 
 
Intervention group: 15 
Control group: 12 
 
 
 
 
 
 
Intervention: 4 months 
aerobic and strength 
exercises, 3 x 60 minute 
sessions per week  
 
 
 
 
 
 
No significant change in LVEF % or end diastolic 
diameter.  
 
Limitations: small study population of young patients 
with CHF and only a small number due to IHD. 
 
 
 
 
 
Study Participants 
 
Protocol Key Findings 
Mandic S, Tymchak W, 
Kim D et al. 
(2009) 
Randomised study 
 
Intervention: aerobic 
exercise n = 14 
Intervention: aerobic 
and resistance exercise 
n = 15 
Control group: 13  
Intervention: 30 
minutes, 3 x per week 
for 12 weeks of either 
aerobic training at 50 – 
70% of HRR or 
combined aerobic and 
resistance training 
Neither aerobic training nor combined aerobic and 
resistance training improved resting left ventricular 
cavity size or systolic function. 
 
Limitations: small sample size. One third of patients 
experienced a change in medication during the 12-
week intervention period. 
 
Santos JMT, Kowatsch 
I, Tsutsui JM et al. 
(2010) 
Randomised study 
 
Intervention group: 13 
Control group: 10 
 
Optimised medication 
Intervention: 4-month 
cycling programme, 3 x 
25 minute per week plus 
10 minutes strength 
exercise 
No changes in LV remodelling or systolic function 
following training. 
 
Limitations: small sample size in each group. Mean 
values not reported. 
 
Meta-analyses and 
reviews 
   
Haykowsky MJ, Liang Y, 
Pechter D et al. 
(2007) 
Evidenced based 
analysis of benefits of 
exercise on left ventricle 
remodelling 
Meta-analysis of the 
effect of exercise 
training on left 
ventricular remodelling 
in heart failure patients.  
14 trials reported LVEF 
data (n = 812 patients). 
7 trials reported both 
EDV and ESV data (n = 
569 patients).  
 
9 trials of aerobic training reported an increase in 
LVEF (9 trials, 538 patients; WMD = 2.59%; 95% CI 
1.44% to 3.74%. I² = 17.2%). 
5 trials of aerobic training reported a decrease in 
EDV (371 patients; WMD = -11.49ml; 95% CI -19.95 
to -3.02ml) and ESV (371 patients; WMD = -
12.87ml; 95% CI -17.80 to -7.93ml. 
 
Limitations: the majority of patients were clinically 
stable younger men. There was a low use of beta-
blockers.  
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Study  Participants  Protocol  Key Findings 
Smart N 
(2011) 
Evidenced based 
analysis of benefits of 
exercise  
Meta-analyses and 
randomised, controlled 
trials reviewed from a 
search of PubMed, 
Cochrane Controlled 
Trial Registry, CINAHL 
and EMBASE in order to 
make 
recommendations. 
Recommendations: 
 
“Evidence suggests exercise training will improve 
systolic function and should be predominantly 
aerobic, and if tolerated, intermittent high intensity in 
nature as this will convey the greatest improvements 
in systolic function.” 
“Evidence suggests exercise training may enhance 
diastolic function.” 
 
Chen YM, Li ZB, Zhu M 
and Cao YM. 
(2012) 
Evidenced based 
analysis of the benefits 
of exercise, based on 
the meta-analysis of 
Haykowsky et al. to 
provide an update. 
 
There was a high use of 
beta- blockers in 8 
recent trials.  
 
Meta-analysis of the 
effect of exercise 
training on left 
ventricular remodelling 
in heart failure patients.  
8 additional RCTs met 
the inclusion criteria. 
12 trials of aerobic training reported an increase in 
LVEF (SMD = 0.44; 95% CI 0.28 to 0.61). 
12 trials of aerobic training reported a significant 
decrease in EDV (574 patients; SMD = -0.33; 95% 
CI -0.49 to -0.16) and ESV (11 trials; 548 patients; 
SMD = -0.40; 95% CI -0.57 to -0.23). 
Long term aerobic exercise (≥ 6 months) had 
marked positive effect on EDV and ESV.  
Effects of combined or strength training alone were 
inconclusive. 
 
Limitations: the majority of participants were low-to-
moderate risk males.  
 
1.6 Effects of pulse pressure on exercise training outcomes in patients 
with CHF 
 
1.6.1 Introduction 
Pulse pressures (PP) can be calculated from the difference of the measured 
systolic and diastolic blood pressures (Blacher and Safar, 2005) using the 
following formula: 
 
PP = P systolic – P diastolic 
 
A low PP ≤20 mmHg caused by a low systolic blood pressure (SBP) (e.g. 90 
mmHg) and a normal diastolic blood pressure (DBP) (e.g. 70 to 90 mmHg), may 
indicate a decreased cardiac output (Gopal et al., 2009) and reflects a reduction 
of stroke volume due to left ventricular dysfunction (Franklin et al., 1999). Wilson 
et al. (1996) concluded that patients with CHF and exercise intolerance fall into 
two general groups: i) those who have normal or nearly normal cardiac output 
during exercise and respond well to an exercise training programme (e.g. >10% 
increase in peak VO2), suggesting that skeletal muscle deconditioning is the 
major contributor to their exercise intolerance, and ii) those who exhibit a 
reduced cardiac output response to exercise. This latter group of patients do 
less well with CR, often finding exercise training exhausting. Thirty four percent 
of patients in their study had reduced cardiac output responses to exercise. The 
authors suggested that their exercise intolerance was due primarily to 
circulatory dysfunction (particularly low skeletal muscle flow) and suggested that 
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haemodynamic responses to exercise can define responders to exercise 
training. 
 
1.6.2 The link between pulse pressure and cardiac index 
A study by Stevenson and Perloff (1989) demonstrated a positive correlation 
between low PP and a reduced cardiac index (cardiac index = cardiac output 
indexed to body surface area) of < 2.2 L/min/m² (Table 1.8). They confirmed 
that cardiac output can be assessed by PP and that it can be used to identify 
the presence of a severely reduced cardiac index rather than to estimate the 
exact cardiac index value. They analysed PP as a proportion of systolic 
pressure in their participants with known chronic dilated left ventricular failure (n 
= 50). It was found that a proportional PP of < 25 mmHg identified 91% of 
patients with a cardiac index ≤ 2.2 L/min/m² (normal cardiac index 2.5 – 4 
L/min/m²). Shelton et al. (2010) have more recently reported that, although 
cardiac index is significantly lower in patients with heart failure compared with 
controls at rest and during incremental exercise, there is no difference in the 
absolute increase in cardiac index from rest to a workload of 60 watts during 
cycle ergometer testing. This indicates that patients with a low PP/reduced 
cardiac index are able to increase their cardiac output in response to 
submaximal exercise. Furthermore, it may explain why these patients might 
actually still benefit from a course of exercise training. 
 
1.6.3 The link between low pulse pressure and mortality 
Low PP has been reported to be an independent predictor of mortality (Table 
1.9) in patients with decompensated heart failure (Aronson and Burger, 2004), 
in patients with advanced CHF (Voors et al., 2005; Petrie at al., 2009; Yildiran et 
al., 2010) and in patients with symptomatic left ventricular dysfunction post 
myocardial infarction (Petrie et al, 2007). Blood pressure data from 489 patients 
enrolled in the Vasodilation in the Management of Acute Congestive (VMAC) 
HF study were used by Aronson and Burger (2004) to determine the 
relationship between PP and survival in patients requiring hospitalisation for 
decompensated HF. At 6-months after hospital discharge low PP at baseline 
was a strong predictor of mortality with a 19% increment for each 10 mmHg 
decrease (p = .0002). In a separate analysis limited to patients in whom blood 
pressure readings were obtained within 24 hours of admission to rule out effects 
of medical therapy, there was an adjusted relative risk of mortality at 6 months 
of 4.2 (CI 95%, 2.0 to 8.6; p < .0001) in the lower PP tertile compared with the 
upper tertile. Furthermore, there was an adjusted 25% increment in mortality for 
each 10 mmHg decrease in baseline PP (p = .001). Voors et al. (2005) studied 
the link between PP and mortality in patients with advanced CHF, and also 
analysed the relationship between PP and natriuretic peptides. They reported 
that patients with a PP ≤ 35 mmHg had a significantly lower survival and those 
with a PP below the median value of 45 mmHg had increased atrial natriuretic 
peptide (ANP) and B-type natriuretic peptide (BNP) levels. Petrie et al. (2007) 
studied the prognostic value of PP in patients 3 to 21 days post myocardial 
infarction, with a mean left ventricular ejection fraction (LVEF) of 33%. Using 
data from 1959 patients recruited to the CAPRICORN clinical trial they found 
that, in asymptomatic patients (n = 1342) PP was not predictive for any 
outcome. However in symptomatic patients (n = 613) low PP predicted all-cause 
mortality (HR 0.83 per 10 mmHg; CI 0.71 – .98; p = .0252), cardiovascular 
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mortality (HR 0.83; CI 0.70 – .98; p = .0245) and sudden death (HR 0.77; CI 
0.60 – 1.00; p = .0470). Somewhat in contrast to these findings, PP was found 
to be an independent predictor of mortality and morbidity only in non-ischaemic 
HF patients in a study by Petrie et al. in 2009. This study cohort of 1901 
patients enrolled in the PRIME II study, however, had a lower mean LVEF of 
26% and advanced HF. In ischaemic HF (n = 1118) PP was not an independent 
predictor of all-cause mortality, but in non-ischaemic HF (n = 783) low PP was 
an independent predictor of all-cause mortality (HR 0.84 per 10 mmHg; p = 
.036). Furthermore, lower PP and higher NYHA class were the only 
independent predictors for first HF hospitalisation in both ischaemic and non-
ischaemic patients. Yildiran et al. (2010) reported that previous studies of the 
prognostic value of PP in heart failure were performed only in specific patient 
groups - those with only mild or only advanced heart failure. Therefore, the 
prognostic value of PP is less clear when all NYHA classes are considered.  
The authors prospectively investigated a relationship between PP and 2-year 
cardiovascular death in 225 patients with CHF and a LVEF < 40%, from all 
NYHA classes. Patients were monitored for a mean period of 670 ± 42 days for 
the occurrence of cardiovascular death. They observed low PP only in patients 
with advanced heart failure; PP decreased as NYHA class worsened (p < .001). 
Twelve patients were lost to follow-up during the study period and in the 
remaining 213 patients, 56 cardiac-related deaths (26.3%) occurred: 42 in 
patients with a PP of less than 35 mmHg, 9 in those with a PP of 35 to 45 
mmHg, 3 in those with a PP of 46 to 55 mmHg, and 2 in those with a PP greater 
than 55 mmHg. Univariate analysis showed that PP was a predictor of death in 
the entire study cohort (p < .01) and multivariate logistic regression analysis 
also revealed PP as an independent predictor of death across the cohort. Every 
1 mmHg decrease in PP increased the risk of death by 24.2%. Furthermore, PP 
independently predicted death in the 178 patients with ischemic heart failure, in 
contrast to the findings by Petrie et al. (2009). In the patients with advanced 
heart failure, 48 cardiac-related deaths occurred, and the only independent 
predictor of death in this group was PP (OR=0.85; 95% CI, 0.79–0.916; p < 
.001). 
 
To date there is only one published study relating to the effects of low PP on 
CHF patients attending CR (Leslie and Buckley, 2012). This retrospective study 
explored the effects of PP on CR outcomes in 86 patients with CHF and 
showed that PP did not influence the efficacy of exercise training. However, as 
a clear indicator of reduced cardiac index and predictor of mortality, it remains 
possible that PP might influence safety and outcomes in CR. This warrants 
further, more robust investigation under research conditions. 
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Table 1.8 Low pulse pressure: predictor of reduced cardiac index in CHF 
Study  Participants  Diagnosis  Protocol  Key Findings 
Stevenson LW and 
Perloff JK. 
(1989) 
50 patients 
 
CHF 
Non-ischaemic aetiology 
in 36 patients 
Proportional PP defined 
as: 
 
(SBP – DBP)/SBP 
Proportional PP 
correlated well with 
cardiac index (r = 0.82; p 
< 0.001). 
A proportional PP ≤ 25% 
identified 91% of patients 
with a cardiac index < 2.2 
L/min/m². 
Conclusion: the adequacy 
of resting cardiac output 
is assessed reliably by 
proportional PP. 
 
 
 
 
 
 
 
Table 1.9 Low pulse pressure: predictor of mortality in CHF 
Study  Participants  Diagnosis  Protocol  Key Findings 
Aronson D, Burger AJ 
(2004) 
489 patients enrolled in 
the VMAC HF study 
 
Decompensated HF 
requiring hospitalisation 
Blood pressure 
measurements 
performed at baseline. 
PP divided into tertiles 
for comparison: first 
tertile PP ≤ 43 mmHg; 
second 44 -58 mmHg; 
third > 59 mmHg. 
6-month follow up after 
hospital discharge. 
Lower PP was 
predictive of an increase 
in all-cause mortality 
with a 19% increment 
for each 10 mmHg 
decrease (p = 0.0002). 
Conclusion: low PP is 
an independent 
predictor of mortality. 
Voors AA, Petrie CJ, 
Petrie MC, Charlesworth 
A et al. 
(2005) 
Data collected from 
1901 patients enrolled in 
the PRIME II study 
 
CHF Blood pressure data 
from the PRIME II study 
were used to calculate 
PP. 
 
Patients with a PP <45 
mmHg had lower SBP 
and DBP, lower LVEF 
and higher heart rate. 
 
Patients with a PP <35 
mmHg had significantly 
lower survival (p = 
0.0005). 
 
Patients with a PP <45 
mmHg had significantly 
higher BNP (p = 0.002) 
and NT-proBNP (p = 
0.002). 
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Study  Participants  Diagnosis  Protocol  Key Findings 
Petrie CJ, Robertson M, 
Voors AA et al. 
(2007) 
Data from 1959 patients 
recruited to the 
CAPRICORN clinical 
trial 
 
CHF PP adjusted for other 
baseline risk factors 
including MAP and 
study treatment. 
 
 
Low PP predicted all-
cause mortality (HR 
0.83 per 10 mmHg; p = 
0.0252), cardiovascular 
mortality (HR 0.83; p = 
0.0245) and sudden 
death (HR 0.77; p = 
0.0470). 
Petrie CJ, Voors AA, 
van Veldhuisen DJ. 
(2009) 
Data collected from 
1901 patients enrolled in 
the PRIME II study 
 
Ischaemic HF n = 1118 
Non-ischaemic HF n = 
783 
The study compares 
prognostic value of PP 
between patients with 
ischaemic and non-
ischaemic advanced 
CHF. 
In ischaemic HF PP was 
not a predictor of 
mortality. 
 
In non-ischaemic HF 
low PP was an 
independent predictor of 
mortality (HR 0.84 per 
10 mmHg; p = 0.036).. 
Yildiran T, Koc M, 
Bozkurt et al. 
(2010) 
225 patients 
Median PP 40 mmHg. 
 
CHF Patients were monitored 
for a mean period of 670 
± 42 days for the 
occurrence of 
cardiovascular death. 
12 patients lost to 
follow-up. 
42/56 deaths in patients 
with a PP < 35 mmHg. 
 
Each 1 mmHg reduction 
in PP increased risk of 
death by 24.2%. 
 
PP was the only 
independent predictor of 
death in advanced HF. 
1.7 Effects of exercise training on quality of life in patients with CHF 
 
1.7.1 Introduction  
Patients with CHF suffer from dyspnoea and fatigue, affecting their ability to 
perform activities of daily living which in turn leads to reports of deteriorating 
QoL (Holst et al., 2001; Giannuzzi et al., 2001). Moreover, depression is 
recognised as an independent risk factor for mortality and morbidity in patients 
with CHF regardless of the cause (Jiang et al., 2004). Depression is not 
uncommon in patients with chronic illness and 22% to 43% of patients with CHF 
suffer clinical depression (Powell et al., 2005; Rutledge et al., 2006). Exercise 
training is considered an effective treatment to improve QoL; as exercise 
capacity increases, patients with CHF experience less fatigue and dyspnoea 
and become more able to perform activities of daily living. This increased 
independence is associated with less depression and improved QoL (Giannuzzi 
et al., 2001). The BACPR (2012) and ACPICR (2009) standards recommend 
the use of valid and reliable measures of QoL for patients with CHF, such as the 
Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983) 
and the disease specific Minnesota Living with Heart Failure (MLHFQ) 
questionnaire (Rector et al, 1987). The MLHFQ measures patient’s perceptions 
of the effects of Heart Failure and its treatment on his or her daily life. The 
questionnaire uses a 21-item, self-administered questionnaire covering 
physical, socio-economic and psychological/emotional impairments associated 
with their heart failure. It allows a quantitative measure of the patient's 
perception of the extent of their impairment and how it is affected by therapeutic 
intervention and lower scores indicate an improvement in QoL (Smart and 
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Murison, 2012). The HADS is a tool to measure anxiety and depression. It is a 
self-assessment mood scale specifically designed for use in non-psychiatric 
hospital outpatient departments, and comprises of 14 items with weighted 
responses (0 to 3 points for each item). These items are divided into anxiety 
and depression subscales, and a score of 11 points or greater in either 
subscale indicates significant anxiety or depression (Zigmond and Smaith, 
1983). 
 
1.7.2 Quality of life following exercise training in CHF patients 
In their systematic review of randomised controlled studies (Table 1.10), Lloyd-
Williams et al. (2002) reported that QoL assessment scores were improved 
following a course of exercise training. The authors reviewed a total of 31 trials, 
only 14 (45%) of which were randomised controlled trials. Just over half (16) of 
the 31 studies reviewed included QoL as an outcome; 69% reported positive 
effects. However, they questioned the suitability of several of the QoL tools that 
were selected as they were not considered appropriate for patients with a 
chronic condition. Only 3 studies used the MLHFQ and none were reported to 
have used the HADS. There were several limitations to this review in addition to 
the large number of non-randomised controlled trials. In 67% of the 31 included 
trials the sample size was 25 participants or fewer, with only 13% of trials 
having a sample size of 51 to 150 participants. The authors did not pool data 
from the trials, perhaps due to the number of different scales used to assess 
QoL, therefore they were not able to provide an estimate of effect size. As with 
many of the studies recruiting CHF patients the mean ages were predominantly 
younger (in 74% of the trials the mean age was 65 years or less) and male and 
patients with co-morbidities were often excluded. Rees et al. (2004) were also 
unable to undertake a pooled analysis in their systematic review due to the 
number of different scales used (Table 1.10). Only nine of 29 (31%) trials 
reported QoL as an outcome, five of which used the MLHFQ. There were no 
studies reported to have used the HADS. Significant improvements were seen 
in the short-term in four of five studies; one of two studies that measured QoL 
over the longer-term of 12 months found that the improvement was maintained. 
Again, the majority of the included trials were small, recruiting mostly men, and 
patients with co-morbidities were often excluded. 
 
 
 
 
89 
 
Table 1.10 Summary of meta-analyses and reviews: effects of exercise training on quality of life 
 
Study  Participants  Protocol  Key Findings 
Lloyd-Williams F, Mair 
FS and Leitner M. 
(2002) 
Evidenced based 
analysis of benefits of 
exercise training in CHF 
patients. 
Systematic review of the 
effect of exercise 
training on QoL in heart 
failure patients.  
31 trials included. 
Sample sizes ranged 
from 25 or less to 150. 
Predominantly male.  
Patients with co-
morbidities often 
excluded. 
 
Positive effects on QoL reported in 69% of studies. 
 
Limitations: quantitative analysis not applied. Poor 
quality/inappropriate assessment/screening tools 
used in some studies. None of the studies used the 
HAD scale. 3 (19%) used the MLHFQ and 1 (6%) 
used a physical activity questionnaire. 
 
 
 
Rees K, Taylor RS, Sigh 
S et al. 
(2004) 
Evidenced based 
analysis of benefits of 
exercise training in CHF 
patients. 
Systematic review of the 
effect of exercise 
training on CHF 
patients.  
9/29 studies reported 
QoL as an outcome. 
5/9 studies used the 
MLHFQ. 
2/5 studies looked at 
long-term benefits 
7/9 studies found an improvement in QoL. 
 
Significant improvements were seen in 4/5 over the 
short-term.  
 
1 study showed improvement was maintained at 12 
months. 
 
Limitations: small trials, recruiting mostly men. 
Patients with co-morbidities often excluded. Results, 
therefore, may not be generalisable to all patients 
with CHF. A variety of different questionnaires used. 
Study  Participants  Protocol  Key Findings 
van Tol BAF, Huijsmans 
RJ, Kroon DW et al. 
(2006) 
Evidenced based 
analysis of benefits of 
exercise training on QoL 
in CHF patients. 
Meta-analysis of the 
effect of exercise 
training on QoL in heart 
failure patients.  
35 randomised 
controlled trials 
included.  
A total of 1486 patients 
included. 
9 studies used MLHFQ. 
MLHFQ scores decreased significantly when pooled 
(463 patients) by 9.7 points (p = 0.0001). 
 
Limitations: mean age and severity of CHF in the 
meta-analysis not representative of the CHF 
populations in epidemiological findings. 
 
 
Rutledge T, Reis VA, 
Linke SE et al. 
(2006) 
Meta-analysis of 
published associations 
between depression and 
HF. 
Meta-analysis of 27 
studies  to show 
prevalence of 
depression in HF 
patients, magnitude of 
the relationship between 
depression and clinical 
outcomes and evidence 
for treatment efficacy. 
Prevalence of depression in HF patients 
approximately 22%; higher in females. 
Two-fold risk of mortality in HF patients with a 
depressive disorder or depressive symptoms. 
 
In the trial using the HADS (Radzewitz et al., 2002) 
there were no significant changes in the answers 
relating to anxiety and depression between baseline 
and follow-up. 
Davies EJ, Moxham T, 
Rees K et al. 
(2010) 
Evidenced based 
analysis of benefits of 
exercise training in CHF 
patients. 
Systematic review of the 
effect of exercise 
training on CHF 
patients.  
10/19 trials reported 
valid QoL measure. 6/10 
used the MLHFQ. 
 
Significant improvements seen in QoL scores 
following exercise training. 
 
Limitations: significant heterogeneity in observations 
on QoL. On the MLHFQ, the exercise group was on 
average 10 points higher than controls. The 
generalisability of the findings may be limited. 
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Study  Participants  Protocol  Key Findings 
Smart N 
(2011) 
Evidenced based 
analysis of benefits of 
exercise in CHF.  
Meta-analyses and 
randomised, controlled 
trials reviewed in order 
to make 
recommendations for 
exercise training for 
CHF patients. 
Summarised Lloyd-Williams et al.’s (2002) 
systematic review which demonstrated that QoL 
improved in 11 of 16 trials; furthermore the meta-
analysis by van Tol et al. (2006) showed that 
patients with CHF can expect an improvement of 
almost 10 points in MLHFQ scores following 
exercise training. 
 
Recommendation: 
 
“Evidence is unequivocal for improvements in QoL.”  
Taylor RS, Sagar VA, 
Davies EJ et al. 
(2014) 
Evidenced based 
analysis of benefits of 
exercise training in CHF 
patients. 
Systematic review of the 
effect of exercise 
training on CHF 
patients.  
19/33 trials reported 
valid QoL measure. 
13/19 trials used 
MLHFQ, 1/19 used 
HADS. 
 
Pooled total MLHFQ scores at 12 months showed a 
clinically significant improvement with exercise 
training. 
 
3 trials that reported MLHFQ scores at follow-up 
longer than 12 months also showed a greater 
improvement in the intervention group compared 
with controls. 
 
Limitations: significant heterogeneity in the exercise-
control difference in MLHFQ scores at follow-up. 
 
 
 
 
 
 
Table 1.11 Summary of studies included in the 2014 Cochrane Review which report Minnesota Living with Heart Failure 
Questionnaire scores or Hospital Anxiety and Depression scores following exercise training  
 
Study  Participants  Intervention Key Findings 
Belardinelli R, Georgiou 
D, Cianci G and Purcaro 
A 
(1999) 
99 patients randomised  
 
Aerobic exercise 3 x per 
week for 8 weeks plus 
12 month maintenance 
programme.  
Mean exercise-control difference at follow-up -11.0 
(95% CI -19.33 to -2.67).  
Gottlieb SS, Fisher ML, 
Freudenberger R et al. 
(1999) 
33 patients randomised 
 
Aerobic exercise 3 x per 
week for 3 months at 
Borg 12 to 13. 
No significant improvement in MLHFQ score at 
follow-up. 
McKelvie RS, Teo KK, 
Roberts R et al. 
(2002) 
181 patients 
randomised  
 
Aerobic and resistance 
exercise 2 x per week, 
months, at 60 – 70% 
max HR. 
No significant improvement in MLHFQ score at 
follow-up (-3.9 ± 1.9, p = 0.28). 
 
Koukouvou G, Kouidi E, 
Iacovides A et al. 
(2004) 
26 patients randomised  
 
Aerobic and resistance 
exercise 3 – 4 x per 
week for 6 months, at 
50 – 75% peak VO2. 
Significant improvement in QoL in trained patients. 
 
Austin J, Williams R, 
Ross L et al. 
(2005) 
200 patients 
randomised  
 
Aerobic endurance 
training and low 
resistance training 2 x 
per week for 8 weeks. 
Baseline score 41, 8 weeks post exercise 25.8 (p < 
0.001), 24 weeks post exercise 22.9 ( p < 0.01). 
Passino C, Severino S, 
Poletti R et al. 
(2006) 
85 patients randomised  
 
Aerobic exercise > 3 x 
per week for 9 months 
at 65% max VO2. 
 
MLHFQ score improved from 54 ± 5 pre exercise 
training to 32 ± 4 post training (p < 0.01). 
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Study  Participants  Intervention Key Findings 
Dracup K, Evangelista 
LS, Hamilton MA et al. 
(2007) 
173 patients 
randomised  
 
Aerobic and resistance 
exercise 4 x per week at 
40 – 60% max HR.  
There was no significant difference between the 
intervention and control groups in QoL. 
 
Nilsson BB, Westheim A 
and Risberg MA.  
(2008) 
80 patients randomised  
 
Aerobic exercise 2 x per 
week for 4 months at 
Borg 15 – 18.  
MLHFQ score reduced from 33 ± 18 at baseline to 
22 ± 12 post exercise (p = 0.034) and 22 ± 14 at 12-
month follow-up (p = 0.002). 
Zwisler AD, Schou L, 
Soja AM et al. 
(2008) 
91 patients randomised  
 
Aerobic and resistance 
exercise 3 x per week 
for 6 weeks at 50% max 
HR. 
Anxiety and depression did not improve significantly 
following exercise. 
Jolly K, Taylor RS, Lip 
GY et al. 
(2009) 
169 patients 
randomised  
 
Aerobic and resistance 
exercise 5 x per week 
for 6 months at 70% of 
peak VO2 or Borg 12 – 
13. 
At 6 months, there was no between-group difference 
in the primary outcome MLHFQ score. 
 
Davidson PM, Cockburn 
J, Newton PJ et al. 
(2010) 
105 patients 
randomised  
 
Aerobic exercise 1 x per 
week for 12 weeks. 
Intensity not reported. 
QoL scores improved at 3 months compared with 
baseline (intervention group -4.37, P<0.0001; control 
group -3.52, P<0.01). 
Gary RA, Dunbar SB, 
Higgins MK et al.  
(2010) 
Comprehensive: 
28 patients randomised  
 
 
Exercise alone: 
37 patients randomised  
 
Aerobic exercise 3 x per 
week for 12 weeks at 
RPE < 15 plus CBT. 
 
Aerobic exercise 3 x per 
week for 12 weeks at 
Borg < 15. 
 
Mean exercise-control difference at follow-up -10.10. 
 
 
 
Mean exercise-control difference at follow-up -3.30. 
Study  Participants  Protocol  Key Findings 
Yeh GY, McCarthy EP, 
Wayne PM et al. 
(2011) 
100 patients 
randomised  
 
Intervention: aerobic 
exercise 2 x per week 
for 12 weeks. Intensity 
not reported. 
Patients in the intervention (tai chi) group had 
greater improvements in MLHFQ scores, −19 (-23, -
3) vs. 1 (-16, 3), p = 0.02). 
 
Belardinelli R, Georgiou 
D, Cianci G and Purcaro 
A. 
(2012) 
123 patients 
randomised  
 
Intervention: aerobic 
exercise 2 – 3 x per 
week for 8 weeks 
supervised then 2 x per 
week maintenance at 60 
– 70% max VO2 for 10 
years. 
QoL score was significantly better in the intervention 
group (43 ± 12 vs. 58 ± 14 in the control group, p < 
0.05). 
 
Witham MD, Fulton RL, 
Greig CA et al. 
(2012) 
107 patients 
randomised  
 
Intervention: aerobic 
and resistance exercise 
2 x per week for 24 
weeks. Intensity not 
reported. 
 
No significant changes in MLHFQ and HADS. 
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The reliability and validity of the MLHFQ is recognised, but in spite of this a 
more recent review by van Tol et al. (2006) showed that only 29% (9/31) of 
studies included in their meta-analysis used this questionnaire (Table 1.10). 
However, pooled data from these nine studies did show a significant decrease 
of almost 10 points, which is considered clinically meaningful (Piña et al., 2003). 
In fact a difference of four points or larger on the MLHFQ has been shown to 
represent a clinically important, meaningful difference for patients (McAlister et 
al., 2004). Interestingly, van Tol et al. (2006) reported that only one study could 
demonstrate a significant correlation between improvements in 
cardiorespiratory outcomes and QoL scores, suggesting that factors other than 
physical fitness determine a patient’s perception of QoL. As with previous 
reviews, there were no trials reported to have used the HADS. However, a 
meta-analysis by Rutledge et al. (2006) did include one study that used the 
HADS to measure depression in an intervention study in patients with CHF 
(Table 1.10), which showed no significant improvement (49 ± 7 vs 48 ± 8, p = 
0.39). 
 
It is worth noting that the HF-ACTION study examined the effects of exercise 
training on QoL (Flynn et al., 2009), but used the Kansas City Cardiomyopathy 
Questionnaire (KCCQ) as their chosen outcome measure. There were a 
considerable 1159 patients in the exercise training group (1171 in the control 
group) and the KCCQ score improved by a significant 5.2 points following 
exercise training. There was also an improvement of 3.3 points in the control 
group; however the 1.9-point difference was significant (p < 0.001). Neither 
group experienced significant changes beyond three months. The HF-ACTION 
study was included in the 2010 Cochrane Review (Davies et al.). Nineteen trials 
(a total of 3647 patients; 2331 from the HF-ACTION study) met the inclusion 
criteria, only eight of which had been included in the previous Cochrane Review 
by Rees et al. (2004). Just over half (53%; 10/19) of the studies reported a 
validated measure of QoL with the majority using the MLHFQ (6/10). Pooled 
MLHFQ results were significant (random-effects mean difference -10.3, 95% CI 
-15.9 to -4.8; p = 0.0003) as were the results when all data were pooled. The 
significant result remained even when excluding HF-ACTION data (Table 1.10). 
The authors noted that there was significant heterogeneity in their observations 
on MLHFQ, with the exercise group on average 10 points higher than controls.  
 
The above reviews and meta-analyses showed that exercise training 
programmes may provide some important improvements in QoL in patients with 
CHF. However, with the relatively young mean age of patients recruited to the 
studies and the frequent absence of co-morbidities is it not clear whether the 
results of these studies are transferrable to the general CHF population 
attending routine CR programmes in the UK. The recently published update of 
the Cochrane Review (Taylor et al., 2014) included 33 trials, 19 of which 
reported the use of a validated QoL measure; 13 used the MLHFQ and 2 used 
the HADS (Table 1.10 and Table 1.11). Again the majority of the included trials 
were small (26 trials had less than 100 participants; HF-ACTION, 2009 
contributed 2331 participants) with a mean age of participants from 51 to 81 
years who were predominantly male. However, there was evidence that more 
female and older participants had been recruited in recent trials since the 2010 
review (Davies et al.). As with the 2010 review, there was evidence of high 
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levels of heterogeneity in the exercise-control difference in the MLHFQ scores 
at follow-up. Nevertheless, when data from the trials reporting total MLHFQ 
scores were pooled there was a clinically significant improvement with exercise 
training (MD -5.8; 95% CI -9.2 to -2.4; p = 0.0007, I² = 70%; Chi² = 40.24, p < 
0.0001, random-effects analysis) demonstrating the efficacy of aerobic exercise 
training, with or without resistance exercise, on QoL in CHF patients. 
 
The HADS questionnaire and the MLHFQ were used in Study 4 (Chapter 5) to 
measure changes in QoL in CHF patients following an exercise training 
programme. 
 
1.8 Conclusions and recommendations 
Individual studies have produced conflicting results. When data are pooled in 
meta-analyses the results clearly demonstrate the efficacy of exercise-based 
rehabilitation by improvements in functional capacity (usually expressed as VO2 
peak), natriuretic peptides and health-related QoL in relatively young patients 
(often males) with stable CHF and few or no co-morbidities. It is evident that 
there are certain shortcomings that make the field worthy of further scrutiny. For 
example, previous investigations have used intensities of VO2 peak and 
treadmill or cycle ergometer exercise training protocols; participants have been 
predominantly young males with few or no co-morbidities. Further scope for 
investigation lies in the mode and intensity of exercise, by selecting protocols 
that are routinely used by CR programmes in the UK, and in the population 
recruited. 
 
1.9 Summary of aims and objectives of the studies within the thesis 
The primary objective of the thesis was to assess the physiological and 
psychological effects of moderate intensity exercise training on patients with 
CHF and to provide new evidence examining the correlation between functional 
capacity, NT-proBNP levels and QoL following a 12-week course of supervised 
exercise. Participants randomised to an early intervention (EI) group 
commenced the exercise programme immediately following an initial 
assessment; participants in a delayed intervention (DI) group - the control group 
- were able to access the exercise programme following a second assessment 
at 12-weeks. Participants in the DI group received educational support from the 
Heart Failure Specialist Nurses but no formal exercise protocol; they were 
invited to continue their usual lifestyle. Two smaller studies were also designed 
to assess the validity and reliability of using a two-minute practice test prior to a 
6MWT and of the Chester step test to assess HR, VO2 and RPE responses in 
CHF patients. A third sub-group study examined the acute kinetics of NT-
proBNP following a moderate intensity exercise session. 
 
The following hypotheses have therefore been explored: 
Study 1: a two-minute practice walk test provides adequate and appropriate 
preparation prior to performing a baseline 6MWT. 
Study 2: a modified CST is a reliable and suitable sub-maximal alternative test 
of functional capacity in patients with CHF. 
Study 3: NT-proBNP does not increase following a moderate intensity exercise 
session. 
Study 4: In a representative sample of the UK CHF population, compared to 
that reported in the current evidence, and by applying current UK guidelines, a 
12-week programme of exercise training: 
 (i) Results in an improved functional capacity. 
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(ii) Results in a reduction in plasma BNP levels and an associated improvement 
in LV function. 
(iii) Results in an improvement in QoL. 
(iv) Demonstrates a strong correlation between changes in functional capacity, 
with changes in plasma BNP levels and changes in QoL. 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
 
 
 
General Methods 
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2.1 Method 
The following section aims to give an overview of a suite of studies on exercise-
based rehabilitation that are encompassed within this thesis for patients 
attending a standardised CR programme at the Royal Wolverhampton NHS 
Trust’s Heart and Lung Centre. This specialised programme is integral to an 
overall CR service that encompasses many cardiovascular conditions including 
IHD, Post-MI, Post-CABG and other related conditions including CVA and PVD. 
 
All trials were incorporated into the standardised service where patients are 
referred to a 12-week programme, attending two sessions per week for 
supervised exercise training. The only change to routine practice to add validity 
to the study design was that some patients were deferred for 12 weeks, in a 
cross-over design, which allowed for an optimisation of a “control” group. This 
ensured that all eligible patients received rehabilitation as opposed to a more 
traditional non-interventional (placebo) control arm. The latter now being 
considered unethical in light of the modern acceptance that rehabilitation is a 
required part of CHF treatment (NICE, 2010). 
 
Figure 2.1 provides an overview of the suite of studies that were encompassed 
within this thesis, followed by Method being applied through a number of these 
studies including: 
1. Experimental Design  
2. Participant recruitment 
3. Planned sample size 
4. Ethics,  Good Clinical Practice and Approval  
5. Consent 
6. Randomisation 
7. Pre-test screening 
8. Testing Procedures and equipment  
a. Resting measures and derived parameters: HR, BP 
and PP  
b. Blood analyses: NT-proBNP 
c. Exercise tests and protocol: Intensity, HR and RPE; 
6MWT; exercise programming, prescription and 
progression 
d. QoL 
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EI = Early intervention DI = Delayed intervention (control) 
 
Figure 2.1 Study flow diagram 
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2.1.1 Experimental design 
There was a small initial study prior to the main study, designed to assess the 
validity and reliability of using a two-minute practice test prior to a baseline 
6MWT. During the main study several subgroups were selected to assess the 
following: 
1. HR, VO2 and RPE responses in CHF patients during an adapted Chester 
step test. 
2.  The kinetics of NT-proBNP following a moderate intensity exercise 
session. 
3. Changes in LV function following a 12-week programme of moderate 
intensity exercise. 
 
The main research (Study 4) was a parallel study, with a cross-over design, 
comparing outcome measures from a cohort of CHF patients who attended a 
12-week supervised exercise programme (Early intervention; EI group) with 
outcome measures from a cohort of CHF patients who followed standardised 
advice from the Heart Failure Specialist Nurse (Delayed intervention; DI group) 
for 12 weeks. All patients had access to the exercise programme; however 
patients in the DI group had a delayed start in order to provide a control group 
(Table 2.1). The study used prospective data from both groups, over a 12 -
month period. It used a repeated measures design, consisting of three main 
testing sessions: initial assessment/baseline (T1), 12-week follow-up (T2) and 
6-month follow-up (T3) (Table 2.1). Patients in the DI group who went on to 
complete the exercise training programme had an additional assessment (T2b), 
at 24 weeks to examine specific outcome measures following the 12-week 
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programme. All testing was performed at the Royal Wolverhampton NHS 
Trust’s CR Department at New Cross Hospital. 
  
 
Table 2.1 Intervention details 
 
Early Intervention Group  Delayed Intervention Group  
a. Initial assessment (T1). 
b. Patients attend a 12-week course 
of supervised exercise in the 
Cardiac Rehabilitation Department 
at New Cross Hospital. 
c. Reassessment at week 12 (T2). 
d. Patients continue self-directed 
activities, following standardised 
advice. 
e. 6 month review (at week 36) (T3). 
a. Initial assessment (T1). 
b. Patients continue self-directed 
activities, following standardised 
advice.  
c. Reassessment at week 12 (T2).  
d. Patients attend a 12-week course 
of supervised exercise in the 
Cardiac Rehabilitation 
Department at New Cross 
Hospital. 
e. Reassessment at week 24 (T2b).  
f. 6 month review (at week 48) (T3). 
 
 
2.1.2 Recruitment process 
Patients diagnosed with left ventricular systolic dysfunction (LVSD) in 
Wolverhampton are seen by a Heart Failure Specialist Nurse for assessment, 
advice and education. Prescription of CHF medication and optimisation of beta-
blocker and ACE inhibitor medication takes place in the Heart Review Clinic at 
the Royal Wolverhampton NHS Trust. Once stable on optimum medication 
patients are referred to a CHF CR exercise programme.  
 
Participants were selected for this study by conforming to the following inclusion 
criteria: 
a. Referred to the CR exercise programme 
b. NYHA class II and III 
c. Stable CHF 
d. Anti-failure medication optimised  
e. Patient consent to joining the study 
 
 
Participants were excluded from the study based on the following exclusion 
criteria: 
a. NYHA class I or IV 
b. Patient declines/withdraws consent 
c. Absolute contraindications to exercise 
 
Eligible patients were invited to participate in the study and received further 
information, including the Patient Information Leaflet (Appendix 1 and 2) prior to 
consent. The patients were given a minimum of 24 hours to consider entry to 
the study and were free to discuss the study with relatives, friends and other 
health professionals if they wished. A screening log was kept of all patients 
approached for the study and whether they agreed to participate or not. 
 
Sample Size 
Due to the nature of this study, a convenience sample was used. The aim was 
to include at least 50 patients, with 25 in each Group. A service audit of clinical 
effectiveness (Leslie and Buckley, 2010) using a sample of 22 patients who had 
completed the CHF exercise programme showed that there was a trend 
towards a reduction in NT-proBNP levels following a 12 week course of 
exercise training (p=0.075). Patients who dropped out of treatment were invited 
to attend for follow-up assessment and these data are included in the analysis.  
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2.2 Ethics 
2.2.1 Good Clinical Practice 
All study procedures were in accordance with the recommendations guiding 
physicians in biomedical research involving human subjects, adopted by the 
18th World Medical Assembly, Helsinki, Finland 1964, amended at Edinburgh in 
2000. The trial was conducted in accordance with ICH GCP. There is no 
documented evidence to suggest that delaying the start of CR exercise training 
for CHF patients is in any way detrimental to their health. 
 
2.2.2 Approval 
Prior to commencing this study ethical approval was granted by NRES and 
Trust approval by The Research and Development (R&D) Directorate at the 
Royal Wolverhampton NHS Trust (Appendix 3 and 4). Further approval was 
granted following a Substantial Amendment to the study (Appendix 5 and 6), 
which included the addition of serial blood samples to examine the acute 
kinetics of NT-proBNP following moderate intensity exercise. Appropriate 
licensing for the use of the MLHFQ was granted by the University of Minnesota. 
 
2.2.3 Data monitoring 
Data was monitored for completeness and quality by the R&D Directorate via 
the Quality Assurance process.  
 
 
 
 
2.2.4 Confidentiality  
The research complies with all aspects of the Data Protection Act 1998. Any 
information which would allow individual patients or clinicians to be identified will 
not be released. 
 
2.2.5 Consent 
Informed consent discussions and a pre-assessment screen took place prior to 
the initial assessment (T1), where patients were encouraged to ask questions 
before giving consent and being entered in the study. Written informed consent 
was obtained prior to randomisation and initial assessment by the patient 
completing the consent form (Appendix 7 and 8). A copy of the consent form 
was offered to the patient, and copies of this form and the Patient Information 
Leaflet were kept in the patient’s CR treatment record. To ensure participant 
confidentiality all participants were allocated a unique identification number. 
 
2.2.6 Randomisation  
Sequentially, following consent, participants were randomised into the EI group 
or the DI group, for practical pragmatic reasons in an attempt to avoid 
disproportionate group sizes (resource and Health & Safety issues in respect to 
class size). 
 
2.3 Test procedures and equipment 
Participants were tested in their usual CR clinics therefore reducing the 
potential stress of attending a hospital environment for the study and also not 
adding any extra journeys for the participants in the study. 
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2.3.1 Resting measures/pre-test screen at T1 
On arrival at the CR clinic, patients were asked to sit on a chair and rest for 10 
minutes, to ensure a more accurate resting heart rate (RHR) was achieved prior 
to the test commencing. During this seated period during T1 participants were 
required to complete the informed consent form and a pre- test health screen 
was undertaken. The findings of the health screen ensured that participants 
were suitable to participate in the study, namely by taking their prescribed 
medications and not having any absolute contraindications to exercise. At all 
assessments, after the 10 minute rest period, participants RHR was taken 
through a radial pulse check for 15 seconds which also allowed for basic 
screening of any potential arrhythmia. Blood pressure was checked using an 
automated sphygmanonometer on the participants left arm, unless there was a 
clinical reason as to why the left arm could not be used.  
 
Exercise training guidelines for patients with CHF set by the Association of 
Chartered Physiotherapists in Cardiac Rehabilitation (ACPICR) (2009) 
recommend a training HR range between 40% and 60% of HRR in order to 
prescribe safe and effective exercise for patients with CHF. HR is a commonly 
used measure of exercise response due to ease of monitoring plus its direct 
relationship with VO2 max; VO2 max being plausibly predicted from sub-maximal 
exercise (Johnson and Siegel, 1981). HRR allows for a more accurate 
relationship between % HR max and VO2 max as it considers the influence of 
varied resting HRs (Karvonen et al., 1957). If the exact HR max is not known 
(i.e. from a maximal exercise tolerance test) then the 220 – age method is often 
used, for which the accuracy has been questioned (Robergs and Landwehr, 
2002). This is particularly relevant for CHF patients due to the prescription of 
beta-blockers and the incidence of chronotropic incompetence. Beta-blockers 
are known to reduce both RHR and HR during exercise by as much as 20 – 
30% (Head, 1999). Chronotropic incompetence has been defined as the 
inability of the heart to increase its rate commensurate with increased activity or 
demand, and failure to achieve at least 80% of maximum HR or HRR during an 
incremental exercise test or inadequate submaximal HR are examples of 
impaired chronotropic response (Brubaker et al., 2011). The underlying 
mechanisms are yet to be completely understood. Wosnich et al. (2003) 
reported a mean resting HR 15 ± 5 beat. min-1 lower in a small cohort of beta-
blocked healthy males compared to a placebo group (p < 0.05). Mean HR was 
also significantly lower at aerobic threshold   (-19 ± 8 beat. min-1), anaerobic 
threshold (-22 ±10 beat. min-1) and maximal workload (-19 ±11 beat. min-1) with 
bisoprolol compared to placebo. Percentage of HRmax was significantly 
reduced at rest aerobic threshold (64% vs 60%) and anaerobic threshold (86% 
vs 82%). The authors recommended the use of RPE to prescribe exercise for 
patients taking beta-blockers. Tabet et al. (2006) later proposed that a modified 
formula should be available for beta-blocked patients. A specialised equation for 
estimating maximum HR in CHF has since been developed by Keteyian et al. 
(2012). 
 
Predicted maximum HR was therefore calculated using the equation by 
Keteyian et al. (2012): 
119 + 0.5(RHR) – 0.5(age) 
 
111 
 
 Sixty percent of HR reserve (HRR) was then calculated as a test termination 
point; this percentage generally corresponds with the first ventilatory threshold 
(Beale et al., 2010). The equation 220 – age has been shown to over-estimate 
measure maximal HR in patients taking beta-blockade therapy, with a prediction 
error of 40 ± 19 beats (Keteyian et al, 2012). Keteyian et al. (2012) used data 
from 767 participants enrolled in the HF-ACTION trial to validate a more 
appropriate equation that used both age and RHR to predict maximum HR in 
patients with CHF taking beta-blockers. The authors considered the above 
equation was helpful with evaluation of chronotropic response, but advised that 
the magnitude of the variation (standard error of the estimate = 18 beat. min-1) 
may render it impractical when prescribing intensity. It is noteworthy that the 
cohort of 767 patients was in sinus rhythm (i.e. no pacemaker and no atrial 
fibrillation) thus the results may not be generalisable to all patients with CHF. 
 
Present at all assessment sessions was another member of the CR team or a 
student physiotherapist, trained in immediate life support.  
 
 
2.3.2 Pulse pressure 
Pulse pressure (PP) was calculated pre-exercise and at end of exercise test 
from the difference of the measured systolic and diastolic blood pressures 
(Blacher and Safar, 2005) using the following formula: 
 
PP = P systolic – P diastolic 
 
2.3.3 Plasma NT-proBNP levels 
Blood was sampled using a polyethylene cannula placed in an antecubital vein 
in the left or right arm by a trained Research Nurse and collected into an EDTA 
(anticoagulant) sampling tube. Blood samples were collected after the initial 
pre-screening and prior to the 6MWT. The blood samples were transferred to 
the hospital’s Clinical Chemistry laboratory and were centrifuged by a laboratory 
technician at 3200rpm for 3 minutes in a Centrifuge Megafuge II. Plasma was 
then separated and immediately aliquoted into labelled cryo-vials and frozen at 
–80°C until analysis. NT-pro-BNP was measured in batches using a 
commercially available electrochemiluminescence immunoassay based on a 
polyclonal antibody-based sandwich chemiluminescence assay (Roche 
Diagnostics) using an autoanalyser. Although BNP levels do not appear to rise 
and fall in any circadian rhythm (Jensen et al., 1997), samples were obtained at 
the same time of day to reduce any possibility of diurnal variation. 
 
 
2.3.4 Rating of perceived exertion 
A rating of perceived exertion (RPE) can complement HR during exercise 
testing and has been recognised as a marker of physiological intensity (Buckley 
et al., 1999); RPE is frequently used to assess fitness, guide exercise 
prescription and monitor safe and effective levels of exercise/activity (Buckley 
and Eston, 2007) as it allows patients to monitor feelings of exercise intensity, 
which in turn allows them to pace themselves accordingly. The reliability of 
Borg’s 6 – 20 RPE scale (Borg, 1998) has been confirmed by Buckley et al. 
(2009). An RPE of 14/15 corresponds to 80% HR max and is therefore 
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considered a reasonable, albeit subjective, end point to a sub-maximal exercise 
test (Buckley et al., 2004). However, Eston and Thompson (1997) reported that 
patients with CHD tend to overestimate exercise intensity compared to healthy 
controls. In contrast, Joo et al. (2004) concluded that a self-reported RPE of 11–
13 in 11 patients with CHD may result in exercise intensity levels that are 
inappropriately high for exercise-based CR, and recommended being aware of 
the effects of beta-blockers on local and overall RPE with respect to the 
cardioselectivity.  These conflicting findings may be the result of different 
cardioselectivity of beta-blockers (Eston and Connolly 1996). Cardioselective 
beta-blockers such as bisoprolol do not seem to have as pronounced effects on 
the RPE response compared to non-cardioselective betablockers, such as 
carvedilol. Therefore, the authors concluded that RPE can be used to determine 
exercise intensity in patients taking cardioselective beta-blockers.  Before 
starting exercise testing participants were presented with the 6 – 20 RPE scale 
(Borg, 1998).  
 
Standardised instructions, specific to using the RPE scale (Figure 2.2) in 
estimation mode were given: 
(i) The top and bottom ratings were anchored to previous experience of no 
exertion at all and maximal effort.  
(ii) Patients were instructed to give an over all rating of the exertion 
incorporating physical, muscular and cardiorespiratory sensations. 
(iii) They were advised that there was no right or wrong answer. 
(iv) Verbal descriptors as well as the numerical values were used. 
(v) The scale was on view at all times throughout the test so that patients could 
report their RPE at any time to ensure their comfort. 
 
The exercise test was stopped if any of the following were reported: 
a. Chest Pain 
b. Intolerable shortness of breath  
c. Dizziness, pallor and diaphoresis 
d. Participant requested the test to be terminated 
e. RPE ≥ 14 on the Borg scale 
 
6 No exertion at all 
7  
8 Extremely light 
9 Very light 
10  
11 Light 
12  
13 Somewhat hard 
14  
15 Hard (heavy) 
16  
17 Very hard 
18  
19 Extremely hard 
20 Maximal exertion 
 
Figure 2.2 Rating of perceived exertion (Borg, 1998) 
 
 
2.3.5 Functional exercise capacity: Sub-maximal exercise test 
Prior to the sub-maximal exercise tolerance test commencing participants were 
fitted with a pulse oximeter to allow HR to be monitored. After validating the use 
of a two-minute practice walk (Study 1, Chapter 3a), this was used prior to the 
baseline 6MWT; the protocol is detailed below. HR and distance were recorded 
at the end of each minute of the walk tests in order to calculate the heart-rate-
walking speed index (Buckley et al., 2010). This was calculated by dividing the 
total number of heart beats by walking distance attained during the test and 
multiplied by 10 to describe heart beats per 10 m walked.  
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2.3.5.1 Walk test protocols 
The 2MWT and the 6MWT were conducted using a standardised approach. A 
20 metre course was marked in a level CR Gymnasium, with chairs placed 
every 5 metres. Before performing the practice test, patients were presented 
with the 6 – 20 RPE scale (Borg, 1998). Standardised instructions regarding 
RPE (Figure 2.1) were given before each participant began walking. The area is 
one that is seldom travelled to avoid disruption. The turnaround points were 
clearly marked with cones. A starting line which marked the beginning and end 
of each lap was marked on one of the cones. The test protocol is based on the 
American Thoracic Society guidelines (2002), which provide a standardised 
approach for performing the test. 
 
Required Equipment 
a. A stopwatch 
b. A lap counter 
c. Small cones to mark the turnaround points 
d. Chairs located along the walking course 
e. A clipboard for paperwork 
f. Access to emergency equipment and a telephone  
g. An electronic blood pressure machine 
h. A pulse oximeter 
i. A Borg Scale of Perceived Exertion (Borg, 1998) 
 
 
 
Patient Preparation 
a. Patients were advised to wear comfortable clothing, with appropriate 
footwear for walking 
b. Patients could use their normal walking aids during the test 
c. The patients were advised to continue to take their normal medication 
d. Patients were asked to avoid eating a meal one hour prior to the test 
e. Patients were advised not have exercised vigorously within 2 hours of the 
test 
f. Blood samples for testing BNP levels were obtained prior to testing 
 
Measurements 
A portable pulse oximeter (Nonin Onyx II 9550 %SpO2 digital fingertip pulse 
oximeter) was used to measure and record baseline heart rate. Pulse 
irregularity was noted before starting the test by a manual check. The pulse 
oximeter was lightweight, battery powered and held in place so that the patient 
did not have to hold or stabilise it and was worn throughout the walk. 
The patient was asked to stand and rate their baseline dyspnoea and overall 
fatigue using the Borg Scale (Borg, 1998). The lap counter was set to zero and 
the timer to 6 minutes, and the patient moved to the starting point 
 
The patient was instructed as follows: 
 
“The object of the test is to walk as far as possible for 6 (or 2 if undertaking two-
minute practice test) minutes. You will walk around these cones. Six minutes is 
a long time to walk, so you will be exerting yourself. You will probably get out of 
breath or become tired. You can slow down, or stop and rest as necessary, but 
you should resume walking as soon as you are able. 
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You will be walking around the cones. You should move quickly around the 
cones and continue without hesitation (demonstrate by walking one lap; walk 
and pivot around the cones briskly). 
 
I am going to use this counter to keep track of the number of laps you complete. 
I will click each time you turn around at this starting line. Remember that the 
object is to walk as far as possible in 2/6 minutes, but don’t try to run or jog. 
 
Start now.” 
 
1. The patient was positioned at the starting line. As soon as the patient 
started to walk, the timer was started. 
2. The patient was not spoken to during the test other than using standard 
phrases of encouragement. Each time the patient returned to the starting 
line, the lap counter was clicked once  
3. Heart rate and rating of perceived exertion were checked at the end of 
each minute and recorded, along with the distance walked and any 
reported symptoms, on the treatment card. At the end of each minute the 
patient was informed that they were doing well and that they had x 
minutes to go. If the patient needed to stop and rest during the test, they 
were reminded to continue to walk as soon as they were able. The timer 
was not paused during rest periods. If the patient stopped before the 2 or 
6 minutes end point and refused to continue/it was considered 
inappropriate for them to continue the test was discontinued. The 
distance, the time stopped and the reason for stopping prematurely was 
recorded on the treatment record. 
4. When the timer was 15 seconds from completion, the patient was 
advised: 
 
“In a moment I am going to tell you to stop. When I do, just stop where you are 
and I will come to you.”  
 
5. When the timer rang, the patient was asked to stop. HR, blood pressure 
and RPE were recorded at the end of the test.  
6. The patient was congratulated and offered a drink of water. 
 
 
 
 
Variability 
Sources of variability caused by the test procedure were controlled as much as 
possible by following the protocol above. Repeat testing was performed at a 
similar time of day to minimise intraday variability. 
 
 
Practice Tests 
A practice test is not needed in most clinical settings, but is recommended when 
undertaking research studies. The baseline 6MWT was performed 20 minutes 
after the practice test (2MWT).  
 
 
Encouragement 
Only the standardised phrases below were used during the test: 
 
At the end of each minute: “You are doing well. You have x minutes to go.” 
 
When a patient stopped to rest: “Continue walking whenever you feel able to.” 
 
When the timer was 15 seconds from completion: “In a moment I am going to 
tell you to stop. When I do this, just stop right where you are and I will come 
over to you.” 
 
When the timer rang: “Stop!” 
 
 
 
 
Interpretation  
Total distance walked was recorded for all tests performed, and changes 
expressed as an absolute value. Total distance walked was also expressed as 
an estimated MET value by calculating the average pace per minute. Distance, 
HR and RPE were recorded at the end of each minute for heart rate-work rate 
comparison. 
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2.3.6 Quality of life 
 
The New York Heart Association (NYHA) classification stratifies patients 
according to physical activity/exercise limitation (Table 2.2). It was used in this 
study to provide a subjective measure of disability, although it has a limited 
relation to objective measures of exercise capacity (Lainchbury and Richards, 
2002). The QoL questionnaires were administered after completion of the 
6MWT. If a patient presented a limitation in completing the questionnaires, such 
as difficulty reading, the health professional offered assistance. The instructions 
at the top of the HADS questionnaire (Appendix 9) were read out to the patient 
and the health professionals encouraged the patients to choose answers based 
on symptoms they had experienced during the previous week and asked them 
to provide spontaneous answers without excessive reflection. The MLHFQ 
(Appendix 10) was then administered. The instructions at the top of the 
questionnaire were read out to the patient and they were asked to circle the 0, 
1, 2, 3, 4 or 5 to indicate how much their life was affected by their condition. If a 
question did not apply to them, they were asked to circle the 0 after that 
question. The National Audit for Cardiac Rehabilitation Physical Activity 
questionnaire (Appendix 11) was used to assess patient exercise/activity levels. 
Patients self-reported the number of occasions during a seven-day period that 
they had carried out strenuous, moderate or low intensity activity for a duration 
in excess of 15 minutes, and indicated whether they were currently taking 
regular physical activity on average 5 times a week active for 30 minutes. Blood 
pressure and HR were checked again prior to the participant leaving the 
department, to ensure that they had returned to baseline levels. 
 
    Table 2.2 New York Heart Association classification 
I  No limitation of activity  
II  Slight limitation of activity 
III  Marked limitation of activity 
IV  Inability to carry out activity 
 
 
2.4 Exercise training protocol 
The training programme followed guidelines of the British Association for 
Cardiovascular Prevention and Rehabilitation (BACPR) (2012) and the 
Association of Chartered Physiotherapists in Cardiac Rehabilitation (ACPICR) 
(2009). Participants attended supervised exercise training sessions twice a 
week for 12 weeks, with an Exercise Physiologist, student physiotherapist and a 
Heart Failure Specialist Nurse present at each session. Sessions consisted of a 
10 to 15 minute warm up, 22 minutes moderate intensity aerobic exercise and 
low intensity resistance/active recovery exercises (Appendix 12). Intensity was 
set in accordance with the ACPICR (2009), using a target HR of 40 – 60% of 
HRR and/or RPE of 12-13 on Borg’s scale. HR is routinely used for exercise 
prescription due to the existing linear relationship between HR and VO2 and the 
use of RPE scales is based on the findings that demonstrate that strain 
perception increases linearly with exercise intensity (Carvalho and Mezzani, 
2011). Borg scale RPE values between 11 and 13 are reliable for exercise 
training prescription in CHF patients on beta-blockers, assuring an energy 
expenditure lying between the first and second ventilatory thresholds (Carvalho 
et al., 2009). Furthermore, with the high incidence of atrial fibrillation in this 
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population the RPE scale is particularly useful as the HR versus intensity 
relationship may be affected. These levels were also recorded in relation to an 
estimated MET level determined from the initial 6MWT. Over the 12 weeks, the 
exercise programme was progressed on the basis of increasing the level of 
work to always attain these levels. A 10-minute cool down period completed the 
exercise session, followed by relaxation activities and education. Blood 
pressure and HR were measured before each session; HR and RPE were 
monitored during the exercise session, with a final HR check following 
relaxation. Valid consent was obtained from the patient prior to each exercise 
session.  
 
In addition to supervised sessions, participants were also asked to undertake 
exercise/physical activity of moderate intensity for 30 minutes on at least three 
days of the week. On completion of the 12-week course participants attended 
for a re-assessment as detailed above (T2 and T2b), with a further assessment 
6 months later (T3). 
 
 
 
 
 
CHAPTER 3 
 
 
The use of walking and step tests in heart failure 
rehabilitation 
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Overview: 
Exercise intensity should be prescribed from an appropriate assessment. The 
gold standard method is an incremental cardiopulmonary exercise test (CPET) 
with respiratory gas analysis, which directly measures VO2 at the first and 
second ventilatory thresholds and peak VO2 (Carvalho and Mezzani, 2011). 
However, in routine clinical practice CPET is seldom available, particularly for 
CHF patients. Sub-maximal tests using HR and RPE as descriptors of energy 
expenditure are therefore used.  
 
In this chapter two tests (a practice test prior to a 6MWT and an adapted 
Chester step test) have been evaluated and adapted for use in CHF 
populations; the aim being to make adaptations to current protocols that can 
enhance their reliability, validity and practicality of use for outpatient clinical 
settings (hospital, community or home venues). Study 1 evaluated the two-
minute walk test (2MWT) as a practice test prior to a 6MWT and Study 2 an 
adapted Chester step test (CST). 
 
 
 
 
 
 
3a, Study 1  
Do patients with chronic heart failure  
need a full six-minute practice test? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aspects of this chapter were presented at the British Cardiovascular Society 
Annual Conference July 2013 (see Appendix 13) 
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3.1 Abstract 
Background: The 6MWT is a useful measure of functional capacity for people 
with moderate to severe cardiorespiratory impairment (e.g. chronic heart failure; 
CHF). A practice 6MWT test is recommended in both clinical practice and 
research to increase the reliability of the test by aiming to filter out influences of 
familiarisation, pacing and motivation on final outcome tests. The effects of 
fatigue from a full six-minute practice test are also of practical concern in 
influencing 6MWT results.  
Objective: The aims of this small study were to examine the efficacy of a two 
minute practice walk test in predicting 6MWD, whilst providing enough 
familiarisation in patients with CHF and to assess the efficacy of a two-minute 
versus a six-minute practice test on pacing and possible fatigue during a 
subsequent 6MWT.  
Methods: Twenty patients diagnosed with CHF (55% following myocardial 
infarction) were recruited. All patients were stable on optimal medical therapy 
for at least four weeks; all had exertional dyspnoea, fatigue or both and were 
classified according to NYHA functional class II to III. Patients were allocated 
into two groups. Group 1 (n = 10; 9 male) performed a two-minute self-paced 
practice walk test (Grp1-2min), had a 20 minute rest, followed by a 6MWT. 
Group 2 (n = 10; 7 male) performed a full six-minute practice test (Grp2-6min), 
had 20 minutes rest, followed by a 6MWT. Heart rate (HR) and ratings of 
perceived exertion (RPE) were monitored throughout all tests.  
Results: Practice and baseline 6MWT distance in Grp2-6min were the same 
(404 ± 94 m vs 424 ± 81; p = .123). Actual baseline 6MWT distance walked in 
Grp1-2min was not significantly different (345 ± 83 m vs 329 ± 96; p = .212) to 
the distance extrapolated from the mean distance walked during the two minute 
practice (115 ± 28 m). Effects of pacing or fatigue on walking pace were 
assessed between practice and baseline 6MWT using a bias ± 95% limits of 
agreement (LoA) analysis. There was no difference (p = .823) in walking pace 
during the two-minute practice test (57.5 ± 3.8 m.min-1) and the baseline 6MWT 
(57.8 ± 14.7 m.min-1). Although walking paces were different  (p = .042) 
between Grp1-2min (56.1 ± 16.1 m.min-1) and Grp2-6min (70.6  ± 13.6 m.min-1) 
in the baseline tests their respective mean heart rate (HR), % heart rate reserve 
(HRR), heart-rate-walking speed index (HRWSI) and rating of perceived 
exertion (RPE) were the same: HR 103 ± 10 beat.min-1 vs 99 ± 11 beat.min-1 (p 
= .360); %HRR  65 ± 28% vs 60 ± 14% (p = .684); HRWSI 19.4 ± 7.9 vs 14.2 ± 
3.1 beats per 10 m walked (p = .068) and RPE 12.7 ± 1.2 vs 11.7 ± .8 (p = 
.052). Comparison of the HRWSI also provides further evidence around 
reliability of a two-minute practice walk.  
Conclusions: A two-minute practice test was as good as a full six-minute 
practice test in predicting baseline 6MWD in this cohort of patients with CHF. 
This demonstrates that a two-minute practice test can be used equally as well 
but saves valuable clinical assessment time (and thus costs). Furthermore a 
two-minute practice may reduce subsequent fatigue (in some low functioning 
patients) during the baseline 6MWT. Ideally a third trial, either on the same day 
or on another day within one week would have added further confirmation to 
whether a two-minute test does suitably achieve the same “reliability” 
improvements as a full six-minute practice test. Comparison of HRWSI provides 
further evidence for demonstrating the reliability effects of a two-minute practice 
test. 
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3.2 Introduction 
The 6MWT is a popular and useful clinical measure of functional capacity, 
aimed particularly at people with moderately severe impairment (ATS, 2002; 
Enright, 2003); thus increased six-minute walk test distance is used routinely as 
an outcome measure for chronic heart failure (CHF)-rehabilitation (Guazzi et al., 
2009). Patients with CHF are restricted by shortness of breath or fatigue during 
exercise. Breathlessness is frequently the prominent symptom during rapidly 
incremental protocols, and fatigue often occurs during gradually incremented 
tests (Tavazzi et al., 2001). The 6MWT therefore gives a more accurate 
representation of the ability of patients with CHF to perform sub-maximal 
activities of daily living due to the self-selected pace/intensity and the ability to 
include breaks to rest (Riley et al., 1992).  
 
The 6MWT is considered a sub-maximal exercise test due to execution time, 
simplicity and greater acceptance by patients (Faggiano et al, 2004). However, 
Kosak and Smith (2005) suggested that the 6MWT may induce significant 
fatigue and the need for rest stops in patients with COPD, thereby being a 
better measure of endurance. Two further studies have demonstrated that 
fatigue occurs during a 6MWT in patients with spinal muscular atrophy (Montes 
et al., 2010) and polio (Skough Vreede et al., 2013).  
In 1997 Faggiano et al. showed that oxygen uptake (VO2) during a 6MWT was 
on average only 15% lower than peak VO2 during a symptom-limited 
cardiopulmonary exercise test. Seven (27%) of 26 CHF patients in the study 
exercised on a predominantly anaerobic metabolism and showed a 6MWT VO2 
equal to or higher than peak VO2. Consequently, the 6MWT appears to have 
features of both a sub-maximal test and a maximal test and could therefore be 
used to assess the maximal functional capacity in some patients with heart 
failure, particularly those with more severe CHF and severely limited exercise 
capacity. Guimarães et al. (2008) also reported that the 6MWT could actually 
demand a high level of exercise intensity from the patient, expressed by a 
respiratory quotient >1.0. Thus standardizing the 6MWT and using the Borg 
scale to guide walking pace was proposed to ensure that patients undergo a 
sub-maximal walking test.  
 
Both in clinical practice and in research when using the 6MWT in CHF, a 
practice test is recommended to increase the reliability of the test by filtering out 
the influences of familiarisation on final outcome tests, as discussed in Chapter 
1. Current recommendations suggest that patients need to perform a full 
practice test, but there is concern that this may induce the need for rest stops. 
The 2MWT is considered a valid and time-efficient measure of self-paced 
walking speed, less hampered by fatigue than longer walking tests (see Chapter 
1).   
 
 
The aim of this study was to examine the efficacy of a two minute practice walk 
test as a time and cost-saving alternative compared to the recommended six-
minute practice test, used to familiarise patients with CHF in order to ensure the 
reporting of reliable outcomes compared to baseline. The following hypothesis 
was explored: a two-minute practice walk test provides adequate and 
appropriate preparation prior to performing a baseline 6MWT.
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3.3 Methods 
3.3.1 Participants 
A subgroup of the larger intervention study (Study 4, Chapter 5) of 20 patients, 
diagnosed with CHF was recruited to this study. All patients were referred to a 
hospital-based CR exercise training programme. Participants were stable on 
optimal medical therapy for at least four weeks and had exertional dyspnoea, 
fatigue or both and were classified according to NYHA functional class II to III. 
See Chapter 2 for details of recruitment, Hospital Trust and Regional Ethical 
approval, Patient Information and consent. 
 
 
3.3.2 Procedures 
Prior to starting the exercise programme participants were randomly allocated 
into two groups. Participants in group 1 (Grp1-2min; n = 10; 9 male) underwent 
a self-paced two-minute practice walk test, followed by 20 minutes rest before 
performing their baseline 6MWT. Patients in group 2 (Grp2-6min; n = 10; 7 
male) underwent a self-paced practice 6MWT, followed by 20 minutes rest 
before performing their baseline 6MWT. Heart rate (HR) and ratings of 
perceived exertion (RPE) were monitored throughout all tests and were 
recorded each minute. Blood pressure (BP) was measured pre and post testing. 
Heart rate reserve (HRR) was calculated using the methods described in 
Chapter 2. Distance walked each minute and total 2MWT distance and 6MWT 
distance were recorded. 6MWT distance was then used to calculate the walking 
pace. HRWSI was calculated using the methods described in Chapter 2. 
 
 
3.3.3 Walk test protocol 
See General Methods, Chapter 2. Standardised instructions, information and 
verbal encouragement were given by the experienced CR Exercise Practitioner 
(a Specialist Physiotherapist or a Senior Exercise Physiologist) throughout all 
walk tests in order to address the problem of reproducibility.  
 
 
3.3.4 Data analysis 
Data were assessed for the normality of their distributions via the Shapiro-Wilk 
prior to analysis. The t-test for independent samples analysed differences in 
between-group baseline characteristics. Following analysis using a factorial 
(mixed) two way Analysis of Variance (ANOVA), between-group differences in 
HR, %HRR walking distance and pace were tested using t-test for independent 
samples. Within-subjects differences were analysed using the t-test for related 
samples (paired t-test); the Mann Whitney U test was used to measure 
between-group differences in RPE and the Wilcoxon signed ranks test for 
within-subjects differences. The 6MWT distance extrapolated from the two 
minute practice walk distance and the actual baseline 6MWT distance were also 
compared using the t-test for related samples (paired t-test), and the Pearson 
Correlation assessed the relationship between the practice 2MWT distance and 
the baseline 6MWT distance in Grp1-2min. Effects of pacing or fatigue on 
walking pace were further assessed between practice and baseline 6MWT 
using a bias ± 95% limits of agreement (LoA) analysis using the equation: mean 
difference ± 1.96(standard deviation), as recommended by Buckley (2011) 
when measuring reliability in exercise tests. Data analysis was conducted using 
SPSS version 21.0 and alpha was set at the.05 level. 
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3.4 Results   
Twenty participants (mean age 69 ± 11 years; 16 male), all prescribed beta-
blockade medication, completed the testing. Table 3.1 summarises patient 
baseline characteristics. 
 
Walk distance: Participants in Grp1-2min walked between 55m – 160m during 
the two minute practice walk test; in Grp2-6min participants walked between 
270m – 550m during the practice 6MWT. Baseline 6MWT distance for Grp1-
2min ranged between 155 m and 495 m and Grp2-6min between 310 m and 
585 m. Practice and baseline 6MWT distance in Grp2-6min were the same (404 
± 94 m vs 424 ± 81; p = .123). Mean walking performance data for distance and 
pace are summarised in Table 3.2. 
 
 
The predicted 6MWT distance in Grp1-2min, calculated from the mean distance 
walked during the two-minute practice (115 ± 28 m), was extrapolated to 345 ± 
83 m in 6 minutes. The actual baseline distance walked in this group was not 
different (329 ± 96; p = .212) to the predicted distance.  
 
 
 
 
 
 
 
Table 3.1 Patient baseline characteristics 
 Grp1-2min Grp2-6min p value 
Mean age (years) 73 ± 10 65 ± 12 .066 
Male/female (n) 9/1 7/3  
Body mass index 
(kg/m²) 
30.7 ± 3.9 31.1 ± 3.0 .436 
CHF cause: 
idiopathic/ischaemic 
(n) 
4/6 4/6  
Left ventricular 
ejection fraction (%) 
34 ± 7 33 ± 9 .774 
NYHA class II/III (n) 5/5 8/2  
Resting heart rate 
(beat. min-1) 
76 ± 11 66 ± 18 .295 
 
 
Walk pace 
There was a significant high correlation between the two-minute practice test 
and the baseline 6MWT in pace (r = .945; p = .0001) and in distance (r = .924; p 
= .0001) in Grp1-2min. There were no significant between-group differences in 
walking pace at two minutes during the practice tests (p < .122). However, 
during the baseline tests there were significant differences in pace (Table 3.2). 
Walking pace at minute 2 of the practice and the baseline tests were the same 
in Grp1-2min (p = .823) but were different in Grp2-6min, who walked 
significantly faster in the baseline test compared with the practice test (68.3 
±15.7 m.min-1 vs 72.0 ± 13.7 m.min-1  ; p = .007). However, pace at minute 6 of 
the practice walk and the baseline test were the same in Grp2-6min (67.3 ± 
15.6 m.min-1 vs 70.6 ± 13.6 m.min-1; p = .123). Walking pace at minutes 2 and 6 
of the baseline test were also the same in Grp1-2min (p = .300). The mean 
difference at minute 2 in Grp1-2min was .250 m.min-1   with the 95% LoA being  
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-6.97 to 6.47 m.min-1; between minutes 2 and 6 of the baseline test the mean 
difference was -1.68 m.min-1 with the 95% LoA being -11.14 to 7.78 m.min-1.  In 
Grp2-6min the mean difference at minute 6 was 3.4 m.min-1 with the 95% LoA 
being -15.5 to 8.82 m.min-1.                   
 
Heart rate and ratings of perceived exertion 
Although there was a significant difference between the two groups in walking 
distance achieved (p = .028) and thus walking speed (p = .038) during the 
baseline 6MWT (Table 3.2) both groups were performing at the same relative 
exercise intensities as noted by the similar HRs, %HRR and RPEs: 
- HR at minute 2: Grp1-2min = 95 ± 9 beat. min-1, Grp2-6min = 92 ± 9 
beat.min-1; p = .461  
- HR at minute 6: Grp1-2min = 103 ± 10 beat.min-1, Grp2-6min = 99 ± 11 
beat.min-1; p = .360)  
-   %HRR at minute 2: Grp1-2min = 44 ± 29%, Grp2-6min = 46 ± 15%; p =                                                        
.865  
- %HRR at minute 6: Grp1-2min = 65 ± 28%, Grp2-6min = 60 ± 14%; p = .684). 
 
In Grp1-2min there were significant differences in the end of test RPEs between 
the practice test and the baseline test, and between RPE at minute 2 and 
minute 6 in the baseline 6MWT (Table 3.3). RPE at minute 2 of the practice and 
the baseline tests were the same in both groups (Table 3.3, p = 1.0), as were 
the RPEs in minutes 2 and 6 in the baseline 6MWT for Grp2-6min (11.2 ± .8 vs 
11.7 ± .8; p = .258). 
 
Table 3.2 Walking distances (SD) and paces (SD) of a six-minute walk test 
(6MWT) preceded by a two-minute or a six-minute practice test in CHF 
patients  
 
Group Practice 
distance 
walked (m) 
Baseline 
6MWT 
distance 
(m) 
Practice 
test walk 
pace at 2 
mins 
(m.min-1) 
Baseline 
6MWT 
walk pace 
at 2 mins 
(m.min-1) 
Baseline 
6MWT walk 
pace at 6 
mins 
(m.min-1) 
1 
(Two 
minute 
practice) 
115 (28) 
 
 
329 (96) 57.5 (13.8) 
 
 
57.8 (14.7)ˠ 
 
 
56.1 (16.1)² 
2 
(Six 
minute 
practice) 
404 (94) *424 (81)ˠ 68.3 (15.7) **72.0 
(13.7)¹ 
 
***70.6 
(13.6)³ 
* Significantly greater walking distance than Group 1 (p = .028)  
**Significantly faster walking pace than Group 1 (p = .038) 
*** Significantly faster walking pace than Group 1 (p = .042) 
ˠ Not significantly different from the practice test 
¹Significantly faster walking pace than practice test at minute 2 (p = .007) 
²Not significantly different from minute 2 
³Significantly slower walking pace than that at minute 2 (p = .040) 
 
 
 
 
Table 3.3 Mean RPE (SD) at minutes 2 and 6 in the practice test and the 
baseline test   
  
 RPE at 2-
minutes 
practice test 
RPE at 2-
minutes in 
baseline 6MWT 
RPE at 6-
minutes in 
baseline 6MWT 
Group 1 
 
*11.5  (1.3) 11.5 (.9)** *12.7 (1.2)** 
Group 2  11.2 (.4) 11.2 (.8) 11.7 (.8) 
* Significant difference between practice test minute 2 and baseline minute 6 (p = .046) 
** Significant difference between baseline minute 2 and baseline minute 6 (p = .026) 
 
Heart-rate-walking speed index 
Participants in Grp1-2min had a mean HRWSI during the practice test of 17.6 ± 
6.3 and 19.4 ± 7.9 at baseline (p = .127). In Grp2-6min the HRWSI during the 
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practice test was 15.1 ± 3.9, and at baseline 14.2 ± 3.1 beats per 10m walked 
(p = .202). HRWSI was the same in both groups during the practice walk (p = 
.314) and during the baseline 6MWT (p = .068). 
 
 
 
 
3.5 Discussion 
The key findings in this study are that the 6MWT distance extrapolated from the 
two-minute practice walk in Grp1-2min was not significantly different to the 
actual baseline distance that they walked (predicted: 345 ± 83 m vs actual: 329 
± 96 m; p = .212). In this cohort regression analysis was not deemed necessary 
to calculate predicted 6MWT performance from the practice 2MWT as speed 
stayed constant (Table 3.3) across practice and baseline tests. From the 
perspective of performance (walking speed), the presence of significant fatigue 
caused by a practice test could not be shown (practice 2MWT pace 57.5 ± 13.8 
m.min-1   vs baseline 6MWT pace 56.1 ± 16.1 m.min-1 ; p = .823). However, 
based on the RPE, it could be postulated that a greater RPE at the end of the 
6MWT compared to the 2MWT practice was a sign of fatigue. Kosak and Smith 
(2005) hypothesised that the overestimation of 6MWD was due to the effects of 
fatigue during the longer test. The small but significant difference in end of test 
RPEs were11.5 ± 1.3 vs 12.7 ± 1.2; p = .046. These results reflect the end of 
test RPE scores reported by Leung et al. (2006) in their study of 45 patients 
with COPD (mean modified Borg Scale RPE in 2MWT 3.0 ± 2.0, in 6MWT 3.3 ± 
.3; p < .05) and support the hypothesis that CHF patients being required to 
perform a full six-minute practice walk may actually cause fatigue in the follow-
up 6MWT in many of the patients; thereby affecting “test performance” of Grp1-
2min. In contrast Grp2-6min reported the same RPE at minutes 2 and 6 of the 
baseline test (11.2 ± .8 vs 11.7 ± .8; p = .258). But although the baseline RPEs 
were the same, the actual walking pace reduced from minute 2 to minute 6 in 
Grp2-6min (from 72.0 ± 13.7 m.min-1 to 70.6 ± 13.6 m.min-1 ; p = .040) 
suggesting an element of fatigue. Montes et al. (2010) also reported that the 
mean distances walked during the first minute (57.5 m) and the sixth minute 
(48.0 m) of a 6MWT were considerably different (p = .0003) in 18 participants 
with spinal muscular atrophy, observing a mean velocity decrease for each 
successive minute walked. Skough Vreede et al. (2013) investigated 18 patients 
with post-polio syndrome and also found a 14% decrease (p < .001) in walking 
pace from the beginning to the end of the 6MWT.  
 
Although mean baseline 6MWT distance in Grp2-6min was higher than the 
practice 6MWT distance, there was no clinically significant (see Chapter 1) or 
statistically significant difference (practice: 404 ± 94 m vs baseline: 424 ± 81; p 
= .123). Grp2-6min walked a significantly greater distance in the baseline 
6MWT than Grp1-2min (Grp2-6min: 424 ± 81 m vs Grp1-2min: 329 ± 96 m; p = 
.028) and although no statistically significant differences between the group 
characteristics, Grp2-6min were around 8 years younger (65 ± 12 years vs 73 ± 
10 years; p = .066) which could account for their significantly faster walking 
pace. But although the mean baseline 6MWT distance and the mean walking 
pace (Grp1-2min 56.1 ± 16.1 m.min-1  vs Grp2-6min 70.6 ± 13.6 ; p = .042) were 
significantly different between groups, participants performed at the same 
relative exercise intensities as noted by the similar HR, RPE, %HRR and 
HRWSI. The RPEs and %HRRs indicate that participants were walking at sub-
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maximal intensities. Interestingly Grp2-6min walked 5% faster (p = .007) during 
the first 2 minutes of the baseline test compared to the practice test, possibly 
due to the effects of familiarisation, but as mentioned above, the pace had 
decreased significantly by minute 6 (p = .040). Another factor designed to 
alleviate such a reliability issue, which influences walking distance/performance 
as an outcome measure, is the use of a heart-rate- walking speed index.  
 
The deviation around the mean at minute 2 in practice and baseline tests was 
6.5 m.min-1 above or 7.0 m.min-1   below and 7.78 m.min-1 above or 11.14 m.min-
1 below for baseline minute 2 vs minute 6 for Grp1-2min;  8.8 m.min-1 above or 
15.5 m.min-1  below for Grp2-6min at 6 minutes. The mean difference for Grp1-
2min at minute 2 and minute 2 vs 6 were small compared with the mean 
2MWDs, and with a bias < 4 it therefore seems that the reliability of the 2MWT 
in terms of LoA was high. 
 
3.6 Conclusion 
It appears that both a two-minute and a six-minute practice test were equally 
effective in predicting baseline 6MWD in this cohort of patients with CHF. The 
significant correlations between 2MWT and 6MWT distance and pace concur 
with the findings of Leung et al. (2006) and suggest the good validity of the 
2MWT, supporting the 2MWT as a practice test in this small cohort of patients 
with CHF. Comparison of HRWSI also appears to provide further evidence 
around reliability of a two-minute practice walk. These data have provided 
preliminary evidence that a two-minute practice test saves valuable clinical 
assessment time and is as effective in influencing pacing as a six-minute 
practice walk for CHF patients being assessed by a 6MWT, whilst potentially 
reducing risk of fatigue seen in a 6MWT. A two-minute practice showed 
encouraging responses as a time-saving (and thus cost-saving) alternative. 
Ideally a third trial, either on the same day or on another day within one week 
would be required to assess whether a two-minute test does suitably achieve 
the same “reliability” needs as a six-minute test.  
 
In summary, this study shows that a two-minute practice walk test achieves the 
same benefit as a full six-minute practice walk test prior to performing a 
baseline 6MWT, and that the use of HRWSI is considered an additional means 
of confirming the effects of familiarisation. 
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3b, Study 2  
Reliability and oxygen cost validity of  
a 4-inch step test in CHF patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.7 Abstract 
 
Background: The assessment of functional capacity in patients with CHF has 
been performed by simple and easy to apply methods that are representative of 
everyday activities, such as the 6MWT. The starting MET values for the lowest 
step height (6-inch) of the current Chester step test (CST) protocol is 3.3 METs 
which, for many CHF patients is too high a starting point and does not allow 
them to perform the ideal 3 to 4 stages of the test to gain relevant data on 
function responses to exertion.  
Objectives: to examine the reliability of a 4-inch (10 cm) step test protocol in 
beta-blocked patients with CHF.  
Methods: 10 patients with CHF performed the CST twice on two separate days 
(CST1 and CST2), with at least five days between tests. CST1 was also 
performed to familiarise participants with the procedures of having to wear 
cardiorespiratory assessment equipment. HR, RPE and total number of steps 
were recorded in both tests and VO2 was measured in CST2. A 3-minute 
duration was used at each stage due to the issues of slowed oxygen kinetics in 
CHF patients, as discussed by Walker et al. (2012) in their unpublished step 
test study.  
Results: The characteristics of the CHF patients in this cohort were 
representative of those attending exercise-based CR programmes; mean age 
was 64 ± 15 years, 50% of patients had a history of IHD, mean LVEF was < 
30%, all were prescribed beta-blockade medication and half had atrial 
fibrillation. There were no intertrial differences between HR each minute of each 
of the stages 1 to 3 (stage 1 p = .086, stage 2 p = .077, stage 3 p = .325) and 
RPE (stage 1 p = .287, stage 2 p = .165, stage 3 p = .289). 95% LoA revealed 
acceptable agreement around mean HR.  HR, RPE and VO2 increased through 
the incremental stages of CST2; the end point of RPE 14 was achieved at a 
mean %HRR of 68.1 ± 18.5%. Measured VO2 was significantly lower than that 
predicted from the ACSM equation (p = .005).  
Conclusion: In this small study on CHF, HR was reliable on a test re-test basis. 
VO2 measures show the delayed oxygen kinetics and HR rise was blunted, all of 
which is in keeping with previous evidence of incremental exercise testing 
responses in CHF. The validity of estimated METs from an adapted CST for 
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CHF patients is questioned due to the discrepancy between estimates made 
using the ACSM (2008) calculation and the actual measures during CST2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.8 Introduction 
3.8.1 Background 
Assessment of cardiorespiratory fitness in CHF research studies is generally by 
the measurement of maximal oxygen uptake (VO2 max) or aerobic capacity. 
Factors considered to influence peak VO2 include resting LVEF, chronotropic 
response, stroke volume response, skeletal muscle mass and vascular function, 
endothelial function and neurohormonal systems (Lainchbury and Richards, 
2012).  VO2 max is usually defined as the point at which VO2 reaches a plateau 
despite a further increase in work rate. In CHF such a plateau is rarely seen and 
thus is defined as peak VO2 (Kemps et al., 2009). The VO2 kinetics in response 
to increasing exercise intensity reflects delayed attainment of steady state in 
CHF patients (Zhang et al., 1993). Although maximal cardiorespiratory testing is 
the ‘gold standard’ method for establishing baseline fitness, exercise 
prescription and for assessing programme outcomes following an intervention, it 
is often impractical to use in CR settings due to costs of the equipment and the 
staffing time and expertise required (Sykes and Roberts, 2004). The use of valid 
outcomes from reliable and inexpensive tools to measure efficacy is vital for the 
National Health Service in the UK. The 6MWT is often used as an outcome 
measure for CHF-rehabilitation (Guazzi et al., 2009), however space may be 
lacking. The Chester step test (CST), designed by Sykes in 1995, can be used 
as a safe and practical outcome measure for CR programmes (ACPICR, 2009). 
It is a 5-stage incremental submaximal test, each stage lasting for 2 minutes. 
The test is externally paced by a metronome, with the stepping rate 
commencing at 15 steps per minute (spm) and progressing by 5 steps per 
minute per stage (Sykes, 2005). Measurements that can be recorded during 
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each minute of the CST include number of steps, HR, RPE and VO2. In the 
existing UK CR guidelines the recommended testing end points include a 75% 
percentage of maximum HR (%HR max) or 60% HRR and/or < 14 RPE (Borg 6 
– 20 scale; Borg, 1998) or Borg 4.5 CR-10. The current protocol is designed for 
using either a 6, 8, 10 or 12 inch step height, but the starting MET value at 
stage 1 using a 6-inch step is considered to be too great to allow for many lower 
functioning CHF patients to be able to complete the ideal of three to four stages 
required for estimating maximal exercise capacity. Having three or four stages 
also allows for establishing a relationship between HR and RPE and a 
corresponding work rate (METs) for physical activity guidance and exercise 
prescription (Latin et al., 2001; Sykes and Roberts, 2004; Buckley et al., 2004; 
ACSM Guidelines, 2008). However, the populations assessed to produce these 
estimates were younger and healthier than CHF populations attending CR 
exercise programmes.  Improvement in CST performance can be quantified in 
terms of either an improvement in predicted peak metabolic equivalents 
(METS), duration to a predetermined HR or a lowered HR or RPE for any given 
work rate.  
 
3.8.2 Reliability and validity of the CST 
The literature review raises questions regarding the validity of sub-maximal 
tests for patients with CHF.  Sykes and Roberts (2004) and Buckley et al. 
(2004) evaluated the use of the CST in healthy subjects. Sykes and Roberts 
(2004) assessed the test-retest repeatability of the CST in 68 healthy 
participants and found it to be good. The results demonstrated that the CST 
was a valid predictor of aerobic capacity in both males and females from a wide 
range of ages (18 – 52 years) and fitness levels (Table 3.4), though its accuracy 
of prediction in subjects with an aerobic capacity of 25 – 68 ml/kg/min was poor 
(5 – 15%).  Results from a relatively young and healthy cohort, however, are not 
likely transferable to a CHF population. The reliability and validity of the 
measures taken during the CST to predict VO2 max and to prescribe aerobic 
exercise were evaluated by Buckley et al. (2004); including HR, RPE, age-
estimated HR max and estimated VO2 of each stage of the test (Table 3.4). The 
CST was performed twice, on different days, by 13 participants (7 males) aged 
22 years. HR, RPE and actual VO2 were the same at each stage for both trials. 
Intertrial bias ± 95% limits of agreement (95% LoA) of HR reached acceptable 
limits at stage 4 of the CST, and for RPE at stages 3 and 4. Age predicted HR 
max significantly overestimated the actual HR max by 5 beats per minute (beat. 
min-1) (p = 0.016); in addition estimated versus actual VO2 at each stage during 
both trials showed errors between 11% and 19%. Thus, in healthy participants 
the CST is a reliable test to detect improvements in aerobic fitness and a valid 
means to estimate metabolic equivalents, but its ability to predict actual VO2 
max is questionable. 
 
There are no published studies to date assessing the use of the CST in patients 
with CHF, yet it is recommended for CR (ACPICR, 2009; BACPR, 2012). Two 
studies (Camargo et al., 2011; Karloh et al., 2013) have tested the reliability 
and/or validity of the CST in patients with Chronic Obstructive Pulmonary 
Disease (COPD). Camargo et al. (2011) examined the reliability of the CST in 
32 patients with COPD and analysed the correlation with pulmonary function 
tests and exercise test results. Thirty two patients undertook 2 tests on different 
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days using a 20cm step; 31 patients completed stage 1 (2 minutes), 19 
completed stage 2 (4 minutes), 7 completed stage 3 (6 minutes) and only 1 
patient completed stage 4 and the first minute of stage 5 of the CST (9 
minutes). The authors reported a significant correlation between the number of 
steps and 6MWD (r = 0.60, p = 0.001). Peak VO2 was estimated from the CST 
in 6 patients only and was higher than that measured at peak of a cycle test 
(30.8 ± 5.1 ml/kg/min vs 17.4 ± 4.5 ml/kg/min, p = 0.001). The number of steps 
in the first and second test was highly reproducible (66 ± 41 steps vs 68 ± 41 
steps) with no difference in HR between the 2 tests at peak exercise or at the 
end of each stage. This is in contrast to an early study by Swinburn et al (1985) 
who reported large inter-subject differences (p < 0.01) in step performance 
(range 14 – 126 steps) between the first and fourth attempts in 17 patients with 
severe chronic lung disease. It appears that the CST used by Camargo et al. 
(2011) was reproducible but was of a very short duration for the majority of 
patients with COPD. The authors therefore considered the CST an exercise 
testing protocol that was difficult for COPD patients to perform as most of their 
patients stopped during the second stage of the test.  It would therefore seem 
that the same would be true for CHF. Karloh et al. (2013) used a 17cm step to 
investigate whether the CST was able to differentiate functional capacity and 
the magnitude of cardiorespiratory response of 10 patients with COPD (mean 
age 64 years) from 10 healthy subjects (mean age 63 years). The authors 
tested participants to 90% of HR max/or any limiting symptom and compared 
CST results with shuttle walk and 6MWT performances. The COPD group 
achieved 27% lower performance in the 6MWT, 42% lower in the shuttle walk 
and 49% lower in the CST, demonstrating that the CST was a valid tool in the 
assessment of functional capacity of COPD patients and was able to distinguish 
them from healthy subjects. Unpublished data from a study by Walker et al. 
(2012) showed that VO2 values at each stage of a CST using the standardised 
protocol were significantly lower in CHF patients than the ACSM estimates, and 
also demonstrated a slowed oxygen kinetics. METs estimates from a step test 
using two minutes at each stage therefore over-estimated exercise intensity for 
patients with CHF.  
 
The prescriptive validity of the CST in relation to participants being treated with 
beta-blockade medication also remains unclear. Due to the blunting of the 
normal HR response to exercise by beta-blockers and chronotropic 
incompetence, VO2 max predicted from the CST could easily be challenged at 
stages above 65% VO2 max (Buckley et al., 2004). Beta-blockers reduce the 
attainable VO2 max (Eston and Connolly, 1996) by causing a significant slowing 
of the kinetics of the oxygen transport system (Kowalchuk and Hughson, 1990). 
The ability to undertake physical activities is enabled by an increase in VO2 in 
healthy adults this is achieved by a 2.2-fold increase in HR plus a 0.3-fold 
increase in stroke volume and a 1.5-fold increase in arterio-venous oxygen 
difference. Thus chronotropic incompetence can be a significant cause 
of/contributor to exercise intolerance and as such has a prominent role in CHF 
(Brubaker et al., 2011). Patients with CHF can have a reduction in peak VO2 
that is 15% to 40% below that of age-matched controls due to reduced cardiac 
output at peak exercise and abnormalities of skeletal muscle and vascular 
function (Sullivan and Hawthorne, 1995). As a result of impaired stroke volume, 
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patients with CHF must rely on increases in HR to augment cardiac output 
which is somewhat ironic as HR is often blunted (Brubaker and Kitzman, 2011).   
 
The aim of this study was to examine the reliability of a commercially available 
step test but with a lowered step height to 4-inches (10 cm) in beta-blocked 
patients with CHF and to look at movement economy as an outcome. However, 
due to issues with equipment liability and patient recruitment the latter was not 
possible. The test was also adapted to using a 3-minute stage duration 
compared to the required 2-minute duration to make further assessments of the 
slowed oxygen kinetics in CHF patients, as discussed by Walker et al. (2012) in 
their unpublished study. The following hypothesis was explored: a modified CST 
is a reliable and suitable sub-maximal alternative test of functional capacity in 
patients with CHF. 
Table 3.4 Reliability and validity of the Chester step test 
Study  Participants  Diagnosis  Protocol  Key Findings 
Sykes K and Roberts A. 
(2004) 
68 subjects 
Mean age 30.6 ± 9.7 
years (range 18 -52 
years) 
69% male 
 
 
 
 
 
 
 
 
Healthy. 
Wide range of abilities. 
VO2 max treadmill test. 
Completed CST on 2 
occasions (CST1, 
CST2). 
30 cm step. 
15 spm initially, 
increasing by 5 spm 
every 2 minutes. End 
points 80% of maximum 
predicted HR or 
perceived exertion of 15 
(Borg) or end of test (10 
minutes). 
High correlation between 
VO2 max and CST1 (r = 
0.92, p < 0.001). 
Good test-retest 
repeatability; mean 
difference between 
repeated predicted 
measures -0.7 mlO2/kg/min.  
LoA analysis showed that 
repeated measures were 
within 4.5 ml/O2/kg/min, 
thus appropriate for use 
where a change in aerobic 
capacity is expected to be 
more than 3.8 mlO2/kg/min 
higher than baseline. 
 
Limitation: transferability to 
CHF populations unclear. 
 
Conclusions: the CST was a 
valid test for the estimation 
of aerobic capacity in this 
group. The error of 
measurement was relatively 
small.  
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Study  Participants  Diagnosis  Protocol  Key Findings 
Buckley JP, Sim J, 
Eston RG et al. 
(2004) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 subjects 
Mean age 22.4 ± 4.6 
years 
54% male 
 
 
 
 
 
 
 
 
 
 
 
Active subjects, 
participating in 
exercise or recreational 
sport 1 – 3 x per week. 
Completed CST on 2 
occasions (CST1, 
CST2), the second test 5 
– 7 days after the first. 
A 30 cm step was used. 
15 spm initially, 
increasing by 5 spm 
every 2 minutes. End 
points 90% of maximum 
predicted HR or 
perceived exertion of 17 
(Borg) or end of test. 
On the third day, less 
than 7 days after CST2, 
a maximal treadmill test 
was performed. 
There was a linear RPE 
response. HR and VO2 
responses were curvilinear. 
RPE, HR and actual VO2 
were the same at each 
stage for CST1 and CST2. 
Measures between CST 
stages were significantly 
different (p < 0.0005). 
LoA of HR reached 
acceptable limits at stage 4 
(-2 ± 10 bpm), and RPE at 
stages 3 (0.2 ± 1.4) and 4 
(0.5 ± 1.9). 
Age-estimated HR max 
significantly overestimated 
actual HR max (p = 0.016).  
 
Limitation: transferability to 
CHF populations unclear. 
 
Conclusion: the reliability of 
the CST to detect 
improvements in aerobic 
fitness was recommended. 
Validity to predict VO2, 
however, was questioned.  
Study  Participants  Diagnosis  Protocol  Key Findings 
de Camargo AA, Justino 
T, de Andrade CHS et 
al. 
(2011) 
32  patients with COPD 
Mean age 69.9 ± 9.0 
years 
91% male 
 
COPD. 
FEV1 < 70% of 
predicted. 
Clinical stability (no 
change in medication 
dosage in the 
preceding 4 weeks). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
On 2 different days, at 
least 48 hours apart, 
patients were 
randomised to perform 
either two 6MWTs (30 
minutes rest between 
the tests) or two CSTs 
(30 minutes rest period 
between the tests). 
 
A 20 cm step was used. 
Two minutes on each 
stage. 
 
The test was terminated 
by the patient (because 
of dyspnoea and/or leg 
fatigue) or by the 
physiotherapist if the 
patient was unable to 
maintain the cadence for 
15 seconds. 
 
HR and SpO2 were 
measured each minute. 
The main outcome of the 
CST was the total 
number of steps taken. 
No differences between 
CST 1 and 2 in HR or SpO2 
at peak exercise or at the 
end of each stage, and the 
reliability analysis revealed 
high ICCs. 
 
The number of steps in the 
first vs the second CST 
showed a mean difference 
of -1.1 spm (LoA -20.2 to 
17.9 steps). 
 
Significant correlation 
between number of steps 
and peak HR (r = 0.55, p = 
0.001). 
 
Limitation: limited stages 
completed, which may have 
limited the accuracy of peak 
VO2 estimates. 
 
Conclusion: The CST is 
highly reproducible in 
patients with COPD, but 
seems to be a difficult test 
for these patients. 
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Study  Participants  Diagnosis  Protocol  Key Findings 
Karloh M, Corrêa KS, 
Martins LQ et al. 
(2013) 
10 patients with COPD 
Mean age 64 ± 10 years 
30% male 
 
10 healthy subjects 
Mean age 63 ± 7 years 
30% male 
COPD diagnosis based 
on clinical and 
spirometry criteria, 
minimum smoking 
history of 20 pack-
years, clinical stability 
in the month prior to 
the beginning of the 
protocol and > 40 
years of age. 
Sedentary individuals, 
with normal spirometry, 
no history of smoking 
and > 40 years of age 
were included in the 
control group. 
Day 1: lung function 
evaluation and shuttle 
walk test. 
Day 2:  the 6MWT. 
Day 3:  the CST. 
 
A 17 cm step was used. 
Two minutes on each 
stage. 
 
End points: 90% of HR 
max/ when the subject 
could no longer keep the 
pace or displayed any 
limiting symptom. 
 
HR, blood oxygen 
saturation (SpO2) and 
dyspnoea (modified 
Borg scale) measured 
before, immediately after 
and at the end of each 
level of the test. 
The COPD group achieved 
a 48.8% lower performance 
in the CST.  
CST level achieved control 
vs COPD group 4.1 ± 1.1 vs 
2.1 ± 0.9 (p < 0.01). 
Number of steps in the CST 
correlated with distance 
walked in the 6MWT (r = 
0.76, p = 0.02). 
Limitation: tests were not 
performed in a randomised 
order.  
 
Conclusion: the CST is valid 
in assessing the functional 
capacity of patients with 
COPD and is able to 
differentiate them from 
healthy individuals. The HR 
response and dyspnoea 
induced by the test was 
similar in the COPD and 
control groups. 
 
 
 
3.9 Methods 
3.9.1 Participants 
A sub-group of 10 patients from the main intervention study were recruited to 
this study; all were referred to a hospital-based CR exercise training 
programme. The characteristics of the CHF participants in this cohort were 
representative of those attending exercise-based CR programmes in the UK 
(NACR, 2013); mean age was 64 ± 15 years, 50% had a history of IHD, mean 
LVEF was < 30%. Participants were stable on optimal medical therapy for at 
least 4 weeks and had exertional dyspnoea, fatigue or both and were classified 
according to New York Heart Association functional class II to III. All were 
prescribed beta-blockade medication and half had atrial fibrillation. Women 
were well represented in this study (50%).  
See Chapter 2 for details of recruitment, Hospital Trust and Regional Ethical 
approval, Patient Information and consent.  
 
 
3.9.2 Procedures 
Each participant performed the adapted CST twice on 2 separate days (CST1 
and CST2), with at least 5 days between tests. CST1 was performed to 
familiarise participants with the procedures of wearing the cardiorespiratory 
assessment equipment where VO2 was not measured, but the face mask was 
worn throughout the test. Testing was conducted using a metronome and a 
commercially-available 4 inch (10 cm) step. This step height was selected due 
to patients with CHF having a decreased exercise tolerance; a lower step 
allowing more of the test to be completed before reaching the end points. 
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Standardised instructions (detailed in Study 1) regarding RPE (Figure 2.1), Borg 
6 – 20 scale (Borg, 1998), were given before each participant began stepping. 
Participants performed the CST using the techniques described in the CST 
manual (Sykes, 2005). Prior to the test commencing they were fitted with a 
pulse oximeter (Nonin Onyx II 9550 %SpO2 digital fingertip pulse oximeter) to 
monitor HR. HR and RPE were recorded within the last 15 seconds of each 
minute of each testing stage. Maximum HR was estimated using the Keteyian 
Method and then used to calculate the test end point of 60% HRR. During CST2 
the actual oxygen cost (VO2; ml/kg/min) was measured continuously via an 
expired gas analysis system - Medgraphics Diagnostics Ultima™ CardiO²® 
CPX Training (MGC Diagnostics Corporation, St Paul, Minnesota). The system 
was calibrated before testing each participant using a 3 litre syringe for flow 
volumes across a range of flow rates and known gases for carbon dioxide and 
oxygen. The reported VO2 was the average over the last 15 seconds of each 
minute at each stage of the CST. The estimated VO2 for each stage of the CST 
was calculated using the ACSM (2008) Guidelines’ equations.  
 
 
3.9.3 Adapted Chester step test protocol 
Resting blood pressure and HR were measured during pre-test screening using 
an automated sphygmomanometer on the left arm.  Once connected to the 
Ultima™ (CST2 only) participants remained seated for 2 minutes before resting 
VO2 and resting HR were recorded, followed by a further recording of both VO2 
and HR after standing for 2 minutes. The metronome was started at a stepping 
rate of 15 spm (stage 1) and participants were asked to commence stepping at 
the appropriate time and step rate for 3 minutes. If required, guidance was 
provided to assist keeping the participant stepping ‘in-time’ with the required 
stepping rate set by the metronome. HR, RPE and actual VO2 (CST2 only) were 
recorded during the last 15 seconds of each minute, while participants 
continued stepping. The CST continued to progress at an increase of 5 spm 
(i.e. stage 3, 25 spm; stage 4, 30 spm) until the participant reached an RPE of 
14 and/or 60% HRR. The maximum test duration for the CST was 12 minutes 
(i.e. end of stage 4). Participants were able to change the lead leg, if they so 
wished, at the beginning of a new step rate. The total number of steps 
performed was recorded at the end of the test. 
 
3.9.4 Data analysis 
Data were assessed for the normality of their distributions via the Shapiro-Wilk 
prior to analysis. Assuming normality, data are expressed as mean ± standard 
deviation (SD) with alpha set to .05. The one-way repeated measures ANOVA 
was used to examine differences between HR, RPE and VO2 (CST2 only) each 
minute of each stage of the two tests.  
 
The analysis then evaluated the difference in HR, RPE and VO2 
a. Across 3 minutes of each stage and 
b. Between stages based on the value captured in the final 15 seconds of 
the stage 
 
The Limits of Agreement (LoA) technique was used to assess the test-retest 
reliability for both HR and RPE between CST1 and CST2 as recommended by 
Buckley (2011). Pearsons correlation coefficient was used to examine 
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relationships between peak HR, peak RPE and total steps in both CST1 and 
CST2. Differences between predicted and actual VO2 (METS) were found not to 
be normally distributed and thus the Wilcoxon signed ranks test was applied. All 
analyses were performed using SPSS version 21.  
 
3.10 Results 
Table 3.5 summarises baseline characteristics.  
In both CST1 and CST2 all participants completed stage 1. Six participants 
completed stage 2 in CST1 and nine in CST2. Five participants completed 
stage 3 in both CST1 and CST2. One participant completed stage 4 in CST1 
and two participants completed stage 4 in CST2.  
 
Table 3.5 Patient baseline characteristics 
Mean age (years) 64 ± 15 
Male/female (n) 5/5 
Body mass index 
(kg/m²) 
30.1 ± 5.1 
CHF cause: 
idiopathic/ischaemic (n) 
5/5 
Left ventricular ejection 
fraction (%) 
29 ± 7 
NYHA class II/III (n) 9/1 
Mean 6-minute walk 
distance (m) 
438 ± 101 
Prescribed beta-
blockade medication 
(%) 
100% 
 
3.10.1 Reliability and reproducibility of the CST in CHF 
Analyses have been performed on stages 1 to 3 as very few participants 
completed stage 4. There were no intertrial differences between HR and RPE 
during stages 1 to 3 (HR: stage 1 p = .089, stage 2 p = .077, stage 3 p = .325; 
RPE: stage 1 p = .287, stage 2 p = .165, stage 3 p = .289). The HR at the end 
of the test was greater by 9 beat. min-1 in CST2 compared to CST1 (CST1  = 91 
± 17, CST2 =  100 ± 16 beat. min-1, p = .0001). RPE at the end of the tests were 
the same (CST 1 = 14.1 ± 0.3, CST2 = 13.9 ± 0.9, p = .202). There was no 
significant difference in the total number of steps between CST1 and CST2 
(149.5 ± 81.8 vs 175 ± 69.8, p = .076). The 95% LoA of HR and RPE are 
summarised in Tables 3.6 and 3.7 respectively.  It was however only possible to 
evaluate responses during stage 1, as in stages 2, 3 and 4 there was only a 
small number of completed pairs of data.  
 
Table 3.6 Limits of Agreement of HR (CST1 vs CST2) taken at minute 2 and 
3 of stage 1 (bias ± 1.96 x SDdiff) 
 
Stage of CST Minute  95% LoA 
(HR- beat. min-1) 
Stage 1 Minute 2 -1.0 ± 18.0 
Minute 3 1.6 ± 11.4 
 
 
Table 3.7 Limits of Agreement of RPE (CST1 vs CST2) taken at minute 2 
and 3 of stage 1 (bias ± 1.96 x SDdiff) 
 
Stage of CST Time 95% LoA 
(RPE) 
Stage 1 2 min -0.5 ± 3.0 
3 min -0.5 ± 2.8 
 
During stage 1 the 95% LoA ranged from 17 beat. min-1 above and 19 beat. 
min-1 below the small mean bias of -1 beat. min-1. Examination of individual data 
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showed that the difference was 23 beats in one patient but in the remaining 9 
patients it was ≤ 8 beats. RPE was as high as 2.5 scale points above or 3.5 
below the mean bias in stage 1, but again this result was due to outliers. One 
patient had an RPE difference of 4 scale points but the remaining patients had 
either no difference, or a difference of 1 or 2 scale points. The small sample 
size of 10 participants does limit robustness of the LoA analysis.  
 
3.10.2 HR, RPE and VO2 responses during CST2 
Six participants completed two CST stages (6 minutes), five completed three 
stages (9 minutes) and two completed all four stages (12 minutes). HR, RPE 
and VO2 responses during each minute of each stage of CST2 can be seen in 
Figures 3.1, 3.2 and 3.3. Mean values show a gradual increase from the mean 
resting VO2 of 2.8 ± .7 ml/kg/min as the intensity of exercise increased through 
the stages. Analysis using the one-way repeated measures ANOVA revealed 
significant differences with p ≤ .05. The t-test for related samples found that HR 
and RPE had increased significantly from minute 1 to minute 3 during stages 1 
and 2. The differences in HR between end stage 1/beginning stage 2, end stage 
2/beginning stage 3 and between end stage 3/beginning stage 4 were not 
significant (p = .109; p = .170; p = .106 respectively). RPE however did increase 
significantly between the stages (p = .004; p = .047; p = .058 respectively). 
Increases in both HR and RPE were not statistically significant during stage 3, 
although the response remained linear (Figures 3.1 and 3.2). VO2 however 
continued to increase significantly from stage 1 until the first minute of stage 4 
(Figure 3.3). The differences in VO2 between end stage 1/beginning stage 2 and 
between end stage 3/beginning stage 4 were also significant (p = .001; p = .059 
respectively). Change between end stage 2/beginning stage 3 was not 
significant (p = .088).  
 
 
 
Minute 1 
HR(bpm) 
Mean(SD) 
Minute 2 
HR(bpm) 
Mean(SD) 
Difference 
HR min 1 
vs HR min 
2 
(p value) 
Minute 3 
HR(bpm) 
Mean(SD) 
Difference 
HR min 1 
vs HR min 
3 
( p value) 
Stage 1 74 (8) 78 (11) .105 82 (10) .013¹ 
Stage 2 86 (34) 91 (7) .23 91 (7) .015² 
Stage 3 92 (12) 95 (16) .190 98 (13) .069 
 
 
 
Figure 3.1 Mean (SD) HR (beat. min-1) at stages 1 to 3 of CST2 
 
 
 
 
 
 
 
H
R
 (
b
p
m
) 
Stage 1 
n = 10 
Stage 2 
n = 9 
Stage 3 
n = 5 
1 
2 
60
65
70
75
80
85
90
95
100
105
Min 1 Min 2 Min 3 Min1 Min 2 Min 3 Min 1 Min 2 Min 3
Mean HR
Linear (Mean
HR)
 
 
 
159 
 
 
 
 
 
 
 
 
 
 
 
 
 Minute 1 
Mean(SD) 
Minute 2 
Mean(SD) 
Difference 
RPE min 1 
vs RPE min 
2 
(p value) 
Minute 3 
Mean(SD) 
Difference 
RPE min 1 
vs RPE min 
3 
(p value) 
Stage 
1 
10.3 (1.3) 10.4 (1.4) .317 10.8 (1.5) .015¹ 
Stage 
2 
11.6 (1.3) 11.8 (1.1) .081 12.4 (1.4) .021² 
Stage 
3 
12.0 (1.0) 12.2 (0.8) .157 12.6 (1.1) .70 
 
 
Figure 3.2 Mean (SD) RPE (Borg 6 – 20 Scale) at stages 1 to 3 of CST2 
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 Minute 1 
Mean(SD) 
Minute 2 
Mean(SD) 
Difference 
VO2 min 1 
vs VO2 min 
2  
(p value) 
Minute 3 
Mean(SD) 
Difference 
VO2 min 1 vs 
VO2  min 3  
(p value) 
Stage 1 6.5 (1.5) 7.7 (1.5) .025¹ 8.2 (1.5)* .006² 
Stage 2 9.3 (1.4) 9.6 (1.7) .012³ 10.1 (1.8)** .0054 
Stage 3 10.0 (2.0) 11.0 (1.9) .0135 11.3 (2.2) .0136 
* Significant difference between VO2 minute 2 and minute 3; p = .001 
** Significant difference between VO2 minute 2 and minute 3; p = .003 
 
 
Figure 3.3 Comparison of mean (SD) VO2 (ml/kg/min) at stages 1 to 3 of 
CST2 in Study 2 with ASCM (2008) predicted VO2 and with the results from 
an unpublished study by Walker et al. (2012) using a three-inch step 
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There were significant modest to high correlations between end of test HR and 
end of test RPE (r = 0.756, p = .011), end of test HR and end of test measured 
(actual) VO2 (r = 0.771, p = .006) and between end of test RPE and end of test 
measured (actual) VO2 (r = 0.659, p = .038). The total number of steps during 
the test had significant high correlations with end of test HR (r = 0.756, p = 
0.011), end of test measured (actual) VO2 (r = 0.717, p = .020) and end of test 
RPE (r = 0.727, p = .017). End of test %HRR ranged from 40% to 95% of 
estimated HRR (mean %HRR 68.1 ± 18.5%) and was significantly higher than 
end of test %HRR during CST1 (51.2 ± 20.2; p = .0001). 
 
The measured VO2 values were significantly lower than the predicted ACSM 
values (p = .005). In stages 1 and 2 actual values were 19% lower than the 
predicted values, in stage 3 they were 23% lower and in stage 4 they were 14% 
lower (Figure 3.5); in addition the actual values were similar to those seen in a 
study by Walker et al. (2012) using a 3-inch step (Figure 3.5). The estimated 
MET values at each stage were therefore also lower; final (estimated) METS 
were 22% lower (p = .005) than those predicted. 
 
 
 
3.11 Discussion 
3.11.1 Reliability and reproducibility  
The CST manual (Sykes, 2005) does not recommend a practice test in order to 
familiarise participants with the test protocol. Initial comparison of HR and RPE 
at stages 1 to 3 of CST1 and CST2 would suggest that a practice test is 
unnecessary, which is similar to young, healthy subjects in keeping with 
Buckley et al. (2004). In this current study end of test HR was statistically and 
clinically higher in CST2 (CST1 91.1 ± 17.5 beat. min-1 vs CST2 100.3 ± 16.7 
beat. min-1, p = .0001). HR reliability was good in nine of the participants; 
although the 95% LoA was 19 beats this seems to be a function of the low 
numbers. RPE was as high as 2.5 scale points above the mean in stage 1, 
which might not be acceptable in a clinical setting as it could be the difference 
between finding exercise moderate (13) and hard (15). But again, with only 10 
participants, the individual variability may have affected the overall results and 
limited the robustness of the LoA analysis. In fact, during stage 1 of CST2, eight 
patients reported an RPE value that was the same or lower than that during 
CST1.   
The similarity between CST1 and CST2 for RPE and total number of steps 
indicated that the CST is reproducible in CHF patients. Although the total 
number of steps was slightly higher in CST2 the difference was not statistically 
significant (p = .076) suggesting that the increase in total steps and final HR 
were due to familiarisation. Whether or not an increase of 25 steps (equivalent 
to an extra minute on stage 3) is clinically significant remains to be confirmed. 
Thus, for moderate intensity activity, the similar HR for the same stepping work 
rate, which led to participants exercising to a higher level on CST2, is a trend 
that appears to concur with previous studies on RPE in younger and older 
adults, including those with IHD (Lamb et al., 1999; Buckley et al., 2000; 
Buckley et al., 2004; Faulkner et al., 2007; Buckley et al., 2009; Buckley and 
Borg, 2011). However, there is little published on the reliability and validity of 
RPE in CHF. 
 
 
 
 
163 
 
3.11.2 HR, RPE and VO2 responses during CST2   
CST2 duration ranged from 5 minutes to 12 minutes, depending on the fitness 
of the individual. All participants completed 3 minutes (stage 1), six of the cohort 
completed 6 minutes (2 stages), five completed 9 minutes (3 stages) and two 
completed all 4 stages (12 minutes) using a low (4-inch step). In order to obtain 
valid data from an exercise test in CHF, small increments in workload and a 
total duration of 8 to 12 minutes are recommended (Lainchbury and Richards, 
2012). Thus the total exercise time in the majority of patients was sufficient and 
useful for assessing cardiorespiratory responses (American Thoracic Society, 
2003).  
There is evidence of a blunted HR response during the CST, as there was no 
significant increase in HR from minute 1 to minute 2 in the first 3 stages of 
CST2 (Figure 3.3). This does not correspond to the VO2 kinetics (Figure 3.5), 
which did show a levelling off; therefore HR in this cohort does correspond well 
to VO2 as in healthy subjects, which is suggestive of chronotropic incompetence 
(discussed later). The end of test %HRR during CST1 (51.2 ± 20.2) was within 
the target %HRR range recommended by the ACPICR guidelines (2009) for 
patients with CHF (40 – 60% HRR) and slightly above the target range during 
CST2 (68.1 ± 18.5). Participants reached an end point of RPE 14 in CST2 
which relates to a %HRR of approximately 70% therefore not dissimilar to the 
68% HRR achieved. The high RPE values at a lower %HRR during CST1 
(51%) could have been caused by participants overestimating RPE due to 
effects of beta-blockers (reduced HR response, reduced kinetics of the oxygen 
transport system and local muscle fatigue) and lack of familiarisation with the 
test. Alternatively, the test duration may have influenced the magnitude of 
symptoms as much as the increments in work rate, which is in contrast to the 
findings of Kearon et al. (1991) who reported that the incremental changes 
during the CST determine the increase in perceived exertion. A shorter test may 
have improved reproducibility, but would not have been appropriate given the 
increases in VO2 seen at each minute of the test.  
The increases in HR were not statistically significant during stage 3, which could 
have been due to chronotropic incompetence. Chronotropic incompetence did 
not limit exercise capacity in a study of 16 patients with CHF (Clarke and Coats, 
1995), and as increases in RPE paralleled HR in this current study it suggests 
that participants were not compromised by a blunted HR response. VO2 
continued to increase significantly until stage 4, which changes the linear 
relationship between HR, RPE and VO2. Nonetheless the significant moderate 
to high correlations between actual end of test VO2 and end of test HR (r = 
0.771, p = .006) and between end of test RPE (r = 0.659, p = .038) suggest that 
there remained a relationship between the values. HR and RPE appear to have 
reduced going into the latter stages, but this is likely to be a function of the 
number of participants reducing from 9 down to 5 and thus the data is based on 
remaining, fitter patients. The total number of steps during the test also had 
significant high correlations with final HR (r = 0.756, p = .011), actual final VO2 (r 
= 0.717, p = .020) and final RPE (r = 0.727, p = .017).  
 
Using the HR-VO2 relationship to estimate peak VO2 could be problematic in 
CHF due to the slowed oxygen kinetics (chronotropic incompetence), where the 
changes in the slopes of their respective responses to a given incremented 
step-height/work rate are not proportional as in healthy individuals (ACSM, 
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2008). There was a significant difference between the estimated (predicted) and 
the measured (actual) final VO2 which intimates that abnormal HR responses 
during the CST can affect this estimate (predicted 14.8 ± 1.9 vs actual 11.7 ± 
2.1 ml/kg/min, p = .005). Debigaré et al (2000) reported that a faster increment 
in work rate resulted in a lower HR observed during testing. Thus it seems that 
even 3 minutes at each stage may have been insufficient to allow appropriate 
HR responses in this cohort. Exercise prescription based on predicted peak VO2 
values and estimated peak METS would therefore be at a higher intensity than 
that using actual values attained and as such may be higher than patients with 
CHF might tolerate. Predicted (estimated) METS were 15 – 24% higher than the 
actual (estimated) METS at each stage; predicted (estimated) final METS being 
significantly higher than actual (estimated) end of test METS (4.2 ± 0.6 vs 3.3 ± 
0.6, p = .005). Interestingly mean VO2 at rest was 0.7 ml/kg/min less than the 
value of 3.5 ml/kg/O2 on which METs estimates are based - 3.5 ml/kg/O2 being 
equal to 1 MET (Buckley et al., 2004). These differences are clinically significant 
for patients with CHF due to their poor exercise capacity; a difference of only 1 
MET could result in some patients working at or above their ventilatory 
threshold. 
 
 
3.12 Conclusions  
The CST using a 4 inch (10 cm) step, and a duration of 3 minutes at each 
stage, appears to be a suitable submaximal exercise test for patients with CHF 
as all 10 participants completed the first stage (3 minutes) of the test, nine 
participants completed stage 2 (6 minutes) and five completed stage 3 (9 
minutes). This test starts at a predicted workload < 3 METS, which appears to 
be acceptable to this cohort of patients with CHF.  The CST was reproducible in 
this small cohort of CHF patients. Although no significant intertrial difference 
was observed in HR and RPE, the deviation around the means suggests that 
further trials with a larger cohort of beta-blocked CHF patients are required to 
confirm this finding. 
In this study on patients with CHF, HR was reliable on a test re-test basis, but 
its validity is challenged as an indicator of oxygen uptake response and kinetics 
in comparison with healthy individuals where these two factors are normally 
closely linked. HR rise over the course of the 3-minute stages did not follow 
proportionate to the VO2. VO2 continued to rise into the third minute, which 
shows the delayed oxygen kinetics, whereas HR rise was blunted (chronotropic 
incompetence), all of which is in keeping with previous evidence of incremental 
exercise testing responses in CHF.  
In summary, an adapted, low CST is a reliable and suitable sub-maximal 
alternative test of functional capacity in patients with CHF, but the validity of 
estimated METs using the ACSM calculations from this test for CHF patients is 
questioned due to the discrepancy between estimates made and the actual 
measures during CST2. New MET estimation equations for CHF across a range 
of activities are likely to be required and warrant further investigation. 
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CHAPTER 4 
 
 
 Study 3:  
Acute response of NT-proBNP following moderate intensity 
exercise in patients with CHF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An abridged version of this chapter was presented at the American College of 
Sports Medicine Conference, May 2014 (Appendix 14) 
4.1 Abstract 
Background: Brain or B-type Natriuretic Peptide (BNP) is a marker of 
myocardial dysfunction and is reported to increase significantly following 
maximal exercise in patients with chronic heart failure (CHF). Little evidence, 
however, exists in relation to BNP response following recommended 
submaximal exercise sessions for patients with CHF. If raised levels of BNP do 
in fact affect physical function and health status, this knowledge may inform 
whether or not rest/recovery days are required between exercise sessions for 
patients with CHF.  
Objective: This study aimed to assess changes to NT-pro BNP levels 
immediately, and at 24, 48 and 72 hours following a recommended CHF 
exercise training session.  
Methods: 18 participants with CHF (14 males; aged 46 to 80 years), had 
venous blood samples taken at four time points following 20 to 30 mins 
continuous moderate intensity exercise (40 – 60% of heart rate reserve and/or 
Borg perceived exertion 12-13).  
Results:  Baseline (resting) and immediate post-exercise BNP levels were 
unchanged: 1741 ± 1991 ng/l and 1700 ± 1618 ng/l, respectively. These 
remained unchanged at 24, 48 and 72 hours post exercise: 1840 ± 2328 ng/l; 
1550 ± 1710 ng/l; 1660 ± 1671 ng/l, although this cohort response does mask 
some of the individual variability as represented by the wide standard 
deviations.  
Conclusion: Moderate intensity exercise training in most NYHA class II and III 
CHF patients does not acutely increase BNP levels and, therefore, there is no 
requirement for ‘rest days’ between exercise training sessions. 
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4.2 Introduction 
The effect of exercise on plasma BNP levels in CHF patients has received little 
attention. As the half-life of BNP in plasma is 5 to 10 times longer than for ANP, 
which is cleared almost immediately, BNP may not be subject to rapid changes. 
The synthesis of BNP is considered to be regulated at a constant rate which 
would suggest that exercise of a short duration might not be sufficient to 
increase BNP secretion and thereby result in an increase in plasma levels (Kato 
et al., 2000). Results have been conflicting (see Chapter 1); with several studies 
reporting increases in plasma BNP levels immediately following exercise and 
others reporting that BNP levels do not increase with exercise. Krüger et al. 
(2004) interestingly reported a decrease in BNP levels following exercise in six 
of the 37 patients in their study. A similar finding was reported only in one 
previous abstract by Lainchbury et al. (2001). 
 
The studies referred to have examined BNP responses only as far as 24 hours 
post acute exercise. This may not be a sufficient duration in pathological 
populations, especially moving beyond 24 hours post exercise where the longer 
term effects of acute exercise will be determined. CR standards and guidelines 
recommend that patients attend supervised exercise sessions at least twice per 
week, but there is no supporting evidence regarding the number of days there 
should be between sessions and knowledge of changes in BNP data would 
provide novel insight into the short and long term stress placed on the 
cardiovascular system by rehabilitation exercise and thus add to the debate 
about adequate recovery between sessions. In addition, it is not known whether 
baseline BNP levels contribute to the conflicting results published to date. 
Further research may help establish clear recommendations regarding the 
frequency of exercise sessions for patients with heart failure (Leslie, 2010), thus 
the aim of this current study was to assess the changes in plasma NT-pro BNP 
immediately after, and at 24, 48 and 72 hours following a supervised CR 
exercise training session for patients with CHF.  
 
The following hypothesis was explored: NT-proBNP does not increase following 
a moderate intensity exercise session. 
 
4.3 Methods 
4.3.1 Participants 
The study population consisted of a subgroup of 18 patients in the main study 
(Study 4, Chapter 5). All participants had LVSD (determined via 
echocardiography) and were referred to a hospital-based CR exercise training 
programme. Participants were stable on optimal medical therapy for at least 4 
weeks and had exertional dyspnoea, fatigue or both and were classified 
according to New York Heart Association functional class II to III.  In contrast 
with several previous studies (Matsumo et al., 1995; Steele et al., 1997; Friedl 
et al., 1999 and McNairy et al., 2002), medication was not withheld prior to 
testing. See Chapter 2 for details of recruitment, Trust and Regional Ethics 
Committee approval, and patient information and consent.  
 
4.3.2 Design and procedures  
The measurements for this study were taken in the participants’ third-week of 
their rehabilitation programme once they had been familiarised with the 
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structure and intensity of the standard exercise session (described in the next 
section). Blood was sampled using a polyethylene cannula placed in an 
antecubital vein in the left or right arm by a trained Research Nurse and 
collected into an EDTA (anticoagulant) sampling tube. Blood samples were 
collected immediately following and at 24, 48, and 72 hours after the exercise 
training session. Participants continued with their normal activities between 
these time points. The blood samples were transferred to the hospital’s Clinical 
Chemistry laboratory as described in Chapter 2.  Although BNP levels do not 
appear to rise and fall in any circadian rhythm (Jensen et al., 1997), samples 
were obtained at the same time of day to reduce the possibility of diurnal 
variation. 
 
4.3.3 Training protocol 
All patients were enrolled in an outpatient supervised exercise training 
programme where they attended twice per week for 12 weeks. The 12-week 
training programme is described in Chapter 2.  
 
4.3.4 Data analysis 
Data analysis was conducted using SPSS version 21.0 and alpha was set at the 
.05 level. Data were assessed for the normality of their distributions via the 
Shapiro-Wilk and for homogeneity of variance prior to analysis. It seems from 
previous research studies that baseline levels could possibly influence the 
kinetics of BNP/NT-proBNP thereby affecting the results; therefore patients 
were subdivided according to baseline levels. The related-samples Friedman’s 
two-way analysis of variance by ranks test was conducted to measure 
differences at each time point both for the cohort group and for the sub groups. 
The Mann Whitney U test was used to examine differences between sub 
groups. Spearman’s rho was conducted to determine correlation coefficients. A 
partial correlation test was used to determine the correlation between NT-
proBNP levels at each time point and also change in NT-proBNP levels 
between each time point, corrected for age. 
 
4.4 Results 
Table 4.1 summarises the patient baseline characteristics.  
Mean resting HR increased from 64.3 ± 10.4 beat. min-1 to 88.8 ± 10.2 beat. 
min-1 during the exercise session, representing a mean of 45.0 ± 19.8% 
predicted HRR, and participants reported mean RPE values of 13.3 ± 0.8. Mean 
NT-proBNP levels (Table 5.2) showed no significant change from baseline (pre-
exercise) through all subsequent time points up to and including 72 hours post 
exercise (p = .288).  
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Table 4.1 Patient baseline characteristics 
 
Mean age (years) 67 (12) 
Male/female (number) 14/4 
Body mass index 
(kg/m²) 
29.0 (4.1) 
CHF cause: 
idiopathic/ischaemic (n) 
5/13 
Left ventricular ejection 
fraction (%) 
32 (8) 
NYHA class II/III (n) 13/5 
Mean 6-minute walk 
distance (m) 
416 (120) 
Beta-blockade: 
bisoprolol/carvedilol (n) 
 
16/2 
ACE inhibitors/ARB-II 
(n) 
12/5 
Diuretics (n) 14 
 NYHA = New York Heart Association  
 ACE = angiotensin-converting enzyme     ARB-II = angiotensin receptor blocker 
 
 
 
Table 4.2 Mean NT-proBNP levels following exercise in 18 patients with 
stable CHF 
 
 Baseline Post 
exercise 
24 hours 
post 
exercise 
48 hours 
post 
exercise 
72 hours 
post 
exercise 
Mean NT-
proBNP 
level 
(ng/l) 
1741  
(1991) 
1700  
(1618) 
1840  
(2328) 
1550 
(1710) 
1660  
(1671) 
 
 
All values expressed as mean (standard deviation)  Change in NT-proBNP levels at all time points NS (p = .288) 
 
 
 
 
Significant modest correlations existed between age and NT-proBNP levels at 
rest and all time points during recovery (baseline r = .56, p = .016; post exercise 
r = .56, p = .015; 24 hours post exercise r = .689, p = .002; 48 hours post 
exercise r = .622, p = .006; 72 hours post exercise r = .621, p = .006) (Figure 
4.1). When corrected for age there remained a significant high correlation 
between NT-proBNP levels at all time points (baseline to post exercise r = .958, 
p = .0001; post exercise to 24 hours r = .973, p = .0001; 24 hours to 48 hours r 
= .976, p = .0001; 48 hours to 72 hours r = .952, p = .0001), confirming that 
there was no significant change in levels at each time point.  Correlations 
between baseline NT-proBNP levels and BMI (r = -.092, p = .717) and LVEF (r 
= -.099, p = .756) were very low (NS), there was a low (NS) correlation between 
baseline NT-proBNP levels and NYHA class (r = .203, p = .419) and a modest 
correlation (NS) with 6MWD (r = -.450, p = .061). 
 There were modest to very high correlations, corrected for age, in the changes 
(Δ) in NT-proBNP levels between time points from baseline to 48 hours, with 
correlations becoming low (NS) at 48 to 72 hours (Δ baseline/post exercise and 
Δ post exercise/24 hours r = -.607, coefficient of determination 37%, p = .010; Δ 
post exercise/24 hours and 24/48 hours r = -.913, coefficient of determination 
83%, p = .0001; Δ 24/48 hours and Δ 48/72 hours r = .203, coefficient of 
determination 4%, p = .434). Despite no significant “cohort” change consequent 
to exercise, the analysis of individual participant changes in NT-proBNP from 
baseline to 72 hours post exercise suggests a degree of heterogeneity  (Figure 
4.2) that are worthy of further examination.  
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Figure 4.1 Acute NT-proBNP responses over 72 hours after exercise and 
its relationship to age in CHF patients  
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Figure 4.3 highlights two subgroups, those who had an increase and those who 
had a decrease in NT-proBNP from baseline to immediately post-exercise. 
Seven of the 10 participants who had resting NT-proBNP values < 1000 ng/l 
demonstrated post-exercise increases from a mean of 540 ± 341 ng/l at 
baseline to a mean of 715 ± 577 ng/l (p = .051).  In contrast, 6 of the 8 
participants who had baseline levels ≥1000 ng/l, demonstrated a decrease from 
a mean of 2848 ± 1967 ng/l at baseline to 2406 ± 1693 ng/l (p = .069).  
Consequently, participants were divided into 2 subgroups for further data 
analysis; group 1 baseline NT-proBNP <1000 ng/l, group 2 baseline NT-proBNP 
≥1000 ng/l (Table 4.3).  
 
 
 
Figure 4.2 Kinetics of NT-proBNP immediately after and at 24, 48 and 72   
hours post exercise, in rank order from the lowest participant’s baseline 
level 
-1500
-1000
-500
0
500
1000
0 5 10 15 ΔNT-proBNP 
level (ng/l) base 
to post exercise 
by patient
 
 
 
177 
 
Figure 4.3 Baseline to immediate post exercise change in NT-proBNP level 
(ng/l) (x-axis is rank order of patients’ resting NT-proBNP level; 0 – 10 had 
NT-proBNP values < 1000 ng/l and 11 – 18 >1000 ng/l) 
 
 
 
 
 
 
 
 
 
Table 4.3 Change in NT-proBNP levels groups 1 and 2 
 
Mean change  Group 1 
baseline < 1000 ng/l 
Group 2 
baseline ≥ 1000 ng/l 
Baseline to post 
exercise 
175(26)* -442(544)* 
Post exercise to 24 
hours 
-137(204) 387(954) 
24 hours to 48 hours -41(103) -419(910) 
48 hours to 72 hours 60(157) -13(599) 
All values expressed as mean (± standard deviation)                    *Δ significantly different between groups, p = .043 
 
 
 
 
 
 
Participants in group 2 were significantly older (Table 4.4): group 1 age 61 ± 14 
years, group 2 age 75 ±  5 years; p = .016 and, by design, had significantly 
higher NT-proBNP levels at all time points (baseline: group 1 540  ±  341 ng/l, 
group 2 2848  ± 1967 ng/l, p = .0001; post exercise: group 1 715  ±  577 ng/l, 
group 2 2406  ± 1693 ng/l, p = .003; 24 hours: group 1 578  ±  494 ng/l, group 2 
2793  ± 2568 ng/l, p = .001; 48 hours: group 1 537  ±  451 ng/l, group 2 2374  ± 
1765 ng/l, p = .001; 72 hours group 1 597  ±  562 ng/l, group 2 2503  ± 1602 
ng/l, p = .001). There was a significant difference between groups (Table 4.3) in 
the change in NT-proBNP levels between baseline and immediately post 
exercise (group 1:  +175 ± 267 ng/l, group 2:  -442 ± 544 ng/l; p = 0.043). The 
mean NT-proBNP levels showed no significant change within the groups from 
baseline through all subsequent time points up to and including 72 hours post 
exercise (group 1 p = .183; group 2 p = .434).   
 
 
 
 
 
 
Table 4.4 Characteristics of sub groups 1 and 2 
 
 Group 1 (n=10) 
< 1000 ng/l 
Group 2 (n=8) 
>1000 ng/l 
p value 
BMI (kg/m²) 28.7(3.8) 29.5(4.9) .705 
LVEF % 33(8) 32(9) .970 
6MWD (m) 457(119) 351(99) .138 
Age (years) 61(14) 75(5) .016 
Male/female 9/1 5/3  
Number of 
sessions pre 
testing 
6(4) 9(9) .192 
Values expressed as mean (± standard deviation)        Group 1 baseline NT-proBNP <1000ng/l, group 2 ≥1000ng/l 
 
 
4.5 Discussion 
In a small cohort of NYHA II and III CHF patients performing a moderate 
intensity exercise programme (%HRR = 45.0 ± 19.8; RPE 13.3 ± 0.8) there was 
no significant change in NT-proBNP levels. The very low (NS) correlations 
between baseline NT-proBNP levels and a number of health markers rule these 
markers out as influencing factors on raised NT-proBNP; BMI (r = -.092, p = 
.717); LVEF (r = -.099, p = .756); NYHA class (r = .203, p = .419); 6MWD (r = -
.450, p = .061). There are conflicting results in the current evidence on the link 
between exercise and raised plasma BNP. Several studies have reported non-
significant changes in plasma BNP levels following exercise in patients with 
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CHF (Friedl et al.,1999; McNairy et al., 2002; Krüger et al., 2004; Normandin et 
al., 2013). The most likely reason for the observed results in this current study is 
that the exercise was not at an intensity sufficient to cause substantive 
increases in preload and thus myocyte stretch that would lead to circulating NT-
proBNP levels to increase. Only 44% of the cohort was exercising at or above 
45%HRR. There are, however, other possible reasons or contributing factors 
that warrant further investigation. Unchanged BNP levels following exercise 
could be a result of increased BNP clearance, due to enhanced enzymatic 
degradation of BNP by neutral endopeptidase (NEP) (Krüger et al., 2004). NEP 
is widely expressed, with the highest concentrations being present in the renal 
proximal tubules (Mangiafico et al., 2013); therefore assessment of differences 
in renal function in future studies may help explain this.   
 
Another pathophysiological mechanism that could be responsible for the results 
of this study includes a reduction in BNP production and/or release during 
exercise (Krüger et al., 2004). In symptomatic CHF, the already compromised 
ventricles may fail to synthesize BNP relative to the demands of the system. 
This would lead to impaired capacity to release and regulate active BNP in 
response to exercise-associated acute volume expansion with corresponding 
increases in ventricular pressure thereby limiting the ability to maintain 
homeostasis in response to the demands placed upon the myocardium. This 
may explain the differences observed in the sub-analysis between groups of 
differentiated baseline NT-proBNP levels, whereby 60% of patients in group 1 
(baseline NT-proBNP level < 1000 ng/l) had a seemingly appropriate small yet 
≥10% increase in NT-proBNP level immediately post exercise compared with 
only 25% in group 2 (baseline NT-proBNP level ≥ 1000 ng/l). In contrast 63% of 
patients in group 2, i.e. those with NT-proBNP levels indicating more severe 
CHF, had a ≥10% decrease in NT-proBNP level immediately post exercise, 
compared with only 10% in group 1. When comparing the mean values at 
baseline and post exercise, in group 1 there was a 24% increase - not of 
statistical significance but possibly of clinical significance (Koglin et al., 2001) - 
and in group 2 a 16% decrease (NS) in NT-proBNP level. In group 1 the mean 
value returned to within 7% of baseline at 24 hours post exercise and was lower 
(NS) than baseline 48 hours post exercise. Although the changes from baseline 
to post exercise were not significant, they demonstrate a trend in both groups 
that could be explored in further, larger studies. These findings are in accord 
with the results of the study by Krüger et al. (2004), as 16% of patients in their 
study also had an observed reduction (NS) in BNP levels following exercise 
(mean age 71 years compared with 57 years in the group with an observed 
increase). Lainchbury et al. (2001) previously reported a similar finding in their 
abstract; although the overall mean BNP increased with exercise in 68 patients 
with NYHA class III to IV CHF (p < 0.05), BNP decreased immediately following 
exercise in a group of 15 CHF patients (-1.5 ± 2.8 pmol/l), seven (45%) of whom 
died in follow-up. Those who died had a higher incidence of IHD, lower LVEF 
and higher baseline BNP (52 ± 20 vs 33 ± 24 pmol/l, p = 0.013). Only eight of 
the 53 (15%) patients who had an increase in BNP during exercise died during 
the two-year follow-up period.  In the study by McNairy et al. (2002), although 
patients with a higher baseline BNP level (1712 ± 356 pg/ml) had an increase in 
BNP (NS) following exercise; it was less of an increase (18%) than those with a 
lower (126 ± 26 pg/ml) baseline level (30%).  
 
 
 
181 
 
 
 As previously discussed in Chapter 1, Mangiafico et al. (2013) stated that there 
is a growing body of evidence suggesting that dysregulation of the natriuretic 
peptide system exists in cardiovascular disease and HF. The authors report that 
increased BNP levels seen in patients with CHF were initially thought to be due 
to the body’s attempt to compensate for the increased water retention and 
cardiac stress associated with LVD. Recent studies using more sensitive 
technologies demonstrate that, in patients with CHF and high plasma BNP 
levels assessed by conventional assays, that there is a lack of mature BNP. 
Thus, despite the elevated levels of BNP seen in advanced CHF, sensitive 
mass-spectrometry indicates that less biologically active precursors and 
multiple degraded forms of BNP are actually present. This suggests that altered 
processing of BNP occurs, resulting in a deficiency of the hormone and thereby 
its protective properties. This factor could also have contributed to the results of 
this study in that the compromised myocardium may have failed to release 
active BNP in response to exercise, particularly in group 2 with baseline NT-
proBNP levels ≥1000 ng/l.  
 
4.6 Limitations 
There are some limitations of this study and specifically the effect of 
medications on BNP. In this study, 89% of patients were prescribed bisoprolol, 
a non-vasodilating beta-blocker, 67% an ACE inhibitor and 78% diuretic 
medication. Diuretics and ACE inhibitors can reduce BNP levels, and some 
beta-blockers can increase them in the short term (Cowie et al., 2010). Even so, 
medication is unlikely to have had an impact on NT-proBNP levels in this study 
as all patients were optimised on CHF medication and were stable for at least 4 
weeks prior to recruitment. Second, the mean number of exercise sessions 
attended prior to undertaking this study was 7, therefore it is possible (albeit 
unlikely) that there had been a minor training effect not seen in previous studies 
of CHF populations. Scharhag et al. (2008) proposed that myocardial response 
or adaptation both during and following exercise might be regulated by the 
release of BNP as a study in healthy athletes showed higher increases in NT-
proBNP levels in nonelite runners with lower training distances. This suggests 
that training reduces BNP production during exercise. Increased release of BNP 
seen in other studies could therefore be due to acute myocardial stress initially 
when commencing exercise (Scharhag et al., 2008) in severely deconditioned 
and non-active patients. Finally, although a relatively small study population of 
18, the sample size is comparable with other published studies investigating the 
kinetics of BNP in response to exercise.  
 
4.7 Conclusion 
The results of this current study, undertaken in routine clinical practice with a 
representative population of UK CHF patients, confirm that moderate intensity 
exercise training does not acutely increase NT-proBNP levels in NYHA class II 
and III patients. It appears that patients with already high NT-proBNP levels do 
not have an increase in NT-proBNP immediately following moderate intensity 
exercise or in a subsequent 72-hour period. The results do, however, reveal 
individual variability in the acute response of NT-proBNP release to exercise 
that is worthy of further study.  At this point in time there are no NT-proBNP 
data that point to a requirement for ‘rest days’ between exercise training 
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sessions. The dose and the mode of exercise that will elicit a physiological 
increase in NT-proBNP are yet to be confirmed. The hypothesis - NT-proBNP 
does not increase following a moderate intensity exercise session – is 
accepted. 
 
CHAPTER 5 
 
 
 
Study 4  
The efficacy of exercise-based cardiac rehabilitation for 
class II and III heart failure patients 
 
 
 
 
 
 
  
 
5.1 Abstract  
Objective: This study investigated the efficacy of a moderate intensity exercise 
rehabilitation programme for participants with heart failure (CHF). Outcomes 
included changes in functional exercise capacity, cardiac biomarkers cardiac 
function and quality of life (QoL).  
Methods: 51 patients (37 male) aged 30 to 84 years were recruited as 
participants into the study. Participants were randomised into either the early 
intervention group (EI, n = 30) or a delayed intervention “control” group (DI, n = 
21). All participants underwent an initial assessment (T1) at baseline including a 
six-minute walk test (6MWT), NT-proBNP levels, cardiac function 
(echocardiography), NYHA class and QoL questionnaire scores. The (EI) group 
performed a 12-week course of supervised exercise training followed by a 
second assessment (T2). During this period the DI group continued to follow 
routine advice and were similarly reassessed at 12 weeks before starting their 
exercise programme. All participants were assessed at 36 – 48 weeks (T3).  
Results: There were no adverse events during or as a result of the exercise 
sessions or during the exercise testing. For a target rating of perceived exertion, 
the 6MWT distance increased from 398 ± 100 m to 423 ± 108 m (p < .0001). 
The corresponding heart-rate-walking speed indexes at these two time points 
were 16.3 ± 7.3 and 15.3 ± 8.7 (p < .0001).  Pre- and post-programme NT-
proBNP levels were 1174 ± 1495 ng/l and 1094 ± 1307 ng/l, respectively (p= 
.381) There were no changes in cardiac function. NYHA scores improved from 
2.3 ± .5 to 1.8 ± .6 (p < .0001) in the EI group and QoL scores were unchanged.   
Conclusion: In following a programme of exercise based on national guidelines 
and systematic reviews, exercise training in a group of CHF participants was 
found not to be detrimental. It enhanced functional exercise capacity with a 
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corresponding improvement in NYHA class. However, unlike some previous 
studies NT-proBNP was unchanged. It is possible that such changes could be 
linked to exercise intensity and that a moderate intensity programme performed 
twice per week was not enough of a stimulus to invoke a change in NT-proBNP 
levels. Further research is required to evaluate the dose of exercise training 
linked to beneficial changes in NT-proBNP levels but in spite of this, moderate 
intensity exercise continues to show a consistent benefit to functional capacity 
and QoL.  
 
5.2 Background 
Wolverhampton’s CR Service has long-established exercise training 
programmes for patients following myocardial infarction, coronary 
revascularisation (coronary artery bypass graft or angioplasty) and cardiac 
valve surgery. Until July 2005, however, there was no such provision for 
patients with CHF. The National Service Framework for Coronary Heart 
Disease (DOH, 2000) suggested that early access to CR should be considered 
as an option for patients with CHF thus funding was secured for a 3 year period 
to provide a 12-week course of exercise training for patients diagnosed with 
CHF. Additional non-recurring funding was secured for NT-proBNP testing for 
the purpose of evaluating the efficacy of the exercise programme and the 
outcome measures were published in the form of a service audit (Leslie and 
Buckley, 2010). Results demonstrated that a structured exercise training 
programme favourably influenced functional capacity and NYHA class, with 
encouraging trends related to NT-proBNP levels. Natriuretic peptide testing is 
invasive and is therefore not recommended as an outcome measure to be used 
routinely by CR departments; however it may provide additional evidence for 
the efficacy of exercise training for patients with CHF to add to the limited body 
of evidence that currently exists.  The ExTraMATCH Collaborative (Piepoli et al, 
2004) recommended that further research should focus on optimising exercise 
programmes and identifying appropriate patient groups to target. Following the 
service audit the proposal for this local study received ethical approval. 
 
5.3 Introduction  
Poor performance on the 6MWT has been related to severity (Guyatt et al., 
1985) and prognosis (Bettencourt et al., 2000) in patients with CHF. Aerobic 
exercise is recognised by current CR guidelines as a safe and well-established 
means of improving the pathophysiological and clinical symptoms of CHF to 
supplement pharmacotherapy. Indeed, individual randomised controlled clinical 
trials and meta-analyses have demonstrated that exercise training is safe, 
improves functional capacity, QoL and NYHA class in patients with CHF. 
Furthermore, neurohormonal factors such as BNP or NT-proBNP also appear to 
be useful markers of severity in patients with CHF and thus a reduction in these 
levels would suggest an improved prognosis. Several studies (see Chapter 1) 
have demonstrated that exercise training reduces NT-proBNP levels in CHF. 
Prescription of appropriate and adequate training intensities is crucial to 
obtaining exercise-induced benefits whilst at the same time guaranteeing 
patient safety. Continuous and interval training are two methods of aerobic 
exercise that have been proposed for CHF patients. Continuous aerobic training 
is typically performed at moderate intensity in steady-state conditions. In 
contrast interval training – not currently recommended in published UK 
guidelines - comprises of high intensity exercise in repeated short bouts (usually 
up to 2 minutes duration) with active recovery periods between (Carvalho and 
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Mezzani, 2011). The majority of the published studies have exercised patients 
at a percentage of VO2 peak (often between 50% and 70%, but occasionally up 
to 95%) using continuous aerobic exercise training on cycle ergometers and 
treadmills. 
 
5.3.1 Aerobic exercise training prescription 
The lower limit of aerobic exercise intensity that can be prescribed in order to 
ensure exercise-induced benefits remains unconfirmed, but intensities as low as 
40% peak VO2 have been proven to be effective in CHF patients (Belardinelli et 
al., 1995). CR providers follow the guidelines recommended by the BACPR 
(2012) and the ACPICR (2009). The ACPICR suggest a target HR of 40 – 60% 
of HRR and/or RPE of 12-13 on Borg’s scale. HR is routinely used for exercise 
prescription due to the existing linear relationship between HR and VO2 and 
Borg scale RPE values between 11 and 13 are reliable for exercise training 
prescription in CHF patients on beta-blockers, assuring an energy expenditure 
lying between the first and second ventilatory thresholds (Carvalho et al., 2009). 
The professional standards and guidelines advocate the use of sub-maximal 
tests to prescribe exercise, with the suggested HR training targets and training 
intensities being somewhat lower than those used in the published trials. CHF 
research studies have invariably used maximal exercise tolerance testing to 
measure peak VO2, a percentage of which is then used to set training targets; 
however, this is not the case with existing routine clinical practice as few CR 
centres have the necessary facilities for maximal testing. Walking tests are 
often used to assess patients with CHF and to provide an outcome measure in 
CR, but walk distance alone can be a misleading outcome due to other 
influencing factors (Buckley et al., 2010). 
 
 
 
5.3.2 Six-minute walk test performance and heart-rate-walking speed 
index 
Increased 6MWD is routinely used as an outcome measure for CHF-
rehabilitation (Guazzi et al., 2009) and correlates with activities of daily living 
and quality of life (Enright, 2003). In order to be considered as related to the 
intervention, the improvement in distance walked must be at least > 5% from 
baseline (Rostagno and Gensini, 2008); however, if the increase in distance is 
less than 10%, even with statistically significant results, the variation is quite 
possibly due to familiarisation (Opasich et al., 1998). Improvements in 6MWT 
performance ranging from 30 m (Guyatt et al., 1985) to 90 m (Spertus et al., 
2005) have all been associated with a significant improvement in walk 
performance. Shoemaker et al. (2012) used a novel approach for triangulating 
the Δ6MWD that should be regarded as clinically meaningful and concluded 
that a Δ6MWD of approximately 45 m exceeded measurement error and was 
associated with significant changes in either aerobic capacity and/or QoL. The 
HRWSI was first proposed by Buckley et al. (2010) as a method of determining 
the contribution of physiological changes to improved walking performance 
following CR, thus providing a more accurate reflection of improvements in 
aerobic fitness regardless of how much or how little walking performance 
improved.  
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5.3.3 Natriuretic peptides 
The levels of natriuretic peptides denote the severity of CHF and also reflect the 
body’s attempt to compensate and maintain homeostasis (Koglin et al., 2001) in 
cardiac function. Interventions to reduce levels of BNP/NT-proBNP are clearly 
of importance in the management of CHF, and evidence demonstrates that 
pharmacotherapy can reduce BNP as a result of the favourable effects on 
cardiac remodelling (McCullogh, 2004). Seven of nine selected individual 
studies included in a meta-analysis by Smart and Steele (2010) demonstrated 
that moderate intensity exercise training, with a minimum weekly energy 
expenditure of 400 to 450 Kcal, reduced BNP and NT-proBNP independent of 
frequency and duration of training. This was conceivably due to a blunted 
neurohormonal response at rest and a consequent reduction in BNP release 
(Passino et al., 2006). 
 
5.3.4 Left ventricle function 
Left ventricle remodelling is a significant process in the progression of HF and 
involves several factors, including neurohormonal and haemodynamic 
derangement. There is progressive chamber enlargement and deterioration in 
“pump” function as a result of increased haemodynamic load and 
neurohormonal stress (Haykowsky et al., 2007). End-diastolic volume (EDV) 
and end-systolic volume (ESV) increase; there is wall thinning and a change in 
left ventricle shape, usually accompanied by a reduction in LVEF. Several 
studies investigating the effect of exercise training on BNP and NT-proBNP 
levels have found a reduction in post training natriuretic peptide levels and a 
corresponding increase in LVEF (Passino et al., 2006; Passino et al., 2008; 
Rengo et al., 2014), a reduction in end-diastolic volume (EDV) (Conraads et al., 
2004; Passino et al., 2006) and an increase in diastolic filling (Conraads et al., 
2004; Giallauria et al., 2006). 
 
5.3.5 Pulse pressure 
Low PP has been reported to be an independent predictor of mortality in 
patients with decompensated heart failure (Aronson and Burger, 2004), in 
patients with advanced CHF (Voors et al., 2005; Petrie at al., 2009; Yildiran et 
al., 2010) and in patients with symptomatic left ventricular dysfunction post 
myocardial infarction (Petrie et al, 2007). The effect of PP on exercise training 
outcomes for patients with CHF has previously been reported in a retrospective 
study (Leslie and Buckley, 2012). However, this warrants further investigation 
under research conditions. 
 
5.3.6 Quality of life 
Pooled data from nine studies in a review by van Tol et al. (2006) showed a 
significant decrease of almost 10 points in the MLHFQ score, which is 
considered clinically meaningful (Piña et al., 2003). As with previous reviews, 
there were no trials reported to have used the HADS. However, a meta-analysis 
by Rutledge et al. (2006) did include one study that used the HADS to measure 
depression in an intervention study in patients with CHF, which showed no 
significant improvement (49 ± 7 vs 48 ± 8, p = 0.39). The recently published 
update of the Cochrane Review (Taylor et al., 2014) included 33 trials, 19 of 
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which reported the use of a validated QoL measure; 13 used the MLHFQ and 2 
used the HADS (see Chapter 1). 
 
5.4 Objectives 
The primary objective of this study was to assess the physiological and 
psychological effects of moderate intensity exercise training on patients with 
CHF and to provide new evidence examining the correlation between functional 
capacity, NT-proBNP levels and QoL following a 12-week course of supervised 
exercise.  
The following hypotheses were explored: 
In a representative sample of a UK CHF population, compared to that reported 
in the current evidence, a 12-week exercise programme applying current UK 
guidelines, will result in:  
 
(i) An improved functional capacity 
(ii) A reduction in plasma BNP levels and an associated improvement in LV 
function 
(iii) An improvement in QoL 
(iv) Demonstrating a strong correlation between changes in functional capacity, 
with changes in plasma BNP levels and in QoL. 
 
 
5.5 Methods 
5.5.1 Participants 
Hospital records of 92 patients referred to the hospital-based CR exercise 
programme were screened to assess suitability for recruitment to the study. All 
patients had LVSD (detailed previously). Patients were stable on optimal 
medical therapy for at least 4 weeks and had exertional dyspnoea, fatigue or 
both and thus were classified according to NYHA functional class II to III.  Of the 
76 that were suitable, four patients  decided that they no longer wished to start 
the exercise programme, three failed to attend, four chose not to join the study 
and three did not fulfil the inclusion criteria when they attended for initial 
screening assessment. A total of 62 patients were recruited and gave their 
written consent to join the study; 38 randomised into the early intervention (EI) 
group and 24 to the delayed intervention (DI) group. See Chapter 2 for details of 
recruitment, approval from the Royal Wolverhampton NHS Trust’s Research 
and Development Committee and from the Regional Ethics Committee, and for 
patient information and consent.  
 
5.5.2 Design and procedures 
General methods and protocols are described in Chapters 2 and 3. Medication 
was not withheld prior to testing. The initial pre-screen was performed during T1 
as described in Chapter 2; all patients performed either a two-minute or a six-
minute practice walk test. All tests and measurements were repeated at T2 and 
T3. 
 
Measurements 
Functional Exercise Capacity Test: Patients were assessed using the 6MWT of 
functional capacity (Butland et al, 1982). Resting and recovery HR and blood 
pressure were recorded pre and post testing. HR, RPE and distance walked 
were recorded at each one-minute interval during the test. The 6MWT was 
stopped if HR exceeded 60% of HRR, if the patient reported an RPE > 13 or 
reported symptoms of discomfort such as increased shortness of breath, chest 
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pain or dizziness. All patients were familiarised with the 6MWT at T1. A two-
minute practice walk was employed following validation in Study 1 (Chapter 3a). 
HRWSI was calculated by dividing total heart beats during the 6MWT by the 
6MWT distance and multiplied by 10 to describe heart beats per 10 m walked 
(see Chapter 2 for further details). Due to the constraints of the study and 
limited resources, it was not possible to perform a planned subgroup CPEX 
analysis using the modified CST (as described in Study 2, Chapter 3b) to 
compare with the results from the 6MWT. 
 
Plasma BNP Levels: A venous blood sample was obtained prior to the 6MWT at 
T1 and T2 to determine the plasma levels of NT-proBNP. Samples were 
immediately sent to the Clinical Chemistry laboratory to be centrifuged and 
serum stored at          -20 ºC prior to analysis with a chemiluminescence 
sandwich immunoassay (see Chapter 2 for further details).  
 
Left Ventricle function - Echocardiography: A subgroup (n=20) was randomly 
selected from both groups to undergo echocardiography at T1 and T2 to 
determine whether there was a significant change in left ventricular function and 
to evaluate cardiac function using tissue doppler imaging. For the protocol see 
Appendix 15. Two-dimensional resting echocardiographic recordings were 
obtained in both the initial and the second assessment, with participants lying in 
the left lateral supine position, using a Philips Epiq (Philips Healthcare) 
Ultrasound system. All measurements (Appendix 15) were obtained by 
experienced British Society of Echocardiography accredited cardiac 
physiologists blinded to group assignment and intervention. Images were saved 
on the Xcelera system and compact disc using the participant’s individual 
identification number. The variables considered were LVEF (using the biplane 
Simpsons method), LV end-systolic and end-diastolic volumes, LV wall 
thickness and internal dimension.  
- Pulse pressure: The retrospective study by Leslie and Buckley (2012) 
provided a basis for the PP investigations in this study (Appendix 16). 
Recordings of SBP and DBP were taken before and immediately after the 
6MWT, in the supported right or left arm of the seated patient with a cuff-size 
adjustment based on arm circumference (Colin Press-mate blood pressure 
monitor, Welch Allyn, Arden, USA). Resting blood pressure was taken after 5 
minutes of quiet rest, and exercise blood pressure was taken immediately on 
cessation of the SETT. PP was calculated from the SBP and DBP readings. 
 
QoL and physical activity questionnaires: The New York Heart Association 
(NYHA) classification, which stratifies patients according to physical 
activity/exercise limitation, was used in this study to provide a subjective 
measure of disability. The MLHFQ and HADS questionnaires (Appendices 9 
and 10) were used to measure QoL. The MLHFQ was designed to measure the 
effects of CHF and treatments for CHF on an individual’s QoL, and is 
considered a responsive tool for distinguishing the changes in QoL in patients 
with CHF (Ni et al, 2000). The HADS Questionnaire is a valid instrument that 
was recommended by the National Service Framework for Coronary Heart 
Disease (2000) for the assessment of psychological needs (see Chapter 2 for 
further details). The National Audit for Cardiac Rehabilitation Physical Activity 
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questionnaire (see Appendix 11) was used to determine patient exercise/activity 
levels.  
 
5.5.3 Exercise training protocol 
All patients were enrolled in an outpatient supervised exercise training 
programme where they attended twice per week for 12 weeks; the EI group 
commenced training immediately following T1, the DI group following T2 (at 12-
weeks). The 12-week training programme is described in Chapter 2.  
 
5.5.4 Data analysis 
Data analysis was conducted using SPSS version 21.0 and alpha was set at the 
.05 level. Data were assessed for the normality of their distributions via the 
Shapiro-Wilk and for homogeneity of variance prior to analysis. The 
independent t-test was applied to investigate differences in baseline 
characteristics between the groups where parametric assumptions were met 
and the Mann Whitney U Test was used for non-parametric data. To measure 
within-subjects differences and interactions the factorial (mixed) two way 
ANOVA was applied, with post hoc analysis. A Bonferroni adjustment was 
performed where appropriate. The Chi-squared (x²) test for association 
compared physical activity levels between groups. Relationships between 
variables were examined using Pearsons Product Moment (parametric data) or 
Spearman’s Rank Correlation Coefficient (non-parametric data). Data are 
presented as mean values ± standard deviation (SD). 
 
5.6 Results 
5.6.1 Participants 
This final study population consisted of 51 participants; 30 in the EI group and 
21 in the DI group. All participants in the EI group completed assessments 1 
and 2 (T1 and T2); 26 (87%) completed assessment 3 (T3). In the DI group, all 
participants completed T1 and T2, and 14 (67%) completed T3. Only 11 of the 
21 participants (52%) in the DI group completed the exercise programme 
following which they completed assessment T2b. There were no adverse 
events during or as a result of the exercise sessions or during the exercise 
testing. There were no differences between the groups (Table 5.1) at baseline 
(T1). Over a quarter of the study participants were female (27%), 78% were 
NYHA class II and 76% had an underlying history of CHD (MI) attributed as the 
main aetiological factor. Over half (53%) of the participants were aged 71 to 84 
years and resting SBP at T1 ranged from 98 – 167 mmHg for the cohort and 
DBP 55 – 89 mmHg. 
 
Table 5.1 Baseline participant characteristics  
 
Variable Early intervention 
group 
(n = 30) 
Delayed intervention 
control group 
(n = 21) 
Median age (years) 73 (16) 72 (14)¹ 
Baseline BMI (kg/m²) 30.4 (4.7) 30.9 (6.1)² 
Baseline LVEF% 33 (7) 33 (9)³ 
NYHA class (II/III) 22/8 18/3 
Gender (m/f) 20/10 17/4 
RHR (beat. min-1) 67 (13) 67 (11)* 
CHF cause 
(IHD/other) 
23/7 16/5 
Prescribed beta-
blocker (%) 
97% 100% 
Prescribed ACE 
inhibitor/ARB (%) 
97% 90% 
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Prescribed diuretic 
(%) 
63% 67% 
Diagnosed AF (%) 70% 62% 
Diagnosed ≥ 1 more 
co-morbidity (%) 
97% 100% 
¹ No significant difference between groups (p = .639)  
² No significant difference between groups (p = .803) 
³ No significant difference between groups (p = .871) 
* No significant difference between groups (p = .903) 
 
5.6.2 Six-minute walk test performance 
Baseline 6MWT distance (Table 5.2): This was the same in both groups (p = 
.608). There were no significant differences in 6MWT distance (p = .060) over 
the trial for both groups. There was, however, a significant interaction effect (p = 
.009)  
 
Walk pace: There were no significant differences in walk pace (p = .289) over 
the trial for both groups. There was a significant difference in walk pace 
between the groups over the three assessments (p = .013). Post hoc analysis 
showed that, during T2, the EI group walked significantly faster than T1 at 
minute 2 (T1 67 ± 14 m vs T2 
 
71 ± 17 m; p = .003), minute 3 (T1 65 ± 21 m vs T2 70 ± 17 m; p = .006), minute 
4 (T1 66 ± 18 m vs T2 70 ± 21 m; p = .005) and minute 5 (T1 67 ± 16 m vs T2 
70 ± 19 m; p = .004). The DI group walked significantly slower at minute 5 in T2 
(T1 65 ± 16 m vs T2 59 ± 18 m; p = .021). 
 
Heart rate: HR increased significantly between minutes 1 and 6 in both groups 
during T1 (EI group minute 1: 89 ± 9 beat. min-1 vs minute 6: 100 ± 10 beat. 
min-1, p < .0001; DI group: 88 ± 8 beat. min-1 vs 97 ± 8 beat. min-1, p = .001), T2 
(EI group minute 1: 85 ± 8 beat. min-1 vs minute 6: 96 ± 8 beat. min-1, p < .0001; 
DI group: 89 ± 8 beat. min-1 vs 100 ± 7 beat. min-1, p < .0001) and T3 (EI group 
minute 1: 87 ± 9 beat. min-1 vs minute 6: 96 ± 10 beat. min-1, p = . 001; DI 
group: 87 ± 6 beat. min-1 vs 99 ± 6 beat. min-1, p = .001). T2 end of test HR was 
significantly lower than T1 end of test HR in the EI group and significantly higher 
in the DI group (Table 5.2).  
 
RPE: There were no between-test differences in RPE values at minutes 1 and 6 
(p = .234). End of test RPE was significantly higher than RPE at minute 1 in 
both groups in T1 (EI group minute 1: 11.3 ± 1.1 vs minute 6: 12.7 ± 1.1, p < 
.0001; DI group: 11.1 ± 1.1 vs 12.7 ± 1.3, p = .001), T2 (EI group minute 1: 11.3 
± 1.2 vs minute 6: 12.8 ± 1.3, p < .0001; DI group: 11.1 ± .8 vs 12.9 ± .7, p < 
.0001) and T3 (EI group minute 1: 11.3 ± 1.4 vs minute 6: 13.1 ± 1.1, p < .0001; 
DI group: 11.6 ± 1.1 vs 12.8 ± 1.3, p = .014). End of test RPEs were the same 
at T1, T2 and T3 in both groups (Table 5.2). 
Percentage of heart rate reserve (%HRR): There were no within-subjects 
differences in %HRR (p = .934); however there was a significant interaction 
effect (p = .002). Post hoc analysis showed that there were significant 
differences in the end of test %HRR during T2 and T3 in both groups compared 
with T1 (Table 5.2). 
 
Total heart beats: The total number of heart beats (THBs) was calculated for 
both groups during T1, T2 and T3. There were no significant differences in 
THBs over the three assessments for both groups (p = .934). There was, 
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however, a significant interaction effect (p = .029). Post-hoc analysis with the t-
test for related samples (paired t-test) showed that the THBs were lower in the 
EI group during T2 compared with T1 (Table 5.3). 
 
Heart-rate-walking speed index: There were no between-groups differences in 
HRWSI in T1, T2 and T3 (p = .214). There was a significant difference in 
HRWSI during T2 and T3 in the EI group compared with T1 (Table 5.3). This 
equated to a saving of 10 heart beats for every 100 m walked during T2 and 12 
heart beats for every 100 m walked during T3. 
 
 
5.6.3 NT-proBNP levels 
Figure 5.1 shows that there were no significant between-groups differences in 
NT-proBNP plasma levels. There was a significant difference in NT-proBNP 
levels over the trial for both groups (p = .020), but there was no interaction 
effect (p = .326).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.2 Mean (SD) six-minute walk test performance  
 
 T1 
Baseline  
T2 
12-weeks  
T3 
6-months  
Early 
intervention 
group 6MWT 
distance (m) 
398 (100) 
(n = 30) 
423 (108)¹ 
(n = 30) 
415 (125) 
(n = 26) 
Delayed 
intervention 
control group 
6MWT distance 
(m) 
384 (95) 
(n = 21) 
379 (93) 
(n = 21) 
366 (152) 
(n = 14) 
Early 
intervention 
group HR 
(bpm) at 
minute 6 
100 (10) 96 (8)² 96 (10)² 
Delayed 
intervention 
control group 
HR (bpm) at 
minute 6 
97 (8) 100 (7)³ 99 (6) 
Early 
intervention 
group RPE at 
minute 6 
12.7 (1.1) 12.8 (1.3) 13.1 (1.1) 
Delayed 
intervention 
control group 
RPE at minute 
6 
12.7 (1.3) 12.9 (.7) 12.8 (1.3) 
Early 
intervention 
group %HRR at 
minute 6 
61 (16) 54 (22)¹¹ 53 (24)¹¹ 
Delayed 
intervention 
control group 
%HRR at 
57 (17) 70 (15)²² 67 (18)²² 
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minute 6 
¹ Significantly higher than T1; p < .0001  
² Significantly lower than T1; p = .010 
³ Significantly higher than T1; p = .030 
¹¹ Significantly lower than T1; p < .035 
²² Significantly higher than T1; p < .032 
 
 
Table 5.3 Mean (SD) total heart beats and heart-rate-walk speed index 
during the six-minute walk test 
 
 Early intervention  group  
 
Delayed intervention 
control group 
 
 T1 
(n = 30) 
T2 
(n = 30) 
T3 
(n = 26) 
T1 
(n = 21) 
T2 
(n = 21) 
T3 
(n = 
14) 
Total 
Heart 
Beats 
578 (44) 557 (39)¹ 558 (49) 562 (33) 581 (34) 577 
(22) 
Heart 
rate-walk 
speed 
index  
(total heart 
beats/6MWD 
x 10 m) 
16.3 (7.3) 15.3 (8.7)² 15.1 
(6.9)³ 
14.9 (3.2) 15.4 (3.2) 16.1 
(6.9) 
¹ Significant difference from T1; p = .004  
² Significant difference from T1; p < .0001 
³ Significant difference from T1; p = .028 
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¹ No significant between-groups differences 
² No significant between-groups differences 
³ Significant reduction in NT-proBNP levels over T1 and T2 for both groups (n = 51); p = .020  
 
 
Figure 5.1 NT-proBNP levels (ng/l) in the early intervention group (post 
training) and the delayed intervention group (no training) at T1 and T2 
 
5.6.4 Echocardiography 
Table 5.4 shows the mean (SD) values of resting LV function of two sub-groups 
of patients; one from the EI group (n = 10) and one from the DI group (n = 10). 
Although there was a statistically significant increase in LV posterior wall 
thickness the result was not clinically significant.  
 
Table 5.4 Echocardiographic resting LV function in sub-groups 
 
 Early 
intervention 
group 
(n = 10) 
Delayed 
intervention 
group 
(n = 10) 
p value 
 T1 T2 T1 T2 Within 
Subjects 
Between 
Groups 
LVEF% 41 (10) 41 (8) 40 (13) 41 (13) .404 .404 
EDV (ml) 101 
(53) 
106 
(59) 
117 
(38) 
103 
(31) 
.442 .097 
ESV (ml) 65 (4) 66 (49) 72 (32) 61 (25) .098 .060 
LV thickness 
septal wall 
(cm) 
1.1 
(.30) 
1.1 
(.25) 
1.1 
(.18) 
1.1 
(.16) 
.806 .464 
LV thickness 
posterior wall 
(cm) 
.95 
(.14) 
1.0 
(.17)¹ 
.99 
(.17) 
1.1 
(.16)¹ 
.035 .838 
LV internal 
dimension 
(cm) 
5.3 (.8) 5.2 (.8) 5.5 (.7) 5.4 (.6) .422 .590 
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¹ Significantly higher value at T2 for the cohort; p = .030 
 
5.6.5 Pulse Pressure 
SBP, DBP and PP values remained the same across T1 to T3. PP at rest 
ranged from 25 – 87 mmHg in the EI group and 32 – 83 mmHg in the DI group. 
Data were analysed to determine the effect of PP on outcomes at T2 compared 
with baseline (T1). There were no significant differences in resting and end of 
test PP, SBP or DBP in T1 and T2 (Table 5.5). There was a very high 
correlation between resting PP and resting SBP at T1 (EI group: r = .867, p < 
.0001; DI group: r = .856, p < .0001) and T2 (EI group: r = .799, p < .0001; DI 
group: r = .886, p < .0001) but not with DBP (EI group T1: r = -.114, p = .548, 
T2: r = -.070, p = .712; DI group T1: r = .042, p = .857, T2: r = .337, p = .136). 
The relationships between PP and SBP remained at the end of test 
measurements (EI group T1: r = .936, p < .0001, T2 r = .792, p < .0001; DI 
group T1: r = .867, p < .0001, T2: r = .862, p < .0001). 
 
To examine whether PP affected 6MWD, NT-proBNP and MLHFQ score, the EI 
group and the DI group were each sub-divided to two groups: group 1 < 51 
mmHg (mean PP value) and group 2 ≥ 51 mmHg (Table 5.6).  
 
 
 
5.6.6 NYHA class and Quality of life 
Mean NYHA class reduced significantly in the EI group following exercise 
training (T2) and at 6-month follow-up (T3), and was significantly lower than 
mean NYHA class in the DI group at T2 (Table 5.7). There were no between-
group differences in NYHA class at T1 (p = .295) and T3 (p = .138). There were 
no significant differences in NYHA class over the three assessments in the DI 
group. 
There were no significant differences or interaction effects in QoL questionnaire 
scores over the trials (Table 5.8). 
 
Table 5.5 Mean (SD) pulse pressure, systolic and diastolic blood pressure 
values 
 
 Early intervention group 
(n = 30) 
Delayed intervention 
control group 
(n = 21) 
 T1 T2 T1 vs T2 
p value 
T1 T2 T1 vs 
T2 p 
value 
Resting PP 
(mmHg) 
51 (14) 51 (13) .967 51 (16) 53 (19) .562 
 
End of test 
PP (mmHg)  
60 (21)¹ 59 (21)¹ .608 64 (19)¹ 60 (21)¹ .105 
 
Resting 
SBP 
(mmHg) 
123 (16) 121 (15) .482 126 (19) 126 (24) .974 
End of test 
SBP 
(mmHg) 
138 
(25)¹ 
135 
(24)¹ 
.462 141 
(19)¹ 
137 
(23)¹ 
.133 
Resting 
DBP 
(mmHg) 
72 (8) 70 (7) .058 74 (10) 73 (11) .351 
 
End of test 
DBP 
(mmHg) 
78 (9) 76 (11) .479 76 (10) 76 (11) .715 
 
¹ Significantly higher than resting value; p < .014 
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Table 5.6 Comparison of pre- and post-exercise training outcome 
measures in patients with a pulse pressure < 51 mmHg compared to a 
pulse pressure ≥ 51 mmHg 
 
 Early intervention group 
 
Delayed intervention 
control group 
 
 Group 1 
PP < 51 
mmHg 
(n = 18) 
Group 2 
PP ≥ 51 
mmHg 
(n = 12) 
Between 
Groups p 
value 
Group 1 
PP < 51 
mmHg 
(n = 12) 
Group 2 
PP ≥ 51 
mmHg 
(n = 9) 
Betwee
n 
Groups 
p value 
Mean PP 
(mmHg) 
42 (7) 64 (12) < 
.0001 
40 (6) 67 (10) < 
.0001 
6MWD T1 
(m) 
379 (119) 412 (65) .538 389 (65) 377 (130) .862 
6MWD T2  
(m) 
399 (130)¹ 445 (62)¹ .379 392 (79) 362 (111) .466 
NT-proBNP 
T1 (ng/l) 
1465 
(1911) 
786 (471) 1.000 1782 (1844) 1034 (846) .345 
NT-proBNP 
T2 (ng/l) 
1285 
(1665) 
839 (541) .767 1554 
(1536)² 
885 (607) .422 
MLHFQ T1 29 (19) 31 (21) 1.000 29 (13) 40 (24) .508 
MLHFQ T2 26 (24) 28 (25) .884 26 (14) 39 (19) .129 
¹ Significantly higher than T1, p < .043 
² Significantly lower than T1, p = .023 
 
 
Table 5.7 Mean (SD) NYHA class  
 
 Early intervention group 
 
Delayed intervention control 
group 
 
 T1 
(n = 30) 
T2 
(n = 30) 
T3 
(n = 26) 
T1 
(n = 21) 
T2 
(n = 21) 
T3 
(n = 14) 
NYHA 2.3 (.5) 1.8 (.6)¹ 
 
1.7 (.7)¹ 2.0 (.6) 
 
2.1 (.3)² 2.0 (.6) 
 
¹ Significantly lower than T1; p < .0001 
² Significantly higher than Early intervention group; p = .011 
 
 
 
Table 5.8 Mean (SD) anxiety, depression and MLHFQ scores  
 Early intervention 
group 
 
Delayed 
intervention control 
group 
 
p values 
mixed 
ANOVA 
 T1 
(n = 
30) 
T2 
(n = 
30) 
T3 
(n = 
26) 
T1 
(n = 
21) 
T2 
(n = 
21) 
T3 
(n = 
14) 
Within 
Subjects 
p value 
Interaction 
Effect      
p value 
Anxiety  7 (4) 6 (4) 7 (4) 5 (4) 5 (4) 5 (3) .448 .254 
Depression  4 (3) 4 (3) 4 (3) 4 (3) 4 (3) 3 (3) .564 .537 
MLHFQ  
score 
31 
(20) 
29 
(23) 
30 
(24) 
26 
(12) 
23 
(12) 
20 
(13) 
.244 .402 
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Figure 5.2 shows the number of participants in each group who reported being 
physically active for 30 minutes on at least five days of the week at T1, T2 and 
T3. There was a significant association between groups and physical activity at 
T1 (x(1) = 5.063; p = .024) and T2 (x(1) = 4.073; p = .044). 
 
 
Figure 5.2 The number of participants in each group who reported being 
physically active for 30 minutes on at least five days of the week at T1, T2 
and T3 
 
 
5.6.7 Correlations 
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At baseline, correlation analyses on corresponding variables of 6MWD, NT-
proBNP level, BMI, age LVEF%, MLHFQ score and PP were performed for the 
cohort. There were significant inverse correlations between 6MWD and NT-
proBNP (r = -.364; p = .009), BMI and age (r = -.352; p = .011) and PP and age 
(r = -.307; p = .029).  
Further correlation analyses were performed for the differences between the 
values in T1 and T2. Results are detailed in Tables 5.9 and 5.10.  
 
 
 
 
 
 
Table 5.9 Correlations of key measures in the Early intervention group 
 
 Δ6MWD ΔHRWSI ΔMLHFQ 
score 
ΔNYHA 
class 
ΔNT-
ProBNP 
Δ6MWD 
(m) 
 r = -.707 
p < .0001* 
r = -.128 
p = .500 
r = -.241 
p = .199 
r = -.151 
p = .426 
ΔHRWSI r = -.707 
p < .0001* 
 r = .199 
p = .310 
r = .257 
p = .186 
r = .109 
p = .583 
ΔMLHFQ 
score 
r = -.128 
p = .500 
r = .199 
p = .310 
 r = -.031 
p = .871 
r = .078 
p = .681 
ΔNYHA 
class 
r = -.241 
p = .199 
r = .257 
p = .186 
r = -.031 
p = .871 
 r = .367 
p = .046* 
ΔNT-
proBNP 
(ng/l) 
r = -.151 
p = .426 
r = .109 
p = .583 
r = .078 
p = .681 
r = .367 
p = .046* 
 
* Significant correlation 
 
 
Table 5.10 Correlations of key measures during the control period in the 
Delayed intervention group 
 
 Δ6MWD ΔHRWSI ΔMLHFQ 
score 
ΔNYHA 
class 
ΔNT-
ProBNP 
Δ6MWD 
(m) 
 r = -731 
p < .0001* 
r = -.231 
p = .313 
r = .372 
p = .097 
r = .212 
p = .356 
ΔHRWSI r = -731 
p < .0001* 
 r = .025 
p = .918 
r = -.339 
p = .144 
r = -.336 
p = .112 
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ΔMLHFQ 
score 
r = -.231 
p = .313 
r = .025 
p = .918 
 r = .296 
p = .193 
r = .037 
p = .873 
ΔNYHA 
class 
r = .372 
p = .097 
r = -.339 
p = .144 
r = .296 
p = .193 
 r = .074 
p = .750 
ΔNT-
proBNP 
(ng/l) 
r = .212 
p = .356 
r = -.336 
p = .112 
r = .037 
p = .873 
r = .074 
p = .750 
 
* Significant correlation 
 
 
5.6.8 Effect of delayed rehabilitation on uptake and functional capacity 
After completing T2, participants in the DI group were invited to join the exercise 
training programme (following a delay of 12 weeks). Eleven patients (52%) 
completed the 12-week programme and attended for a further assessment 
(T2b). 6MWD increased (Table 5.11), there was a significant decrease in end of 
test HR (T2 92 ± 8 beat. min-1 vs T2b 87 ± 6 beat. min-1; p = .05), THBs (Table 
5.11) and HRWSI (Table 5.11) at the same RPE (T2 13 ± .7 vs T2b 13 ± 1; p = 
.414). NYHA class also improved (T2 2 ± 0 vs T2b 1.7 ± .4; p = .038). At T3 the 
results remained the same as at T2b. 
 
 
Table 5.11 Mean (SD) 6MWT distance, total heart beats and heart-rate-walk 
speed index in the 11 participants of the Delayed intervention group who 
completed the 12-week exercise training programme 
 
 T2 (after 12-
weeks of no 
training) 
 
(n = 11) 
T2b (post 12-
weeks exercise 
training) 
 
(n = 11) 
T3 (6-month 
follow-up) 
 
 
(n = 11) 
6MWD (m) 393 (85) 
 
431 (83)¹ 
 
412 (104) 
 
 
 
Total Heart Beats 585 (38) 566 (25)² 573 (19) 
Heart-rate-walk 
speed index  
(total heart beats/6MWD 
x 10 m) 
15.5 (3.6) 13.6 (2.8)³ 15.0 (5.3) 
¹ Significantly higher than T2; p = .002  
² Significantly lower than T2; p = .018 
³ Significantly lower than T2; p = .002 
 
5.7 Discussion 
This study characterises the responses of CHF patients referred to a moderate 
intensity CR exercise training programme, and uses recommended outcome 
measures to demonstrate the effectiveness of this intervention. The 
demographic data collected in this current study compare favourably with 
reported data (British Society of Heart Failure, 2013). National Guidelines 
(NICE, 2010) and key systematic reviews (Rees et al., 2004; Piepoli et al. 2004; 
Davies et al., 2010; Taylor et al., 2014) have reported exercise training to be 
safe in young, predominantly male CHF populations, with little or no co-
morbidities. This study confirms that a moderate intensity exercise training 
programme, following UK standards and guidelines, is safe for CHF populations 
that are typical of those attending UK CR centres. 
 
6MWT performance: Following exercise training in EI group, the mean 
increase in 6MWT distance was statistically significant (25 ± 35 m; p < .0001). 
However, this change has been reported not to be of clinical significance as 
noted by the similar distance changes reported by Shoemaker et al., (2012). 
They deemed an increase of 45m was required to be of a significant influence in 
aerobic capacity and QoL. Whilst it could be claimed the distance walked was 
not clinically significant, physiologically the patients had improved because they 
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were walking at a faster pace for given RPE (~12) but with significantly lower 
heart rates (Table 5.2). During the 6MWT , patients did show signs of fatigue as 
demonstrated by the upward drift in RPE from minute 1 to minute 6, confirming 
the findings of Study 1. The relationship between heart rate and walking speed, 
as described by the HRWSI, may therefore provide an additional perhaps more 
physiologically precise marker of change compared to a simply reporting of 
distance walked (HRWSI EI group: T1 16.3 ± 7.3 vs T2 15.3 ± 8.7 heart beats 
per 10 m walked, p < .0001). These findings support the suggestion that the 
6MWT distance alone may not be sensitive to changes in functional capacity 
(McKelvie et al., 2002).  Attitudes, mood and motivation all influence 
performance in walking speed and distance covered (Guyatt et al., 1985). It is 
therefore recommended that the combined use of the HRWSI and 6MWT 
distance is used to report meaningful changes in the 6MWT as highlighted in 
Tables 5.2 and 5.3. The exercise-induced benefits remained at 6-month follow-
up (T3) in the EI group for 6MWD, %HRR and HRWSI. In conclusion, in a 
representative sample of the UK CHF population, by applying current UK 
guidelines, a 12-week programme of exercise training results in an improved 
functional capacity. 
 
NT-proBNP: This study demonstrated that, despite the significant improvement 
in functional capacity in the EI group (increased 6MWT distance at a lower HR, 
lower %HRR and improved HRWSI), there were no significant changes in NT-
proBNP levels (-75 ± 401 ng/l; p = .381) following a 12-week exercise training 
programme. Similarly, Nilsson et al. (2010) reported significantly improved 
walking distances without significant changes in NT-proBNP levels. In 
accordance with the current study they found no significant correlation between 
ΔNT-proBNP and Δ6MWD in spite of a significant inverse correlation between 
baseline 6MWD and NT-proBNP (r = -.24; p = .035). The authors suggested 
that improvements in functional capacity may have been too small to influence 
NT-proBNP levels and that the peripheral changes that occur following exercise 
training (such as improved capillarisation, increased number and size of 
mitochondria and increased oxidative enzyme activity), which lead to 
improvements in functional capacity, do not affect NT-proBNP levels. This 
speculation corresponds with the small improvements in 6MWD seen in this 
study.  
The results of the current study support the suggestion that NT-proBNP is not a 
reliable marker for measuring changes in functional capacity in a stable CHF 
population with optimal medical treatment (Meyer et al., 2004; Nilsson et al. 
2010). The participants in the current study were representative of the 
population attending CR programmes in the UK (British Society for Heart 
Failure, 2013), whereas other studies that have demonstrated the positive 
effects of exercise training on natriuretic peptides likely produced divergent 
results due to differences in the population, the mode and the duration of 
exercise. It is worth noting the paper by Koglin et al. (2001) which discussed the 
important protective role of BNP in delaying the progression of CHF. The 
authors refer to studies that used an infusion of synthetic BNP, which resulted in 
a rapid and sustained improvement of the patient’s clinical status and 
suggested a possible relationship between increased BNP levels, impaired BNP 
activity and mortality in CHF. This would support the proposals by Mangiafico et 
al. (2013) who reported a lack of mature plasma BNP in its protective form in 
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patients with CHF, plus the presence of less biologically active precursors and 
degraded forms of BNP. The authors referred to a study by Miller et al. (2011) 
who proposed that the BNP that is detected by clinical assays is actually 
degradation products and less active forms of BNP.  
 
LV function: It was not possible to follow the echocardiogram protocol in its 
entirety due to the incidence of atrial fibrillation in the cohort, making such an 
evaluation difficult. Furthermore the availability of equipment meant that several 
echocardiography parameters could not be measured. The NT-proBNP findings 
in the EI group are supported by the results of the echocardiograms which 
indicated that there were no significant changes in LV dimension or LVEF, 
previously reported as a contributory factor to changes in NT-proBNP levels 
(Rengo et al., 2014). The echocardiogram findings are in accordance with those 
of Giannuzzi et al. (2003), Giallauria et al. (2008) and Haykowsky et al. (2007) 
who reported that exercise training of less than 6-months duration does not 
reverse remodelling. In summary, in a representative sample of the UK CHF 
population, by applying current UK guidelines, a 12-week programme of 
exercise training did not result in a reduction in plasma BNP levels and an 
associated improvement in LV function. 
 
Pulse pressure: The results of this study demonstrate that the benefits CHF 
patients derive from participating in a CR programme are not negatively 
influenced by baseline PP, confirming previous findings (Leslie and Buckley, 
2012). There was a significant correlation between resting PP and SBP at both 
T1 (EI group r = 0.867, p <.0001; DI group r = .856, p < .0001) and at T2 (EI 
group r = .799, p < .0001; DI group r = .886, p < .0001) but not between PP and 
DBP at either assessment. This indicates that, in this cohort, PP levels were 
closely linked to SBP, indicative of cardiac output (Franklin et al., 1999), and 
that the possible variability in DBP was lower than that of SBP. Regardless of 
resting levels, SBP increased appropriately during exercise whilst DBP 
remained unchanged, leading to a corresponding increase in PP. Exercise 
training did not influence resting levels or end of test levels of SBP or PP at T1, 
T2 and T3. 
 
NYHA class and QoL: NYHA class improved significantly (it was lower) in the 
EI group (p < .0001) and at T2 was significantly lower than the DI group (p = 
.011). Furthermore there was a significant correlation (though somewhat low) 
between ΔNYHA class and ΔNT-proBNP in the Early intervention group (r = 
.367, p = .046) suggesting some link between changes in NT-proBNP and 
NYHA class.  NYHA score also improved in the DI cohort who completed the 
exercise training programme (T2 2 ± 0 vs T2b 1.7 ± .4; p = .038). HADS scores 
did not improve in either group, which echoes the findings reported in two other 
studies using this questionnaire (Radzewitz et al., 2002; Witham et al., 2012). 
Despite the reported prevalence of depression in patients with CHF (Rutledge 
et al., 2006), the baseline scores were not indicative of any clinical signs of 
anxiety or depression in either group which probably explains why there were 
no changes in HADS. Smart et al. (2011) reported that clinicians should expect 
a reduction of approximately 10 points on the MLHFQ, but the scores at T1, T2 
and T3 were unchanged in this study. Similar to HADSs, the baseline scores 
were relatively low (good), which could have caused a basement effect. The 
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mean scores were < 30% of the maximum score possible (105 points). This 
could be a result of the patients already being optimised on their CHF 
medication and stable prior to recruitment, thereby improving QoL prior to 
recruitment. Self-reported levels of physical activity were higher in both groups 
at T2 and T3 compared with T1, suggesting that anything from a brief 
intervention with a health care professional to a 12-week exercise programme 
can influence behaviour change.  In conclusion, in a representative sample of 
the UK CHF population performing 12 weeks exercise training in keeping with 
UK guidelines, results in an improvement in QoL demonstrated by the 
improvements seen in NYHA class and self reported levels of physical activity. 
 
Correlation between changes in functional capacity, with changes in 
plasma BNP levels and changes in QoL: As summarised in Tables 5.9 and 
5.10 changes in functional capacity were not related to any changes in either 
cardiac biomarkers, LV function or QoL. The intensity of the exercise may have 
been a factor, where in most other studies (cited in systematic reviews) 
demonstrating such changes, the participants were younger, with fewer co-
morbidity and working at higher intensities.  Therefore, in a representative 
sample of the UK CHF population participating in a 12-week programme of 
exercise in keeping with UK guidelines relevant to age and co-morbidity, does 
not have an influence on either plasma BNP levels or QoL.  
 
 Effects of delaying cardiac rehabilitation: The DI group achieved similar 
outcomes on completion of the exercise training programme following a delay of 
12 weeks, which is reassuring. The drop-out rate was high, however. Only 48% 
of participants in the DI group completed the 12-week course following 
assessment T2. The high drop-out rate concurs with the findings of Parker et al. 
(2011) who reported that early access to CR following acute ST-elevation 
myocardial infarction resulted in a 3-fold increase in patient participation. 
Delaying commencement of CR reduces the number of patients who could 
benefit, which supports the evidence and the goals cited by the BACPR 
(Buckley et al., 2013). 
 
5.8 Limitations 
Rate of referral and group capacity were the main limiting factors for the sample 
size for this study and thus the small numbers may have affected the results, 
nonetheless the overall results are encouraging. The mode of exercise and the 
intensity of training differed to those used in many of the published reviews and 
meta-analyses.  
In addition the CHF population recruited to the current study was more 
representative of patients attending CR programmes in the UK. The results from 
the current study may therefore not be comparable with previously published 
studies.  
 
5.9 Conclusion 
For a given physiological strain, this group of optimally medical treated patients 
with CHF improved in physical function (6MWD and HRWSI) with a 
corresponding improvement in their perceived functional ability (NYHA 
functional class). There were no adverse events during or as a result of the 
exercise sessions or during the exercise testing, which concurs with the 
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National Guidelines (NICE, 2010) and key systematic reviews (Rees et al., 
2004; Piepoli et al. 2004; Davies et al., 2010; Taylor et al., 2014) and training 
did not adversely affect cardiac function. Delaying the start of supervised 
exercise training had a detrimental effect on uptake and compliance but not 
outcomes. Despite the significant improvement in functional capacity following 
moderate intensity exercise training, no significant changes in NT-proBNP were 
found in the EI group. NT-proBNP measurement in this cohort appears to be of 
limited value, suggesting that exercise training at moderate intensity is unable to 
significantly influence the neurohormonal burden associated with CHF. This 
area requires further study on a greater number of patients, to confirm exercise 
intensities that will produce both clinically and statistically significant outcomes.  
The findings of this study support the value of exercise-based rehabilitation for 
patients with CHF and reinforce the importance of offering timely access to 
supervised exercise training programmes for all patients diagnosed with stable 
CHF.  
 
 
 
 
  
 
Chapter 6 
 
General Discussion 
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6.1 Overview 
Often, studies such as this are undertaken in a non-clinical research 
environment, with access to far more resources than a routine clinical setting 
would allow in the UK. Access to equipment and facilities such as those used in 
large clinical trials was limited, unlike Europe and the US, as was capacity for 
supervised exercise sessions. Although the number of eligible patients was also 
limited, the uptake in the UK is actually far greater than in Europe and the US 
(NACR, 2013). The standard operating procedures that are followed within the 
Royal Wolverhampton Trust resulted in lengthy delays, initially in recruitment 
then later impeding the use of equipment on loan from the University of 
Chester. Support from other areas such as Clinical Chemistry, the Respiratory 
Centre and Cardiac Investigations Department was available, which proved 
invaluable. 
 
These clinically-based and ecologically valid studies, although generating 
several challenges, have led to several novel research findings. In addition they 
have confirmed previously reported findings.  
 6.2 Main findings 
6.2.1 An alternative to the 6MWT practice  
The 6MWT is frequently recommended for patients with CHF due to it being a 
self-paced, sub-maximal test that has proven reliability and validity in CHF. A 
practice 6MWT test is recommended in both clinical practice and in research to 
increase the reliability of the test by aiming to filter out influences of 
familiarisation, pacing and motivation on final outcome tests. The effects of 
fatigue on walking performance, based on the increasing RPE values during the 
6MWT (Chapters 3 and 5), are of concern. Furthermore, in clinical practice a 
practice test proves to be time consuming. Study 1 verified the efficacy of a two-
minute practice walk in a small cohort of patients with CHF.  Actual baseline 
6MWT distance walked in Grp1-2min was not significantly different (345 ± 83 m 
vs 329 ± 96; p = .212) to the distance predicted from the mean distance walked 
during the two minute practice (115 ± 28 m). Effects of pacing or fatigue on 
walking pace were assessed between practice and baseline 6MWT using a bias 
± 95% limits of agreement (LoA) analysis. In Grp1-2min mean walking pace 
during minute 2 of the practice test was 57.5 ± 3.8 m.min-1  and during the 
baseline 6MWT 57.8 ± 14.7 m.min-1. Walking pace was not different (95%LoA p 
= .823) between the practice and 6MWT. Thus both a two-minute and a six-
minute practice test were equally effective in predicting baseline 6MWD in this 
cohort of patients with CHF. This data have provided preliminary evidence that 
a two-minute practice test saves valuable clinical assessment time and is as 
effective in influencing pacing as a six-minute practice walk for CHF patients 
being assessed by a 6MWT, whilst reducing risk of fatigue seen in a 6MWT.  
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6.2.2 Further validation of an adapted Chester step test in CHF 
Although the 6MWT is recommended for patients with CHF, it requires a 
significant amount of space. Study 2 (Chapter 3b) demonstrated that a low (4-
inch) step test is a valid alternative to the 6MWT, particularly where space might 
be an issue. The similarity between CST1 and CST2 for HR, RPE and total 
number of steps indicated that the CST is reproducible in CHF patients. 
Noteworthy in this study were the HR and VO2 responses to incremental 
exercise in this clinical population. HR was reliable on a test re-test basis, but its 
validity in this study was challenged as an indicator of oxygen uptake response 
and kinetics. Typically, validity is measured against VO2 max; however this 
study questions the validity of estimates of VO2 max/peak and METs when 
METs estimates are based on 3.5 ml/kg/O2 being equal to 1 MET (Buckley et 
al., 2004). Resting VO2 value was 2.8 ml/kg/O2 in this cohort of patients with 
CHF. Actual VO2 measures were suggestive of altered oxygen kinetics and HR 
rise was blunted, all of which is in keeping with previous evidence of 
incremental exercise testing responses in CHF. HR rise over the course of the 
three-minute stages was not proportionate to the rise in VO2. VO2 continued to 
rise into the third minute, which showed the delayed oxygen kinetics.  
 
CST2 duration ranged from 5 minutes to 12 minutes, thus the total exercise 
time in the majority of patients was sufficient and useful for assessing 
cardiorespiratory responses (American Thoracic Society, 2003). The CST, 
designed and validated for use in healthy subjects, uses two-minute stages 
when applied according to the manual. It seems, however, that three minutes at 
each stage, as used in this study, may have also been insufficient to allow 
appropriate HR responses in this cohort and so further studies to determine the 
optimum duration for each stage are recommended. 
 
  
6.2.3 Acute and chronic responses of NT-proBNP to exercise 
Examination of the acute response of NT-proBNP levels to moderate intensity 
exercise revealed individual variability that is worthy of further investigation. 
From the sub-group analysis it appears that patients with baseline NT-proBNP 
levels ≥ 1000 ng/l fail to release NT-proBNP in response to acute exercise, 
therefore further investigation of CHF patients with high levels of circulating 
natriuretic peptides are warranted. Furthermore, it appears from the results of 
the main clinically-based study that the current CR exercise prescription 
guidelines (12-weeks of exercise training at 40 – 60% HRR) do not achieve 
those NT-proBNP results and associated changes in LV function seen in 
published meta-analyses. This suggests that the recommended intensity is too 
low and the frequency insufficient to result in a clinically significant reduction in 
NT-proBNP levels post training despite the observed improvements in 
functional capacity and NYHA class. The use of highly sensitive equipment in 
future studies may increase our understanding of the acute physiological 
responses to exercise. 
 
6.2.4 Functionality  
Although the increase in 6MWT distance in the EI group (25 ± 35 m; p < .0001) 
was not considered to be of clinical significance within the limits of variability 
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and reliability of the tool, the statistically significant increase was associated 
with a lower HR and %HRR at the same RPE. Furthermore there was a 
significant improvement in the HRWSI compared to T1. This clearly 
demonstrated that training resulted in an improvement in physical function. 
Patients in the DI group also achieved similar outcomes when they completed 
training, indicating that patients can still benefit from exercise even after a 12-
week delay prior to commencing supervised exercise training. The use of 
HRWSI demonstrates a new step in reporting 6MWT performance.  
6.2.5 Pulse pressure 
Patients with CHF often have low PP due to low SBP (a result of reduced stroke 
volume) and normal DBP, and may exhibit a reduced cardiac output response 
to exercise (Wilson et al., 1996). The main intervention study (Chapter 5) 
confirmed the initial findings of a preliminary retrospective study (Leslie and 
Buckley, 2012), which revealed that patients with CHF do benefit from CR 
regardless of PP. Thus it appears that PP neither limits nor influences 
improvements in exercise capacity and QoL in patients with CHF. Furthermore, 
a course of exercise training does not affect PP. 
 
6.2.6 Quality of life 
NYHA class improved (T1 2.3 ± .5 vs T2 1.8 ± .6; p < .0001) following exercise 
training; however there were no significant changes in HADS and MLHFQ 
scores.  
 
6.2.7 Correlation between changes in functional capacity, with changes in 
plasma BNP levels and changes in QoL 
ΔNYHA class correlated with ΔNT-proBNP levels following exercise training and 
there was a significant negative correlation between Δ6MWT distance and 
ΔHRWSI (r = -.707, p < .0001). A significant negative correlation was also found 
in the DI group, between Δ6MWT distance and ΔHRWSI (r = -.731, p < .0001).  
This demonstrates the worth of using HRWSI to emphasise small changes in 
functional capacity that might be of significant benefit to CHF patients.  
6.3 Recommendations for practice 
This study demonstrates that a 12-week course of moderate intensity exercise 
increases functional capacity but has little effect on NT-proBNP. When there 
has been a reported change in natriuretic peptides it appears to be in studies 
using a higher exercise intensity (i.e. above ventilatory threshold). The first 
ventilatory threshold has been proposed as the maximum training intensity for 
the CHF population; however emerging evidence suggests that it might be 
possible to train CHF patients above this threshold without additional risk. 
Indeed, CHF patients have been reported to exercise at a high percentage of 
VO2 peak during a sub-maximal 6MWT (Faggiano et al., 1997).  Furthermore, 
they are known to perform activities of daily living at a higher percentage of their 
VO2 peak compared to healthy individuals (Giannuzzi et al., 2001). It seems, 
therefore, that patients with stable NYHA class I to II and perhaps in class III are 
able to exercise safely at intensities equal to the first ventilatory threshold 
(Carvalho and Mezzani, 2011). Indirect measures of exercise intensity 
assessment and prescription used routinely in CR settings, however, have 
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several limitations. Absolute exercise intensity can only be determined by 
carrying out a CPET and thus it appears that CPET may be advisable in order 
to avoid inadequate exercise prescription. This would prove impractical and 
even impossible for most CR providers in a clinical setting. More practical 
measures, such as 6MWT, cycle ergometer tests and step tests are used in 
clinical practice. Chronotropic incompetence and altered oxygen kinetics make 
interpretation of the findings of both maximal and sub-maximal exercise tests 
difficult.  
 
Additionally, the guidelines regarding lower intensity limits lack standardisation 
and, certainly from the results of this study, it appears that the recommended 
training intensities are not sufficient to bring about the results seen in published 
reviews and meta-analyses. Emerging evidence suggests that high intensity 
interval training is safe for CHF patients, thus making the prescription of a 
specific aerobic training intensity complex for CR clinicians. Research in the 
field of exercise training for elderly CHF patients with existing co-morbidities 
should focus on the development of appropriate evidence-based guidelines and 
standards for exercise prescription, complimented by clinical evaluation and risk 
assessment of exercise-related adverse event. 
 
6.4 Future research 
A significant number of patients with CHF are elderly, female and many are frail, 
with a substantial burden of co-morbid disease. Many of the CHF participants 
recruited into exercise training trials were young, male, and had little co-morbid 
disease. It remains to be confirmed whether the outcomes of the relatively high 
intensity exercise programmes that have been reported in the meta-analyses 
can be successfully applied to older, female and frail patients who routinely 
attend CR in the UK. Similarly, the diagnosis of heart failure with preserved 
ejection fraction is becoming more commonplace and again it is not clear 
whether the results of trials that recruited patients with poor LVEF are 
transferrable to this population. 
 
Neurohormonal factors are predictive of survival in CHF when measured at rest, 
and measurement of natriuretic peptides appears to be a superior prognostic 
marker than other parameters such as LVEF (Lainchbury and Richards, 2012). 
The additional measurement of natriuretic peptide concentrations and their 
response to exercise may be valuable. The results presented in Chapter 5 
suggest that further research is warranted to measure acute serial changes in 
natriuretic peptide levels using high-sensitivity equipment following exercise. 
This may establish clear recommendations regarding the frequency and 
intensity of exercise sessions for patients with CHF; as yet it appears that ‘rest 
days’ are not essential. Measurement of natriuretic peptides following a course 
of exercise at a selection of intensities may help establish clearer guidelines 
regarding exercise prescription, and link to function, QoL and survival.  
 
6.5 Conclusion 
Preliminary findings suggest that a two-minute practice walk prior to a 6MWT 
can reliably predict pace and 6MWT distance, and reduce the risk of fatigue 
seen during a full 6MWT. The additional use of HRWSI demonstrates a new 
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step in reporting 6MWT performance. This technique is particularly useful as 
small improvements in functional capacity, demonstrated by an increased 
6MWT distance, seen in routine clinical practice can often have a significant 
impact on perceived QoL. These small improvements are repeatedly 
considered insignificant in published studies. Where space is limited an adapted 
low (4-inch) CST is a reliable alternative to the 6MWT. Further testing is 
recommended to confirm the optimum duration for each stage due to the altered 
oxygen kinetics seen in patients with CHF.  
The participants recruited to this study are not comparable with the majority 
recruited to published individual studies and systematic reviews, and the 
median age is not as old as that reported in the recent national heart failure 
audit (British Society of Heart Failure, 2013); however they are more 
representative of the CHF population attending UK-based CR programmes 
(NACR, 2013). The findings reported in Chapter 5 are reassuring but in order 
for all patients to fully realise the benefits of exercise training, we need to design 
and study exercise programmes that are at an appropriate exercise intensity for 
elderly, frail and female patients, rather than the atypical minority of young, 
male CHF patients studied to date. The participants recruited to this current 
study all had confirmed LVSD, but we must also consider those with preserved 
ejection fraction and thereby establish clear, effective exercise prescription 
guidelines for CHF-rehabilitation programmes. Delaying the start of CHF-
rehabilitation did not affect the outcomes for those patients in the DI group who 
completed the 12-week course; however the delay clearly affected uptake and 
adherence. To ensure that all patients benefit from supervised exercise by 
making the transition from referral to actual attendance, clinicians must offer 
early access to CR. 
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Rosalind Leslie 
Telephone: 01902 694226 
 
 
Title of Project: The efficacy of exercise therapy for Class II and III Heart Failure 
Patients 
 
Patient Information Sheet 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  
 
Please read the following information carefully and if you have any queries, 
please discuss them with friends, relatives, hospital doctors or your GP if you 
wish. Ask me if there is anything that is not clear or if you would like more 
information. 
 
Who is organising the research study? 
This research study is being co-ordinated by Rosalind Leslie, Specialist 
Physiotherapist in Cardiac Rehabilitation, and will contribute towards an 
educational qualification (PhD) with Chester University. Rosalind is based in 
The Heart and Lung Centre at New Cross Hospital and has extensive clinical 
experience, having been involved in cardiac rehabilitation for 20 years. 
 
What is the purpose of the study? 
The Heart Failure Nurse has referred you to the Heart Failure Exercise 
Programme.  We aim to compare results of a 12-week course of supervised 
exercise with results after following advice-only to determine the benefit of 
exercise on your physical and psychological well being, and on the symptoms 
associated with heart failure. 
 
Do I have to take part? 
No. It is up to you to decide whether or not you would like to take part in the 
study. If you decide to take part you will be given this information sheet to keep 
and will be asked to sign a consent form. If you do take part, you can stop at 
any time without giving a reason. A decision to stop at any time, or a decision 
not to take part, will not affect the standard of care you receive and you can 
continue to attend the exercise programme.  
 
What will happen if I take part? 
If you agree to take part in the study your participation will last for approximately 
12 months, which includes the 12-week duration of a course of exercise, a 12-
week period where you will be asked to follow advice given by the Heart Failure 
Nurse and a subsequent 6-month follow-up. The decision as to whether you join 
the exercise programme first or follow advice first will be taken at random 
(effectively the toss of a coin – in other words you will not be able to choose 
which you do first).You will undergo a 30-minute assessment before and after 
each 12-week period and at a 6-month follow-up. All tests and measurements 
and the exercise sessions are part of standard care for the Heart Failure 
Exercise Programme. The blood samples at each assessment will be frozen, 
stored and then analysed by the Clinical Chemistry Department at New Cross 
Hospital. There is one heart-specific blood test that is undertaken using these 
blood samples. By signing the Written Informed Consent Form you are giving 
permission for this to be done. The results of these assessments will be used in 
the study. You may, by a process of random selection, be requested to 
undertake a more in-depth assessment using a piece of equipment that will 
measure your body’s ability to use oxygen. This will involve some discomfort as 
you will be required to wear a facemask and a heart rate chest strip during the 
short exercise tolerance test, with a lightweight transmitting unit attached to you 
with a harness. Information will be transmitted to a computer for analysis.  You 
may, by a process of random selection, be requested to have an 
echocardiogram. An echocardiogram uses sound waves to build up a detailed 
picture of your heart and to see how well it is functioning. Lubricating jelly is 
rubbed on the chest and a probe is then used to produce a pulse of high 
frequency sound waves which pass through the skin. A picture of your heart can 
be seen on the screen. A decision not to undertake either of these assessments 
will not affect your care. 
 
What do I have to do? 
You must be willing to follow advice, to complete the Heart Failure Exercise 
Programme and also attend a maximum of four appointments for assessment. 
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It is important that you tell the Cardiac Rehabilitation Exercise Specialist or 
Heart Failure Nurse about all the medicines you take, including those sold over 
the counter from a chemist shop or supermarket. You must also tell them if you 
change the dose or stop any medicines.  
 
What are the benefits of taking part in this study? 
We hope that attending the exercise programme will improve your fitness and 
quality of life more so than following advice-only. However, this cannot be 
guaranteed. The information that we get from this study may help us to provide 
better treatment to patients with Heart Failure in the future. 
 
What are the possible risks and disadvantages in taking part? 
We do not anticipate any untoward effects as a result of taking part in this study. 
There is no documented evidence to suggest that delaying the start of cardiac 
rehabilitation exercise training is in any way detrimental to your health. 
 
 
Will my taking part in this study be kept confidential? 
 All information that is collected about you during the Exercise Programme will 
be kept strictly confidential. Data that is required for the research study will be 
stored and analysed in a computer and will be treated confidentially. If any 
information about you needs to leave the hospital it will have your name and 
address removed so that you cannot be recognised from it. 
 
Certain Trust auditors may wish to look at your records to check that the study 
has been performed correctly. By signing the Written Informed Consent Form 
you are giving permission for this to be done. 
 
Your confidentiality will be maintained, in accordance with the UK Data 
Protection Act, 1998, or as local laws permit. 
 
 
What happens if I suffer as a result of the study? 
This is unlikely, but if you wish to complain or have any concerns about any 
aspect of the way that you were treated during the course of this study, the 
normal National Health Service complaints mechanism will be available to you. 
  
You do not lose any rights by being in this research. 
 
If you wish to seek some independent advice or have any concerns or 
complaints, then please contact: 
 
Pauline Boyle, Research Manager 
Research & Development Directorate, New Cross Hospital 
Telephone Number 01902 695065 or 
24 hour contact telephone number: 07776 132837 
 
What will happen to the results of the research study? 
The results of the study will be published in about 4 years as it takes time to 
analyse the results. You will be sent a copy of the results if you wish at that 
time. You will not be identified in any report/publication.   
 
 
 
 
Who should I contact for further information? 
 
Whenever you want to get more information about this study please contact: 
Rosalind Leslie, Clinical Physiotherapist Specialist 
Cardiac Rehabilitation Services, Heart and Lung Centre, New Cross Hospital 
Telephone number 01902 694226 
 
You can also discuss it with the Patient Advice Liaison Service (PALS), Patient 
Liaison Centre, New Cross Hospital, Wolverhampton. Telephone number 01902 
695362  
 
 
Thank you for taking the time to read this information. 
 
 
 
 
Parallel study. Version number 2, dated 
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Rosalind Leslie 
Telephone: 01902 694226 
 
Title of Project: The efficacy of exercise therapy for Class II and III Heart Failure 
Patients 
 
Patient Information Sheet 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  
 
Please read the following information carefully and if you have any queries, 
please discuss them with friends, relatives, hospital doctors or your GP if you 
wish. Ask me if there is anything that is not clear or if you would like more 
information. 
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Who is organising the research study? 
This research study is being co-ordinated by Rosalind Leslie, Specialist 
Physiotherapist in Cardiac Rehabilitation, and will contribute towards an 
educational qualification (PhD) with Chester University. Rosalind is based in 
The Heart and Lung Centre at New Cross Hospital and has extensive clinical 
experience, having been involved in cardiac rehabilitation for 20 years. 
 
What is the purpose of the study? 
The Heart Failure Nurse has referred you to the Heart Failure Exercise 
Programme.  We aim to compare results of a 12-week course of supervised 
exercise with results after following advice-only to determine the benefit of 
exercise on your physical and psychological well being, and on the symptoms 
associated with heart failure. 
 
Do I have to take part? 
No. It is up to you to decide whether or not you would like to take part in the 
study. If you decide to take part you will be given this information sheet to keep 
and will be asked to sign a consent form. If you do take part, you can stop at 
any time without giving a reason. A decision to stop at any time, or a decision 
not to take part, will not affect the standard of care you receive and you can 
continue to attend the exercise programme.  
 
What will happen if I take part? 
If you agree to take part in the study your participation will last for approximately 
12 months, which includes the 12-week duration of a course of exercise, a 12-
week period where you will be asked to follow advice given by the Heart Failure 
Nurse and a subsequent 6-month follow-up. The decision as to whether you join 
the exercise programme first or follow advice first will be taken at random 
(effectively the toss of a coin – in other words you will not be able to choose 
which you do first). 
You will undergo a 30-minute assessment before and after each 12-week 
period and at a 6-month follow-up. All tests and measurements and the exercise 
sessions are part of standard care for the Heart Failure Exercise Programme. 
The blood samples at each assessment will be frozen, stored and then 
analysed by the Clinical Chemistry Department at New Cross Hospital. There is 
one heart-specific blood test that is undertaken using these blood samples. By 
signing the Written Informed Consent Form you are giving permission for this to 
be done. The results of these assessments will be used in the study. You may, 
by a process of random selection, be requested to have additional blood tests 
whilst attending exercise sessions. This will involve one blood test at the end of 
an exercise session on a Monday and then a daily blood test until your next 
exercise session on Thursday. This may provide useful information to help 
determine the ideal frequency of exercise sessions for patients with Heart 
Failure. You may, by a process of random selection, be requested to undertake 
a more in-depth assessment using a piece of equipment that will measure your 
body’s ability to use oxygen. This will involve some discomfort as you will be 
required to wear a facemask and a heart rate chest strip during the short 
exercise tolerance test, with a lightweight transmitting unit attached to you with 
a harness. Information will be transmitted to a computer for analysis.  You may, 
by a process of random selection, be requested to have an echocardiogram. An 
echocardiogram uses sound waves to build up a detailed picture of your heart 
and to see how well it is functioning. Lubricating jelly is rubbed on the chest and 
a probe is then used to produce a pulse of high frequency sound waves which 
pass through the skin. A picture of your heart can be seen on the screen. A 
decision not to undertake either of these assessments will not affect your care.  
 
What do I have to do? 
You must be willing to follow advice, to complete the Heart Failure Exercise 
Programme and also attend a maximum of four appointments for assessment. 
It is important that you tell the Cardiac Rehabilitation Exercise Specialist or 
Heart Failure Nurse about all the medicines you take, including those sold over 
the counter from a chemist shop or supermarket. You must also tell them if you 
change the dose or stop any medicines.  
 
What are the benefits of taking part in this study? 
We hope that attending the exercise programme will improve your fitness and 
quality of life more so than following advice-only. However, this cannot be 
guaranteed. The information that we get from this study may help us to provide 
better treatment to patients with Heart Failure in the future. 
 
What are the possible risks and disadvantages in taking part? 
We do not anticipate any untoward effects as a result of taking part in this study. 
There is no documented evidence to suggest that delaying the start of cardiac 
rehabilitation exercise training is in any way detrimental to your health. 
 
 
Will my taking part in this study be kept confidential? 
 All information that is collected about you during the Exercise Programme will 
be kept strictly confidential. Data that is required for the research study will be 
stored and analysed in a computer and will be treated confidentially. If any 
information about you needs to leave the hospital it will have your name and 
address removed so that you cannot be recognised from it. 
 
Certain Trust auditors may wish to look at your records to check that the study 
has been performed correctly. By signing the Written Informed Consent Form 
you are giving permission for this to be done. 
 
Your confidentiality will be maintained, in accordance with the UK Data 
Protection Act, 1998, or as local laws permit. 
 
What happens if I suffer as a result of the study? 
This is unlikely, but if you wish to complain or have any concerns about any 
aspect of the way that you were treated during the course of this study, the 
normal National Health Service complaints mechanism will be available to you. 
  
You do not lose any rights by being in this research. 
 
If you wish to seek some independent advice or have any concerns or 
complaints, then please contact: 
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Pauline Boyle, Research Manager 
Research & Development Directorate, New Cross Hospital 
Telephone Number 01902 695065 or 
24 hour contact telephone number: 07776 132837 
 
What will happen to the results of the research study? 
The results of the study will be published in about 4 years as it takes time to 
analyse the results. You will be sent a copy of the results if you wish at that 
time. You will not be identified in any report/publication.   
 
 
 
Who should I contact for further information? 
 
Whenever you want to get more information about this study please contact: 
Rosalind Leslie, Clinical Physiotherapist Specialist 
Cardiac Rehabilitation Services, Heart and Lung Centre, New Cross Hospital 
Telephone number 01902 694226 
 
You can also discuss it with the Patient Advice Liaison Service (PALS), Patient 
Liaison Centre, New Cross Hospital, Wolverhampton. Telephone number 01902 
695362  
 
Thank you for taking the time to read this information 
Parallel study. Version number 3, dated 29/04/10 
 
Appendix 3 
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Appendix 6 
 
 
Appendix 7 
 
 
CONSENT FORM   
 
Title of Project: The efficacy of exercise therapy for Class II and III Heart 
Failure Patients  
 
Name of Researcher: Rosalind Leslie, Clinical Physiotherapist Specialist, 
Cardiac Rehabilitation Services. Telephone 01902 694226 
 
Patient Identification Number: 
 
 
 
 
1. I confirm that I have read, understood and received a copy of  
the information sheet version 2 for the above study. 
 
2. The study has been explained to me and I have had the opportunity  
to ask questions and all my questions have been answered to my 
satisfaction. 
 
3. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason. 
 
4. I understand that the data collected about me may be looked at by 
responsible individuals from regulatory authorities of the Trust, where it is 
relevant to my taking part in research. I give my permission for these 
individuals to have access to my data. 
 
5.  Consent for storage  
 
 I agree that the blood sample I have given and the information gathered   
 about me can be stored by Rosalind Leslie from Cardiac Rehabilitation,  
 Heart and Lung Centre, New Cross Hospital, for the purpose of this study.  
 
6. I agree to take part in the above study.  
 
_________________________ ______________ _________________ 
Name of Subject                                  Date                            Signature 
 
 
_________________________ ______________ ___________________ 
Name of Person                                   Date                            Signature 
taking consent 
 
Each individual who signs this document must PERSONALLY date his or her 
signature. One copy for patient, 1 for researcher. 
Parallel study consent     Version 2. Page 276 of 290    23/04/10 
Patient 
please 
initial 
box 
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Appendix 8 
 
 
CONSENT FORM   
 
Title of Project: The efficacy of exercise therapy for Class II and III Heart 
Failure Patients  
 
Name of Researcher: Rosalind Leslie, Clinical Physiotherapist Specialist, 
Cardiac Rehabilitation Services. Telephone 01902 694226 
 
Patient Identification Number: 
 
 
 
 
5. I confirm that I have read, understood and received a copy of 
 the information sheet version 3 for the above study. 
 
6. The study has been explained to me and I have had the opportunity to  
ask questions and all my questions have been answered to my satisfaction. 
 
7. I understand that my participation is voluntary and that I am free to  
withdraw at any time, without giving any reason. 
 
8. I understand that the data collected about me may be looked at by 
responsible individuals from regulatory authorities of the Trust, where it is 
relevant to my taking part in research. I give my permission for these 
individuals to have access to my data. 
 
5.  Consent for storage  
 
I agree that the blood sample I have given and the information gathered 
about me can be stored by Rosalind Leslie from Cardiac Rehabilitation,  
Heart and Lung Centre, New Cross Hospital, for the purpose of this study.  
 
6. I agree to take part in the above study.  
 
 
_________________________ ______________ _________________ 
Name of Subject                                  Date                            Signature 
 
 
_________________________ ______________ ___________________ 
Name of Person                                   Date                            Signature 
taking consent 
 
Each individual who signs this document must PERSONALLY date his or her 
signature. One copy for patient, 1 for researcher. 
Parallel study consent     Version 3. Page 277 of 290    29/04/10 
Patient 
please 
initial box 
Appendix 9 
HAD Scale 
Name:           Date: 
Doctors are aware that emotions play an important part in most illnesses.  If your doctor knows about these 
feelings he will be able to help you more. 
This questionnaire is designed to help your doctor to know how you feel.  Read each item and place a firm tick 
in the box opposite the reply which comes closest to how you have been feeling in the past week. 
Don’t take too long over your replies: your immediate reaction to each item will probably be more accurate 
than a long thought-out response. 
Tick only one box in each section 
I feel tense or ‘wound up’:    I feel as if I am slowed down:   
 Most of the time 
............................... 
    Nearly all the time 
......................... 
  
 A lot of the time 
............................... 
    Very often 
...................................... 
  
 Time to time, Occasionally 
.............. 
    Sometimes 
..................................... 
  
 Not at all 
.......................................... 
    Not at all 
........................................ 
  
 
 
I still enjoy the things I used to 
enjoy: 
   I get a sort of frightened feeling 
like ‘butterflies’ in the stomach: 
  
 Definitely as much 
.......................... 
    Not at all 
........................................ 
  
 Not quite so much 
........................... 
    Occasionally 
.................................. 
  
 Only a little 
..................................... 
    Quite often 
..................................... 
  
 Hardly at all 
.................................... 
    Very often 
...................................... 
  
 
I get a sort of frightened feeling 
as if something awful is about to 
happen: 
    
I have lost interest in my 
appearance: 
  
 Very definitely and quite badly 
....... 
    Definitely 
.......................………… 
  
 Yes, but not too badly 
...................... 
    I don’t take so much care as I 
should 
  
 A little, but it doesn’t worry me 
...... 
    I may not take quite as much 
care .. 
  
 Not at all 
.......................................... 
    I take just as much care as ever 
...... 
  
 
I can laugh and see the funny 
side of things: 
   I feel restless as if I have to be 
on the move: 
  
 As much as I always could 
.............. 
    Very much indeed 
......................... 
  
 Not quite so much now 
.................... 
    Quite a lot ... 
.................................. 
  
 Definitely not so much now 
............. 
    Not very much 
............................... 
  
 Not at all 
........................................... 
    Not at all 
........................................ 
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Worrying thoughts go through 
my mind: 
   I look forward with enjoyment 
to things: 
  
 A great deal of the time 
................... 
    As much as ever I did 
.................... 
  
 A lot of the time 
.............................. 
    Rather less than I used to 
............... 
  
 From time to time but not too 
often . 
    Definitely less than I used to 
.......... 
  
 Only occasionally 
............................ 
    Hardly at all 
.................................... 
  
 
I feel cheerful:    I get sudden feelings of panic:   
 Not at all 
.......................................... 
    Very often indeed 
.......................... 
  
 Not often 
......................................... 
    Quite often ... 
................................. 
  
 Sometimes 
....................................... 
    Not very often 
................................ 
  
 Most of the time 
.............................. 
    Not at all 
........................................ 
  
 
 
I can sit at ease and feel relaxed: 
   I can enjoy a good book or radio 
or TV programme: 
  
 Definitely 
........................................ 
    Often 
.............................................. 
  
 Usually 
............................................ 
    Sometimes 
..................................... 
  
 Not often 
......................................... 
    Not often 
...................................…. 
  
 Not at all 
......................................... 
    Very seldom 
................................... 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upjohn Printed as a service to medicine 
by 
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 MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE  
 
The following questions ask how much your heart failure (heart condition) affected your life 
during the past month (4 weeks). After each question, circle the 0, 1, 2, 3, 4 or 5 to show how 
much your life was affected. If a question does not apply to you, circle the 0 after that question.  
Did your heart failure prevent  
you from living as you wanted during   
the past month (4 weeks) by –                     
 
                                                                                           Very                           Very                                                                                  
__________________________________________No__Little_____________Much 
 
1. causing swelling in your ankles or legs?             0 1 2 3 4 5 
2. making you sit or lie down to rest during  
the day? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
3. making your walking about or climbing  
stairs difficult? 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
4. making your working around the house  
or yard difficult?                                                       
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
5. making your going places away from                
home difficult?                                                         
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
6. making your sleeping well at night  
difficult?                                                                   
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
7. making your relating to or doing things  
with your friends or family difficult?                         
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
8. making your working to earn a living  
difficult?                                                                   
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
9. making your recreational pastimes, sports  
or hobbies difficult?                                                      
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
10. making your sexual activities difficult?              0 1 2 3 4 5 
11. making you eat less of the foods you  
like?                                                                         
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
12. making you short of breath?                                 0 1 2 3 4 5 
13. making you tired, fatigued, or low on  
energy?                                                                    
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
14. making you stay in a hospital?                           0 1 2 3 4 5 
15. costing you money for medical care?                0 1 2 3 4 5 
16. giving you side effects from treatments?           0 1 2 3 4 5 
17. making you feel you are a burden to your  
family or friends?                                                     
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
18. making you feel a loss of self-control in your life?                0 1 2 3 4 5 
19. making you worry?                                            0 1 2 3 4 5 
20. making it difficult for you to concentrate  
or remember things?                                               
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
21. making you feel depressed?                             0 1 2 3 4 5 
 
______________________________________________________________________
©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce without 
permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents of the 
University of Minnesota 
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    PHYSICAL ACTIVITY 
  1 Considering a 7-day period (a week), how many times on average   
do you do the following kinds of exercise for more than 15 minutes 
(write the appropriate number in the boxes)?     
 a. Strenuous Activity (heart beats rapidly/tiring)?             Number of times              
(e.g. running, jogging, vigorous long distance cycling,  
circuit training, aerobic dance, skipping, football,  
squash, basketball, roller skating, vigorous swimming) 
 b. Moderate Activity (not exhausting)? 
(e.g. fast walking, mowing the lawn, tennis, easy cycling, 
badminton, easy swimming, ballroom dancing, fast or 
high step ups) 
 c. Mild Activity (minimal effort)? 
(e.g. easy walking, slow dancing, standing active 
fishing, bowling, golf, low step-ups) 
 
  2 Considering a 7-day period (a week), how often do you 
engage in any regular activity long enough to work up a sweat 
(heart beats rapidly)?   Please tick        
  one box 
 
  A Often 
  
  
  B Sometimes 
   
 
  C Never/Rarely 
  
  Please tick                                                    
one   box 
3 Do you take regular physical activity of at least  
 30 minutes duration on average 5 times a week? 
 
Thank you 
 
 
YES NO 
Appendix 12 
 
Cardiac Rehabilitation/Heart Failure Exercise Circuit 
2 minutes at each exercise station, working at moderate effort. 
Speak to the Exercise Specialist if you have difficulty with any of the exercises. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SEATED KNEE 
RAISES 
4 
BIKE 
 
6 
SIT TO 
STAND 
5 
ARM 
PULLEY/MARCH 
ON SPOT 
7 
STEP UPS 
8 
WALL BAR 
PRESS UPS 
9 
ROWING 
MACHINE/WALK 
10 
LEG PRESS 
 
11 
 BIKE 
 
1 
15 x BICEP 
CURLS/MARCH 
ON SPOT 
2 
TREADMILL 
3 
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EFFICACY OF A TWO-MINUTE VERSUS A SIX-MINUTE PRACTICE WALK  
BEFORE A SIX-MINUTE WALK TEST IN HEART FAILURE PATIENTS 
R. Leslie 
1,2
, K.George
3
, J.P. Buckley
2
  
¹Royal Wolverhampton NHS Trust, UK; ²University of Chester, UK; 3Liverpool John Moore’s University, UK 
            Methods:   
 20 NYHA Class II & III CHF patients (55% from coronary heart 
disease) recruited: 
 - Stable on optimal medical therapy ≥ 4 weeks  
 - Symptoms of exertional dyspnoea and/or fatigue 
 Group 1 (n = 10; 9 male) performed a 2-minute self-paced 
practice walk test +20 mins rest, followed by a 6MWT.  
 Group 2 (n = 10; 7 male) performed a full 6-minute practice test 
+20 mins rest, followed by a 6MWT.  
 Heart rate (HR) and ratings of perceived exertion (RPE) were 
monitored throughout all tests.  
 A two factor (group by trial) repeated measures ANOVA was used 
to assess differences in HR and RPE (in the first two minutes) and 
walking pace (m.min-1) throughout all tests.  
 Effects of pacing or fatigue on walking pace were further assessed 
between practice and follow-up 6MWT using a bias +/- 95% limits 
of agreement (LoA) analysis.  
           
  Results:  
 Mean (SD) walking distances and paces in Table 1.  
 Within group walking pace was the same for practice and 6MWT 
(p < .12)   
 Although walking paces were different between groups (p = .03), 
the relative HR (Grp1 = 82%HRmax v Grp2 = 80%HRmax) and RPE 
(Grp1 = 11.5 v Grp2 =11.2) were the same (p > .37) 
             
        Conclusions:  
 Within each of the two groups, walking pace was not significantly different between the practice and the actual 
6MWT. This was best confirmed by the same 95%LoA, between the practice and the actual test, being 12.1 m.min
-1
 
 Although the full 6-minute practice showed no sign of causing fatigue, this data provides good preliminary evidence 
that a 2-minute practice achieves the same purpose whilst saving valuable clinical assessment time 
 Further data collection and analysis of the effects of a 2-minute versus 6-minute practice test on longer-term 
reliability (e.g. between beginning and end of programme) of the 6MWT is still required. 
Introduction: The 6-minute walk test (6MWT) is a useful measure of functional capacity for people with moderate to severe cardiorespiratory impairment. Both in 
clinical practice and in research when using the 6MWT in chronic heart failure (CHF), a practice test is recommended. Current recommendations require patients to 
perform a full practice test, but there is concern that it may induce fatigue and a 30 min rest before the actual test. A two minute walk test (2MWT) has been 
reported to be reliable, valid and sensitive in the assessment of patients with moderate to severe COPD (Leung et al, 2006), neurologic impairment (Rossier and 
Wade, 2001), stroke (Kosak and Smith, 2005) and cardiac surgery (Brooks et al, 2004).  
Aims:  To assess the efficacy of a 2-minute versus a 6-minute practice test on pacing and possible fatigue during a subsequent 6MWT.  
LoA = Limits of Agreement ,  *Significantly faster walking pace than Group 1 (p = .03) 
Table 1. Practice v  test walk pace and distance  
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Post-exercise Brain Natriuretic Peptide levels  
in chronic heart failure patients: a pilot study 
R. Leslie
1,2
, K.George FACSM
3
, J.P. Buckley
2
  
¹Royal Wolverhampton NHS Trust, UK; ²University of Chester, UK; 
3
Liverpool John Moores University, UK 
Introduction: Brain or B-type Natriuretic Peptide (BNP) and its N-terminal propeptide (NT-proBNP) are   
markers of myocardial wall stress. Levels are reported to increase significantly following maximal  
exercise in patients with chronic heart failure (CHF). Little evidence however exists on BNP levels  
following standard and recommended submaximal exercise sessions for CHF.  
Aims: This pilot study, as part of a larger study, aimed to assess changes to BNP levels immediately, and at 24, 48 and 
72 hours following a recommended CHF exercise training session.  
Methods: Five (4 males) NYHA Class II & III CHF patients (60% from coronary heart disease) were recruited. All were 
stable on optimal medical therapy ≥ 4 weeks. 
NT-proBNP levels measured via venous blood samples taken pre-exercise (baseline,) immediately post-exercise and 
again at 24, 48, and 72 hours post-exercise, at the same time of day. 
Patients exercised at 40 – 60% heart rate reserve (HRR) and a rating of perceived exertion (RPE) of 12 -13 on the Borg 
Scale for 20 to 30 minutes. 
  
Results: Baseline patient characteristics are summarised in Table 1. Figure 1 illustrates changes in NT-proBNP across 
the five time points, where there were no significant changes following the exercise session.    
Figure 1. Three-day post exercise BNP responses to exercise in patients with CHF Abstract: Brain Natriuretic Peptide (BNP) is a marker of myocardial damage and reported to 
increase significantly following maximal exercise in patients with chronic heart failure (CHF). Little 
evidence however exists on BNP levels following standard and recommended submaximal exercise 
sessions for CHF. Purpose: This pilot study, as part of a larger study, aimed to assess changes to BNP 
levels immediately, and at 24, 48 and 72 hours following a recommended CHF exercise training 
session. Methods: Five participants (Table 1) with CHF, had venous blood samples taken at four time 
points following 20 to 30 mins continuous exercise at 40 – 60% of heart rate reserve (and/or Borg RPE 
12-13). Results: summarised in Figure 1. Conclusions: No participant had an increase in BNP, either 
immediately or serially over three days, following exercise. These results provide preliminary 
evidence for exercising CHF participants in multiple weekly sessions without the need for recovery 
days to prevent accumulated rises in BNP. Data is currently being collected on larger numbers of 
participants to further substantiate these findings (Table 2). 
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Table 2.   
Post-abstract submission results: Three-day post exercise BNP responses to exercise in patients with CHF (n = 16) 
Summary and Conclusion: The results of this pilot study support the findings of several studies, which all reported only 
minor changes in plasma BNP levels following both moderate and maximal-intensity exercise in patients with CHF 
(Friedl et al.,1999; McNairy et al., 2002; Krüger et al., 2004;  Normandin et al., 2013).  Future studies are required to 
assess the possible mechanisms of why some studies report increases in BNP levels and others do not, which could 
include the evaluation of BNP clearance and/or the inability of the compromised ventricles to synthesize BNP 
relative to the demands of the system. These results provide preliminary evidence for exercising CHF participants in 
multiple weekly sessions without the need for recovery days to prevent accumulated rises in BNP. Table 1. Patient baseline characteristics 
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Appendix 15 
 
 
ACQUISITION FPS MODE NOTES 
OFFLINE 
MEASURES 
SAVE EXAMPLE 
PLAX 40-90 2D 
Parallel IVS and PW; MV centred 
in sector; adjust depth so that LV 
fills sector; focal point in line with 
valves 
Using post-hoc M-Mode with 
angle correction for BOTH LV 
and LA (LVIDd, LVIDs, PWd, 
PWs, IVSD, IVSs, LAIDs) 
CLIP 
 
 
PLAX 40-90 M-Mode (LV) 
Align cursor to tips of MV, 
perpendicular to IVS and PW; 
adjust angle if required 
LVIDd, LVIDs, PWd, PWs, 
IVSD, IVSs 
IMAGE 
 
PLAX 40-90 
M-Mode (Ao 
Root/LA) 
Align cursor through Ao root and 
centre of LA 
* all measures taken in systole IMAGE 
 
 
PSAX – BASE 40-90 2D 
Clear endo- and epi- definition, just 
below MV; no dropout throughout 
cycle 
Myocardial Speckle tracking 
(circumferential, radial 
strain/strain rate; rotation) 
CLIP 
 
 
PSAX – MID 40-90 2D 
As above but at level of papillary 
muscles; increase depth and adjust 
sector width as needed; focus point 
in centre of cavity 
Myocardial Speckle tracking 
(circumferential, radial 
strain/strain rate; rotation) 
CLIP 
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PSAX – APEX 40-90 2D 
As above but just before LV 
obliteration; move down a rib space 
and laterally to maximise image 
acquisition 
Myocardial Speckle tracking 
(circumferential, radial 
strain/strain rate; rotation; 
torsion) 
CLIP 
 
 
A4C 40-90 2D Whole image LV and LA volume (biplane) CLIP 
 
 
A4C (LV,LA only) 40-90 2D 
Adjust depth to include LV, MV 
and LA only 
LV, LA volume (biplane) CLIP 
 
 A4C (LV only) 40-90 2D 
Focus on LV only; no wall dropout 
throughout cycle 
Myocardial speckle tracking 
(longitudinal strain/strain rate) 
CLIP 
 
 
A4C 40-90 PW DOPPLER 
Overlay MV with colour to 
determine point of greatest flow, 
adjust sample volume to tips of MV 
Transmitral E, A, E/A, other 
timing/flow measures 
IMAGE 
 
 
A4C >200 
COLOUR TDI 
(TVI) 
Narrow sector to increase FPS; 
adjust gain to reduce noise 
Velocity, displacement, strain, 
strain rate 
CLIP 
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A4C (IVS only) >200 
COLOUR TDI 
(TVI) 
Narrow sector to include IVS, at 
mitral annulus, only; adjust gain to 
reduce noise 
Velocity, displacement, strain, 
strain rate 
CLIP 
 
 
A4C (PW Only) >200 
COLOUR TDI 
(TVI) 
Narrow sector to include lateral 
wall only; adjust gain to reduce 
noise 
Velocity, displacement, strain, 
strain rate 
CLIP 
A5C 40-90 PW DOPPLER 
Position sample volume inside LV, 
at the mid-point between MV and 
LVOT 
Timing, flow measures IMAGE 
 
 
A2C (LV, LA only) 40-90 2D 
Find A4C and rotate probe until 
A2C view; ensure clear definition 
of 
LV, LA volume (biplane) CLIP 
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